id	sid	tid	token	lemma	pos
dpc-5015	1	1	dermatology	dermatology	NOUN
dpc-5015	1	2	:	:	PUNCT
dpc-5015	1	3	practical	practical	ADJ
dpc-5015	1	4	and	and	CCONJ
dpc-5015	1	5	conceptual	conceptual	ADJ
dpc-5015	1	6	original	original	ADJ
dpc-5015	1	7	article	article	NOUN
dpc-5015	1	8	|	|	ADV
dpc-5015	1	9	dermatol	dermatol	ADJ
dpc-5015	1	10	pract	pract	NOUN
dpc-5015	1	11	concept	concept	NOUN
dpc-5015	1	12	.	.	PUNCT
dpc-5015	2	1	2025;15(3):5015	2025;15(3):5015	NUM
dpc-5015	2	2	1	1	NUM
dpc-5015	2	3	serum	serum	NOUN
dpc-5015	2	4	endoglin	endoglin	NOUN
dpc-5015	2	5	and	and	CCONJ
dpc-5015	2	6	endocan	endocan	ADJ
dpc-5015	2	7	levels	level	NOUN
dpc-5015	2	8	in	in	ADP
dpc-5015	2	9	rosacea	rosacea	NOUN
dpc-5015	2	10	and	and	CCONJ
dpc-5015	2	11	their	their	PRON
dpc-5015	2	12	association	association	NOUN
dpc-5015	2	13	with	with	ADP
dpc-5015	2	14	cardiovascular	cardiovascular	ADJ
dpc-5015	2	15	risk	risk	NOUN
dpc-5015	2	16	factors	factor	NOUN
dpc-5015	2	17	:	:	PUNCT
dpc-5015	2	18	a	a	DET
dpc-5015	2	19	case	case	NOUN
dpc-5015	2	20	-	-	PUNCT
dpc-5015	2	21	control	control	NOUN
dpc-5015	2	22	study	study	NOUN
dpc-5015	2	23	melodi	melodi	PROPN
dpc-5015	2	24	çekiç1	çekiç1	PROPN
dpc-5015	2	25	,	,	PUNCT
dpc-5015	2	26	ayşın	ayşın	PROPN
dpc-5015	2	27	köktürk2	köktürk2	PROPN
dpc-5015	2	28	,	,	PUNCT
dpc-5015	2	29	lülüfer	lülüfer	VERB
dpc-5015	2	30	tamer3	tamer3	ADJ
dpc-5015	2	31	,	,	PUNCT
dpc-5015	2	32	rojda	rojda	NOUN
dpc-5015	2	33	tanrıverdi3	tanrıverdi3	NOUN
dpc-5015	2	34	1	1	NUM
dpc-5015	2	35	department	department	NOUN
dpc-5015	2	36	of	of	ADP
dpc-5015	2	37	dermatology	dermatology	NOUN
dpc-5015	2	38	,	,	PUNCT
dpc-5015	2	39	acıbadem	acıbadem	PROPN
dpc-5015	2	40	mehmet	mehmet	PROPN
dpc-5015	2	41	ali	ali	PROPN
dpc-5015	2	42	aydınlar	aydınlar	PROPN
dpc-5015	2	43	university	university	NOUN
dpc-5015	2	44	school	school	NOUN
dpc-5015	2	45	of	of	ADP
dpc-5015	2	46	medicine	medicine	NOUN
dpc-5015	2	47	,	,	PUNCT
dpc-5015	2	48	i̇stanbul	i̇stanbul	ADV
dpc-5015	2	49	,	,	PUNCT
dpc-5015	2	50	turkey	turkey	PROPN
dpc-5015	2	51	2	2	NUM
dpc-5015	2	52	department	department	NOUN
dpc-5015	2	53	of	of	ADP
dpc-5015	2	54	dermatology	dermatology	NOUN
dpc-5015	2	55	,	,	PUNCT
dpc-5015	2	56	faculty	faculty	NOUN
dpc-5015	2	57	of	of	ADP
dpc-5015	2	58	medicine	medicine	NOUN
dpc-5015	2	59	,	,	PUNCT
dpc-5015	2	60	mersin	mersin	PROPN
dpc-5015	2	61	university	university	PROPN
dpc-5015	2	62	,	,	PUNCT
dpc-5015	2	63	mersin	mersin	PROPN
dpc-5015	2	64	,	,	PUNCT
dpc-5015	2	65	turkey	turkey	PROPN
dpc-5015	2	66	3	3	NUM
dpc-5015	2	67	department	department	PROPN
dpc-5015	2	68	of	of	ADP
dpc-5015	2	69	biochemistry	biochemistry	NOUN
dpc-5015	2	70	,	,	PUNCT
dpc-5015	2	71	faculty	faculty	NOUN
dpc-5015	2	72	of	of	ADP
dpc-5015	2	73	medicine	medicine	NOUN
dpc-5015	2	74	,	,	PUNCT
dpc-5015	2	75	mersin	mersin	PROPN
dpc-5015	2	76	university	university	PROPN
dpc-5015	2	77	,	,	PUNCT
dpc-5015	2	78	mersin	mersin	PROPN
dpc-5015	2	79	,	,	PUNCT
dpc-5015	2	80	turkey	turkey	PROPN
dpc-5015	2	81	key	key	ADJ
dpc-5015	2	82	words	word	NOUN
dpc-5015	2	83	:	:	PUNCT
dpc-5015	2	84	rosacea	rosacea	NOUN
dpc-5015	2	85	,	,	PUNCT
dpc-5015	2	86	endocan	endocan	ADJ
dpc-5015	2	87	,	,	PUNCT
dpc-5015	2	88	endoglin	endoglin	NOUN
dpc-5015	2	89	,	,	PUNCT
dpc-5015	2	90	cardiovascular	cardiovascular	ADJ
dpc-5015	2	91	risk	risk	NOUN
dpc-5015	2	92	,	,	PUNCT
dpc-5015	2	93	inflammation	inflammation	ADJ
dpc-5015	2	94	citation	citation	NOUN
dpc-5015	2	95	:	:	PUNCT
dpc-5015	2	96	çekiç	çekiç	PROPN
dpc-5015	2	97	m	m	PROPN
dpc-5015	2	98	,	,	PUNCT
dpc-5015	2	99	köktürk	köktürk	VERB
dpc-5015	2	100	a	a	DET
dpc-5015	2	101	,	,	PUNCT
dpc-5015	2	102	tamer	tame	ADJ
dpc-5015	2	103	l	l	NOUN
dpc-5015	2	104	,	,	PUNCT
dpc-5015	2	105	tanrıverdi	tanrıverdi	PROPN
dpc-5015	2	106	r.	r.	PROPN
dpc-5015	2	107	serum	serum	PROPN
dpc-5015	2	108	endoglin	endoglin	PROPN
dpc-5015	2	109	and	and	CCONJ
dpc-5015	2	110	endocan	endocan	ADJ
dpc-5015	2	111	levels	level	NOUN
dpc-5015	2	112	in	in	ADP
dpc-5015	2	113	rosacea	rosacea	NOUN
dpc-5015	2	114	and	and	CCONJ
dpc-5015	2	115	their	their	PRON
dpc-5015	2	116	association	association	NOUN
dpc-5015	2	117	with	with	ADP
dpc-5015	2	118	cardiovascular	cardiovascular	ADJ
dpc-5015	2	119	risk	risk	NOUN
dpc-5015	2	120	factors	factor	NOUN
dpc-5015	2	121	:	:	PUNCT
dpc-5015	2	122	a	a	DET
dpc-5015	2	123	case	case	NOUN
dpc-5015	2	124	-	-	PUNCT
dpc-5015	2	125	control	control	NOUN
dpc-5015	2	126	study	study	NOUN
dpc-5015	2	127	.	.	PUNCT
dpc-5015	3	1	dermatol	dermatol	NOUN
dpc-5015	3	2	pract	pract	PROPN
dpc-5015	3	3	concept	concept	NOUN
dpc-5015	3	4	.	.	PUNCT
dpc-5015	4	1	2025;15(3):5015	2025;15(3):5015	NUM
dpc-5015	4	2	.	.	PUNCT
dpc-5015	4	3	doi	doi	PROPN
dpc-5015	4	4	:	:	PUNCT
dpc-5015	4	5	https://doi.org/10.5826	https://doi.org/10.5826	PROPN
dpc-5015	4	6	/dpc.1503a5015	/dpc.1503a5015	PROPN
dpc-5015	4	7	accepted	accept	VERB
dpc-5015	4	8	:	:	PUNCT
dpc-5015	4	9	march	march	PROPN
dpc-5015	4	10	18	18	NUM
dpc-5015	4	11	,	,	PUNCT
dpc-5015	4	12	2025	2025	NUM
dpc-5015	4	13	;	;	PUNCT
dpc-5015	4	14	published	publish	VERB
dpc-5015	4	15	:	:	PUNCT
dpc-5015	5	1	july	july	PROPN
dpc-5015	5	2	2025	2025	NUM
dpc-5015	5	3	copyright	copyright	NOUN
dpc-5015	5	4	:	:	PUNCT
dpc-5015	5	5	©	©	PROPN
dpc-5015	5	6	2025	2025	NUM
dpc-5015	5	7	çekiç	çekiç	NOUN
dpc-5015	5	8	et	et	PROPN
dpc-5015	5	9	al	al	PROPN
dpc-5015	5	10	.	.	PUNCT
dpc-5015	6	1	this	this	PRON
dpc-5015	6	2	is	be	AUX
dpc-5015	6	3	an	an	DET
dpc-5015	6	4	open	open	ADJ
dpc-5015	6	5	-	-	PUNCT
dpc-5015	6	6	access	access	NOUN
dpc-5015	6	7	article	article	NOUN
dpc-5015	6	8	distributed	distribute	VERB
dpc-5015	6	9	under	under	ADP
dpc-5015	6	10	the	the	DET
dpc-5015	6	11	terms	term	NOUN
dpc-5015	6	12	of	of	ADP
dpc-5015	6	13	the	the	DET
dpc-5015	6	14	creative	creative	ADJ
dpc-5015	6	15	commons	common	NOUN
dpc-5015	6	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-5015	6	17	license	license	NOUN
dpc-5015	6	18	(	(	PUNCT
dpc-5015	6	19	by	by	ADP
dpc-5015	6	20	-	-	PUNCT
dpc-5015	6	21	nc-4.0	nc-4.0	NOUN
dpc-5015	6	22	)	)	PUNCT
dpc-5015	6	23	,	,	PUNCT
dpc-5015	6	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5015	6	25	,	,	PUNCT
dpc-5015	6	26	which	which	PRON
dpc-5015	6	27	permits	permit	VERB
dpc-5015	6	28	unrestricted	unrestricted	ADJ
dpc-5015	6	29	noncommercial	noncommercial	ADJ
dpc-5015	6	30	use	use	NOUN
dpc-5015	6	31	,	,	PUNCT
dpc-5015	6	32	distribution	distribution	NOUN
dpc-5015	6	33	,	,	PUNCT
dpc-5015	6	34	and	and	CCONJ
dpc-5015	6	35	reproduction	reproduction	NOUN
dpc-5015	6	36	in	in	ADP
dpc-5015	6	37	any	any	DET
dpc-5015	6	38	medium	medium	NOUN
dpc-5015	6	39	,	,	PUNCT
dpc-5015	6	40	provided	provide	VERB
dpc-5015	6	41	the	the	DET
dpc-5015	6	42	original	original	ADJ
dpc-5015	6	43	authors	author	NOUN
dpc-5015	6	44	and	and	CCONJ
dpc-5015	6	45	source	source	NOUN
dpc-5015	6	46	are	be	AUX
dpc-5015	6	47	credited	credit	VERB
dpc-5015	6	48	.	.	PUNCT
dpc-5015	7	1	funding	funding	NOUN
dpc-5015	7	2	:	:	PUNCT
dpc-5015	7	3	mersin	mersin	PROPN
dpc-5015	7	4	university	university	PROPN
dpc-5015	7	5	,	,	PUNCT
dpc-5015	7	6	medical	medical	ADJ
dpc-5015	7	7	school	school	NOUN
dpc-5015	7	8	research	research	NOUN
dpc-5015	7	9	grant	grant	NOUN
dpc-5015	7	10	,	,	PUNCT
dpc-5015	7	11	project	project	NOUN
dpc-5015	7	12	number	number	NOUN
dpc-5015	7	13	:	:	PUNCT
dpc-5015	7	14	2021	2021	NUM
dpc-5015	7	15	-	-	SYM
dpc-5015	7	16	1	1	NUM
dpc-5015	7	17	-	-	PUNCT
dpc-5015	7	18	tp3	tp3	NOUN
dpc-5015	7	19	-	-	PUNCT
dpc-5015	7	20	4149	4149	NUM
dpc-5015	7	21	.	.	PUNCT
dpc-5015	8	1	competing	compete	VERB
dpc-5015	8	2	interests	interest	NOUN
dpc-5015	8	3	:	:	PUNCT
dpc-5015	8	4	none	none	NOUN
dpc-5015	8	5	.	.	PUNCT
dpc-5015	9	1	authorship	authorship	NOUN
dpc-5015	9	2	:	:	PUNCT
dpc-5015	9	3	all	all	DET
dpc-5015	9	4	authors	author	NOUN
dpc-5015	9	5	have	have	AUX
dpc-5015	9	6	contributed	contribute	VERB
dpc-5015	9	7	significantly	significantly	ADV
dpc-5015	9	8	to	to	ADP
dpc-5015	9	9	this	this	DET
dpc-5015	9	10	publication	publication	NOUN
dpc-5015	9	11	.	.	PUNCT
dpc-5015	10	1	corresponding	correspond	VERB
dpc-5015	10	2	author	author	NOUN
dpc-5015	10	3	:	:	PUNCT
dpc-5015	10	4	melodi	melodi	PROPN
dpc-5015	10	5	çekiç	çekiç	PROPN
dpc-5015	10	6	,	,	PUNCT
dpc-5015	10	7	md	md	PROPN
dpc-5015	10	8	,	,	PUNCT
dpc-5015	10	9	acıbadem	acıbadem	PROPN
dpc-5015	10	10	mehmet	mehmet	PROPN
dpc-5015	10	11	ali	ali	PROPN
dpc-5015	11	1	aydınlar	aydınlar	PROPN
dpc-5015	11	2	university	university	PROPN
dpc-5015	11	3	no:16	no:16	PROPN
dpc-5015	11	4	,	,	PUNCT
dpc-5015	11	5	i̇stanbul	i̇stanbul	INTJ
dpc-5015	11	6	,	,	PUNCT
dpc-5015	11	7	turkey	turkey	PROPN
dpc-5015	11	8	.	.	PUNCT
dpc-5015	12	1	orcid	orcid	NOUN
dpc-5015	13	1	i	i	PRON
dpc-5015	13	2	d	d	NOUN
dpc-5015	13	3	:	:	PUNCT
dpc-5015	13	4	0000	0000	NUM
dpc-5015	13	5	-	-	PUNCT
dpc-5015	13	6	00021679	00021679	NUM
dpc-5015	13	7	-	-	PUNCT
dpc-5015	13	8	9107	9107	NUM
dpc-5015	13	9	.	.	PUNCT
dpc-5015	14	1	e	e	X
dpc-5015	14	2	-	-	NOUN
dpc-5015	14	3	mail	mail	NOUN
dpc-5015	14	4	:	:	PUNCT
dpc-5015	15	1	melodilif@gmail.com	melodilif@gmail.com	X
dpc-5015	15	2	introduction	introduction	NOUN
dpc-5015	15	3	:	:	PUNCT
dpc-5015	15	4	rosacea	rosacea	NOUN
dpc-5015	15	5	,	,	PUNCT
dpc-5015	15	6	a	a	DET
dpc-5015	15	7	chronic	chronic	ADJ
dpc-5015	15	8	skin	skin	NOUN
dpc-5015	15	9	disease	disease	NOUN
dpc-5015	15	10	characterized	characterize	VERB
dpc-5015	15	11	by	by	ADP
dpc-5015	15	12	facial	facial	ADJ
dpc-5015	15	13	redness	redness	NOUN
dpc-5015	15	14	,	,	PUNCT
dpc-5015	15	15	is	be	AUX
dpc-5015	15	16	believed	believe	VERB
dpc-5015	15	17	to	to	PART
dpc-5015	15	18	involve	involve	VERB
dpc-5015	15	19	inflammation	inflammation	NOUN
dpc-5015	15	20	and	and	CCONJ
dpc-5015	15	21	angiogenesis	angiogenesis	NOUN
dpc-5015	15	22	in	in	ADP
dpc-5015	15	23	its	its	PRON
dpc-5015	15	24	pathogenesis	pathogenesis	NOUN
dpc-5015	15	25	.	.	PUNCT
dpc-5015	16	1	endocan	endocan	ADJ
dpc-5015	16	2	and	and	CCONJ
dpc-5015	16	3	endoglin	endoglin	NOUN
dpc-5015	16	4	,	,	PUNCT
dpc-5015	16	5	biomarkers	biomarker	NOUN
dpc-5015	16	6	associated	associate	VERB
dpc-5015	16	7	with	with	ADP
dpc-5015	16	8	vascular	vascular	ADJ
dpc-5015	16	9	and	and	CCONJ
dpc-5015	16	10	inflammatory	inflammatory	ADJ
dpc-5015	16	11	processes	process	NOUN
dpc-5015	16	12	,	,	PUNCT
dpc-5015	16	13	might	might	AUX
dpc-5015	16	14	play	play	VERB
dpc-5015	16	15	roles	role	NOUN
dpc-5015	16	16	in	in	ADP
dpc-5015	16	17	rosacea	rosacea	NOUN
dpc-5015	16	18	and	and	CCONJ
dpc-5015	16	19	cardiovascular	cardiovascular	ADJ
dpc-5015	16	20	comorbidities	comorbiditie	NOUN
dpc-5015	16	21	.	.	PUNCT
dpc-5015	17	1	objectives	objective	NOUN
dpc-5015	17	2	:	:	PUNCT
dpc-5015	17	3	this	this	DET
dpc-5015	17	4	study	study	NOUN
dpc-5015	17	5	aimed	aim	VERB
dpc-5015	17	6	to	to	PART
dpc-5015	17	7	assess	assess	VERB
dpc-5015	17	8	serum	serum	NOUN
dpc-5015	17	9	levels	level	NOUN
dpc-5015	17	10	of	of	ADP
dpc-5015	17	11	endocan	endocan	PROPN
dpc-5015	17	12	and	and	CCONJ
dpc-5015	17	13	endoglin	endoglin	NOUN
dpc-5015	17	14	in	in	ADP
dpc-5015	17	15	individuals	individual	NOUN
dpc-5015	17	16	with	with	ADP
dpc-5015	17	17	rosacea	rosacea	NOUN
dpc-5015	17	18	and	and	CCONJ
dpc-5015	17	19	the	the	DET
dpc-5015	17	20	function	function	NOUN
dpc-5015	17	21	of	of	ADP
dpc-5015	17	22	these	these	DET
dpc-5015	17	23	biomarkers	biomarker	NOUN
dpc-5015	17	24	in	in	ADP
dpc-5015	17	25	indicating	indicate	VERB
dpc-5015	17	26	comorbidities	comorbiditie	NOUN
dpc-5015	17	27	associated	associate	VERB
dpc-5015	17	28	with	with	ADP
dpc-5015	17	29	rosacea	rosacea	NOUN
dpc-5015	17	30	.	.	PUNCT
dpc-5015	18	1	methods	method	NOUN
dpc-5015	18	2	:	:	PUNCT
dpc-5015	18	3	a	a	DET
dpc-5015	18	4	total	total	NOUN
dpc-5015	18	5	of	of	ADP
dpc-5015	18	6	forty	forty	NUM
dpc-5015	18	7	-	-	PUNCT
dpc-5015	18	8	four	four	NUM
dpc-5015	18	9	patients	patient	NOUN
dpc-5015	18	10	diagnosed	diagnose	VERB
dpc-5015	18	11	with	with	ADP
dpc-5015	18	12	rosacea	rosacea	NOUN
dpc-5015	18	13	and	and	CCONJ
dpc-5015	18	14	thirty	thirty	NUM
dpc-5015	18	15	-	-	PUNCT
dpc-5015	18	16	three	three	NUM
dpc-5015	18	17	healthy	healthy	ADJ
dpc-5015	18	18	controls	control	NOUN
dpc-5015	18	19	were	be	AUX
dpc-5015	18	20	included	include	VERB
dpc-5015	18	21	in	in	ADP
dpc-5015	18	22	this	this	DET
dpc-5015	18	23	case	case	NOUN
dpc-5015	18	24	-	-	PUNCT
dpc-5015	18	25	control	control	NOUN
dpc-5015	18	26	study	study	NOUN
dpc-5015	18	27	.	.	PUNCT
dpc-5015	19	1	the	the	DET
dpc-5015	19	2	endocan	endocan	ADJ
dpc-5015	19	3	and	and	CCONJ
dpc-5015	19	4	endoglin	endoglin	NOUN
dpc-5015	19	5	levels	level	NOUN
dpc-5015	19	6	in	in	ADP
dpc-5015	19	7	serum	serum	NOUN
dpc-5015	19	8	samples	sample	NOUN
dpc-5015	19	9	from	from	ADP
dpc-5015	19	10	both	both	DET
dpc-5015	19	11	groups	group	NOUN
dpc-5015	19	12	were	be	AUX
dpc-5015	19	13	measured	measure	VERB
dpc-5015	19	14	.	.	PUNCT
dpc-5015	20	1	results	result	NOUN
dpc-5015	20	2	:	:	PUNCT
dpc-5015	20	3	no	no	DET
dpc-5015	20	4	significant	significant	ADJ
dpc-5015	20	5	difference	difference	NOUN
dpc-5015	20	6	in	in	ADP
dpc-5015	20	7	endocan	endocan	ADJ
dpc-5015	20	8	and	and	CCONJ
dpc-5015	20	9	endoglin	endoglin	NOUN
dpc-5015	20	10	levels	level	NOUN
dpc-5015	20	11	was	be	AUX
dpc-5015	20	12	observed	observe	VERB
dpc-5015	20	13	between	between	ADP
dpc-5015	20	14	the	the	DET
dpc-5015	20	15	patient	patient	ADJ
dpc-5015	20	16	and	and	CCONJ
dpc-5015	20	17	control	control	NOUN
dpc-5015	20	18	groups	group	NOUN
dpc-5015	20	19	.	.	PUNCT
dpc-5015	21	1	however	however	ADV
dpc-5015	21	2	,	,	PUNCT
dpc-5015	21	3	their	their	PRON
dpc-5015	21	4	levels	level	NOUN
dpc-5015	21	5	were	be	AUX
dpc-5015	21	6	associated	associate	VERB
dpc-5015	21	7	with	with	ADP
dpc-5015	21	8	various	various	ADJ
dpc-5015	21	9	clinical	clinical	ADJ
dpc-5015	21	10	features	feature	NOUN
dpc-5015	21	11	,	,	PUNCT
dpc-5015	21	12	including	include	VERB
dpc-5015	21	13	symptom	symptom	NOUN
dpc-5015	21	14	and	and	CCONJ
dpc-5015	21	15	disease	disease	NOUN
dpc-5015	21	16	severity	severity	NOUN
dpc-5015	21	17	.	.	PUNCT
dpc-5015	22	1	a	a	DET
dpc-5015	22	2	notable	notable	ADJ
dpc-5015	22	3	association	association	NOUN
dpc-5015	22	4	was	be	AUX
dpc-5015	22	5	identified	identify	VERB
dpc-5015	22	6	between	between	ADP
dpc-5015	22	7	waist	waist	NOUN
dpc-5015	22	8	circumference	circumference	NOUN
dpc-5015	22	9	,	,	PUNCT
dpc-5015	22	10	body	body	NOUN
dpc-5015	22	11	mass	mass	PROPN
dpc-5015	22	12	index	index	NOUN
dpc-5015	22	13	,	,	PUNCT
dpc-5015	22	14	and	and	CCONJ
dpc-5015	22	15	endoglin	endoglin	NOUN
dpc-5015	22	16	levels	level	NOUN
dpc-5015	22	17	.	.	PUNCT
dpc-5015	23	1	however	however	ADV
dpc-5015	23	2	,	,	PUNCT
dpc-5015	23	3	this	this	DET
dpc-5015	23	4	association	association	NOUN
dpc-5015	23	5	was	be	AUX
dpc-5015	23	6	not	not	PART
dpc-5015	23	7	evident	evident	ADJ
dpc-5015	23	8	for	for	ADP
dpc-5015	23	9	endocan	endocan	ADJ
dpc-5015	23	10	.	.	PUNCT
dpc-5015	24	1	conclusions	conclusion	NOUN
dpc-5015	24	2	:	:	PUNCT
dpc-5015	24	3	this	this	DET
dpc-5015	24	4	study	study	NOUN
dpc-5015	24	5	suggests	suggest	VERB
dpc-5015	24	6	endocan	endocan	PROPN
dpc-5015	24	7	and	and	CCONJ
dpc-5015	24	8	endoglin	endoglin	NOUN
dpc-5015	24	9	may	may	AUX
dpc-5015	24	10	play	play	VERB
dpc-5015	24	11	roles	role	NOUN
dpc-5015	24	12	in	in	ADP
dpc-5015	24	13	rosacea	rosacea	NOUN
dpc-5015	24	14	pathogenesis	pathogenesis	NOUN
dpc-5015	24	15	,	,	PUNCT
dpc-5015	24	16	with	with	ADP
dpc-5015	24	17	endoglin	endoglin	NOUN
dpc-5015	24	18	potentially	potentially	ADV
dpc-5015	24	19	associated	associate	VERB
dpc-5015	24	20	with	with	ADP
dpc-5015	24	21	increased	increase	VERB
dpc-5015	24	22	cardiovascular	cardiovascular	ADJ
dpc-5015	24	23	risk	risk	NOUN
dpc-5015	24	24	.	.	PUNCT
dpc-5015	25	1	abstract	abstract	ADJ
dpc-5015	25	2	2	2	NUM
dpc-5015	25	3	original	original	ADJ
dpc-5015	25	4	article	article	NOUN
dpc-5015	25	5	|	|	ADV
dpc-5015	25	6	dermatol	dermatol	ADJ
dpc-5015	25	7	pract	pract	NOUN
dpc-5015	25	8	concept	concept	NOUN
dpc-5015	25	9	.	.	PUNCT
dpc-5015	26	1	2025;15(3):5015	2025;15(3):5015	NUM
dpc-5015	26	2	introduction	introduction	NOUN
dpc-5015	26	3	rosacea	rosacea	NOUN
dpc-5015	26	4	is	be	AUX
dpc-5015	26	5	a	a	DET
dpc-5015	26	6	chronic	chronic	ADJ
dpc-5015	26	7	inflammatory	inflammatory	ADJ
dpc-5015	26	8	skin	skin	NOUN
dpc-5015	26	9	disease	disease	NOUN
dpc-5015	26	10	typified	typify	VERB
dpc-5015	26	11	by	by	ADP
dpc-5015	26	12	facial	facial	ADJ
dpc-5015	26	13	redness	redness	NOUN
dpc-5015	26	14	,	,	PUNCT
dpc-5015	26	15	telangiectasias	telangiectasia	NOUN
dpc-5015	26	16	,	,	PUNCT
dpc-5015	26	17	occurrence	occurrence	NOUN
dpc-5015	26	18	of	of	ADP
dpc-5015	26	19	papulopustular	papulopustular	ADJ
dpc-5015	26	20	lesions	lesion	NOUN
dpc-5015	26	21	,	,	PUNCT
dpc-5015	26	22	and	and	CCONJ
dpc-5015	26	23	phymatous	phymatous	ADJ
dpc-5015	26	24	changes	change	NOUN
dpc-5015	26	25	.	.	PUNCT
dpc-5015	27	1	it	it	PRON
dpc-5015	27	2	predominantly	predominantly	ADV
dpc-5015	27	3	affects	affect	VERB
dpc-5015	27	4	females	female	NOUN
dpc-5015	27	5	and	and	CCONJ
dpc-5015	27	6	individuals	individual	NOUN
dpc-5015	27	7	with	with	ADP
dpc-5015	27	8	fitzpatrick	fitzpatrick	PROPN
dpc-5015	27	9	skin	skin	NOUN
dpc-5015	27	10	types	type	NOUN
dpc-5015	27	11	1	1	NUM
dpc-5015	27	12	or	or	CCONJ
dpc-5015	27	13	2	2	NUM
dpc-5015	28	1	[	[	SYM
dpc-5015	28	2	1	1	NUM
dpc-5015	28	3	-	-	SYM
dpc-5015	28	4	7	7	NUM
dpc-5015	28	5	]	]	PUNCT
dpc-5015	28	6	.	.	PUNCT
dpc-5015	29	1	the	the	DET
dpc-5015	29	2	histopathology	histopathology	NOUN
dpc-5015	29	3	of	of	ADP
dpc-5015	29	4	rosacea	rosacea	PROPN
dpc-5015	29	5	is	be	AUX
dpc-5015	29	6	generally	generally	ADV
dpc-5015	29	7	nonspecific	nonspecific	ADJ
dpc-5015	29	8	,	,	PUNCT
dpc-5015	29	9	hence	hence	ADV
dpc-5015	29	10	the	the	DET
dpc-5015	29	11	diagnosis	diagnosis	NOUN
dpc-5015	29	12	is	be	AUX
dpc-5015	29	13	predominantly	predominantly	ADV
dpc-5015	29	14	based	base	VERB
dpc-5015	29	15	on	on	ADP
dpc-5015	29	16	clinical	clinical	ADJ
dpc-5015	29	17	observations	observation	NOUN
dpc-5015	29	18	.	.	PUNCT
dpc-5015	30	1	in	in	ADP
dpc-5015	30	2	pathology	pathology	PROPN
dpc-5015	30	3	,	,	PUNCT
dpc-5015	30	4	findings	finding	NOUN
dpc-5015	30	5	such	such	ADJ
dpc-5015	30	6	as	as	ADP
dpc-5015	30	7	spongiosis	spongiosis	NOUN
dpc-5015	30	8	,	,	PUNCT
dpc-5015	30	9	perivascular	perivascular	ADJ
dpc-5015	30	10	lymphohistiocytic	lymphohistiocytic	ADJ
dpc-5015	30	11	infiltration	infiltration	NOUN
dpc-5015	30	12	,	,	PUNCT
dpc-5015	30	13	dilated	dilated	ADJ
dpc-5015	30	14	capillaries	capillary	NOUN
dpc-5015	30	15	,	,	PUNCT
dpc-5015	30	16	and	and	CCONJ
dpc-5015	30	17	solar	solar	ADJ
dpc-5015	30	18	elastosis	elastosis	NOUN
dpc-5015	30	19	are	be	AUX
dpc-5015	30	20	commonly	commonly	ADV
dpc-5015	30	21	observed	observe	VERB
dpc-5015	30	22	[	[	X
dpc-5015	30	23	8	8	NUM
dpc-5015	30	24	]	]	PUNCT
dpc-5015	30	25	.	.	PUNCT
dpc-5015	31	1	immunologically	immunologically	ADV
dpc-5015	31	2	,	,	PUNCT
dpc-5015	31	3	various	various	ADJ
dpc-5015	31	4	factors	factor	NOUN
dpc-5015	31	5	such	such	ADJ
dpc-5015	31	6	as	as	ADP
dpc-5015	31	7	t	t	PROPN
dpc-5015	31	8	helper	helper	NOUN
dpc-5015	31	9	(	(	PUNCT
dpc-5015	31	10	th	th	NOUN
dpc-5015	31	11	)	)	PUNCT
dpc-5015	31	12	1	1	NUM
dpc-5015	31	13	and	and	CCONJ
dpc-5015	31	14	th17	th17	PROPN
dpc-5015	31	15	lymphocytes	lymphocyte	NOUN
dpc-5015	31	16	,	,	PUNCT
dpc-5015	31	17	tumor	tumor	NOUN
dpc-5015	31	18	necrosis	necrosis	NOUN
dpc-5015	31	19	factor	factor	NOUN
dpc-5015	31	20	(	(	PUNCT
dpc-5015	31	21	tnf	tnf	PROPN
dpc-5015	31	22	)	)	PUNCT
dpc-5015	31	23	alpha	alpha	NOUN
dpc-5015	31	24	,	,	PUNCT
dpc-5015	31	25	inflammasome	inflammasome	VERB
dpc-5015	31	26	complex	complex	ADJ
dpc-5015	31	27	,	,	PUNCT
dpc-5015	31	28	interleukin	interleukin	NOUN
dpc-5015	31	29	(	(	PUNCT
dpc-5015	31	30	il)-17a	il)-17a	PROPN
dpc-5015	31	31	,	,	PUNCT
dpc-5015	31	32	vascular	vascular	ADJ
dpc-5015	31	33	endothelial	endothelial	ADJ
dpc-5015	31	34	growth	growth	NOUN
dpc-5015	31	35	factor	factor	NOUN
dpc-5015	31	36	(	(	PUNCT
dpc-5015	31	37	vegf	vegf	PROPN
dpc-5015	31	38	)	)	PUNCT
dpc-5015	31	39	,	,	PUNCT
dpc-5015	31	40	toll	toll	NOUN
dpc-5015	31	41	-	-	PUNCT
dpc-5015	31	42	like	like	ADJ
dpc-5015	31	43	receptor	receptor	NOUN
dpc-5015	31	44	(	(	PUNCT
dpc-5015	31	45	tlr)-2	tlr)-2	NOUN
dpc-5015	31	46	expression	expression	NOUN
dpc-5015	31	47	,	,	PUNCT
dpc-5015	31	48	and	and	CCONJ
dpc-5015	31	49	cathelicidin	cathelicidin	VERB
dpc-5015	31	50	molecules	molecule	NOUN
dpc-5015	31	51	have	have	AUX
dpc-5015	31	52	been	be	AUX
dpc-5015	31	53	associated	associate	VERB
dpc-5015	31	54	with	with	ADP
dpc-5015	31	55	the	the	DET
dpc-5015	31	56	pathophysiology	pathophysiology	NOUN
dpc-5015	31	57	of	of	ADP
dpc-5015	31	58	rosacea	rosacea	NOUN
dpc-5015	31	59	[	[	X
dpc-5015	31	60	9	9	NUM
dpc-5015	31	61	-	-	SYM
dpc-5015	31	62	22	22	NUM
dpc-5015	31	63	]	]	PUNCT
dpc-5015	31	64	.	.	PUNCT
dpc-5015	32	1	endoglin	endoglin	NOUN
dpc-5015	32	2	(	(	PUNCT
dpc-5015	32	3	cd105	cd105	PROPN
dpc-5015	32	4	)	)	PUNCT
dpc-5015	32	5	acts	act	VERB
dpc-5015	32	6	as	as	ADP
dpc-5015	32	7	a	a	DET
dpc-5015	32	8	coreceptor	coreceptor	NOUN
dpc-5015	32	9	for	for	ADP
dpc-5015	32	10	ligands	ligand	NOUN
dpc-5015	32	11	of	of	ADP
dpc-5015	32	12	the	the	DET
dpc-5015	32	13	transforming	transform	VERB
dpc-5015	32	14	growth	growth	NOUN
dpc-5015	32	15	factor	factor	NOUN
dpc-5015	32	16	(	(	PUNCT
dpc-5015	32	17	tgf)-beta	tgf)-beta	PROPN
dpc-5015	32	18	family	family	NOUN
dpc-5015	32	19	and	and	CCONJ
dpc-5015	32	20	has	have	VERB
dpc-5015	32	21	a	a	DET
dpc-5015	32	22	molecular	molecular	ADJ
dpc-5015	32	23	weight	weight	NOUN
dpc-5015	32	24	of	of	ADP
dpc-5015	32	25	180	180	NUM
dpc-5015	32	26	kilodaltons	kilodalton	NOUN
dpc-5015	32	27	(	(	PUNCT
dpc-5015	32	28	kda	kda	NOUN
dpc-5015	32	29	)	)	PUNCT
dpc-5015	32	30	.	.	PUNCT
dpc-5015	33	1	endoglin	endoglin	PROPN
dpc-5015	33	2	is	be	AUX
dpc-5015	33	3	predominantly	predominantly	ADV
dpc-5015	33	4	secreted	secrete	VERB
dpc-5015	33	5	by	by	ADP
dpc-5015	33	6	activated	activate	VERB
dpc-5015	33	7	endothelial	endothelial	ADJ
dpc-5015	33	8	cells	cell	NOUN
dpc-5015	33	9	and	and	CCONJ
dpc-5015	33	10	plays	play	VERB
dpc-5015	33	11	a	a	DET
dpc-5015	33	12	crucial	crucial	ADJ
dpc-5015	33	13	role	role	NOUN
dpc-5015	33	14	in	in	ADP
dpc-5015	33	15	angiogenesis	angiogenesis	NOUN
dpc-5015	33	16	,	,	PUNCT
dpc-5015	33	17	closely	closely	ADV
dpc-5015	33	18	associated	associate	VERB
dpc-5015	33	19	with	with	ADP
dpc-5015	33	20	the	the	DET
dpc-5015	33	21	vegf	vegf	PROPN
dpc-5015	33	22	molecule	molecule	NOUN
dpc-5015	34	1	[	[	X
dpc-5015	34	2	23	23	NUM
dpc-5015	34	3	-	-	SYM
dpc-5015	34	4	28	28	NUM
dpc-5015	34	5	]	]	PUNCT
dpc-5015	34	6	.	.	PUNCT
dpc-5015	35	1	endocan	endocan	PROPN
dpc-5015	35	2	is	be	AUX
dpc-5015	35	3	a	a	DET
dpc-5015	35	4	proteoglycan	proteoglycan	NOUN
dpc-5015	35	5	with	with	ADP
dpc-5015	35	6	a	a	DET
dpc-5015	35	7	dermatan	dermatan	ADJ
dpc-5015	35	8	sulfate	sulfate	NOUN
dpc-5015	35	9	structure	structure	NOUN
dpc-5015	35	10	[	[	X
dpc-5015	35	11	29	29	NUM
dpc-5015	35	12	]	]	PUNCT
dpc-5015	35	13	.	.	PUNCT
dpc-5015	36	1	it	it	PRON
dpc-5015	36	2	is	be	AUX
dpc-5015	36	3	secreted	secrete	VERB
dpc-5015	36	4	from	from	ADP
dpc-5015	36	5	the	the	DET
dpc-5015	36	6	human	human	ADJ
dpc-5015	36	7	vascular	vascular	ADJ
dpc-5015	36	8	endothelium	endothelium	NOUN
dpc-5015	36	9	and	and	CCONJ
dpc-5015	36	10	is	be	AUX
dpc-5015	36	11	also	also	ADV
dpc-5015	36	12	found	find	VERB
dpc-5015	36	13	freely	freely	ADV
dpc-5015	36	14	circulating	circulate	VERB
dpc-5015	36	15	in	in	ADP
dpc-5015	36	16	the	the	DET
dpc-5015	36	17	bloodstream	bloodstream	NOUN
dpc-5015	37	1	[	[	X
dpc-5015	37	2	30	30	NUM
dpc-5015	37	3	]	]	PUNCT
dpc-5015	37	4	.	.	PUNCT
dpc-5015	38	1	it	it	PRON
dpc-5015	38	2	participates	participate	VERB
dpc-5015	38	3	in	in	ADP
dpc-5015	38	4	diverse	diverse	ADJ
dpc-5015	38	5	cellular	cellular	ADJ
dpc-5015	38	6	mechanisms	mechanism	NOUN
dpc-5015	38	7	,	,	PUNCT
dpc-5015	38	8	including	include	VERB
dpc-5015	38	9	cell	cell	NOUN
dpc-5015	38	10	proliferation	proliferation	NOUN
dpc-5015	38	11	,	,	PUNCT
dpc-5015	38	12	migration	migration	NOUN
dpc-5015	38	13	,	,	PUNCT
dpc-5015	38	14	angiogenesis	angiogenesis	NOUN
dpc-5015	38	15	,	,	PUNCT
dpc-5015	38	16	and	and	CCONJ
dpc-5015	38	17	inflammation	inflammation	NOUN
dpc-5015	38	18	[	[	X
dpc-5015	38	19	29,31,32	29,31,32	NUM
dpc-5015	38	20	]	]	PUNCT
dpc-5015	38	21	.	.	PUNCT
dpc-5015	39	1	the	the	DET
dpc-5015	39	2	correlation	correlation	NOUN
dpc-5015	39	3	between	between	ADP
dpc-5015	39	4	these	these	DET
dpc-5015	39	5	molecules	molecule	NOUN
dpc-5015	39	6	and	and	CCONJ
dpc-5015	39	7	concurrent	concurrent	ADJ
dpc-5015	39	8	conditions	condition	NOUN
dpc-5015	39	9	such	such	ADJ
dpc-5015	39	10	as	as	ADP
dpc-5015	39	11	diabetes	diabete	NOUN
dpc-5015	39	12	,	,	PUNCT
dpc-5015	39	13	coronary	coronary	ADJ
dpc-5015	39	14	artery	artery	NOUN
dpc-5015	39	15	disease	disease	NOUN
dpc-5015	39	16	,	,	PUNCT
dpc-5015	39	17	metabolic	metabolic	NOUN
dpc-5015	39	18	syndrome	syndrome	NOUN
dpc-5015	39	19	,	,	PUNCT
dpc-5015	39	20	and	and	CCONJ
dpc-5015	39	21	hypertension	hypertension	NOUN
dpc-5015	39	22	has	have	AUX
dpc-5015	39	23	been	be	AUX
dpc-5015	39	24	seen	see	VERB
dpc-5015	39	25	in	in	ADP
dpc-5015	39	26	numerous	numerous	ADJ
dpc-5015	39	27	research	research	NOUN
dpc-5015	39	28	studies	study	NOUN
dpc-5015	39	29	[	[	X
dpc-5015	39	30	28,30,31,33	28,30,31,33	NUM
dpc-5015	39	31	]	]	PUNCT
dpc-5015	39	32	.	.	PUNCT
dpc-5015	40	1	objectives	objective	VERB
dpc-5015	40	2	the	the	DET
dpc-5015	40	3	purpose	purpose	NOUN
dpc-5015	40	4	of	of	ADP
dpc-5015	40	5	this	this	DET
dpc-5015	40	6	research	research	NOUN
dpc-5015	40	7	was	be	AUX
dpc-5015	40	8	to	to	PART
dpc-5015	40	9	investigate	investigate	VERB
dpc-5015	40	10	the	the	DET
dpc-5015	40	11	involvement	involvement	NOUN
dpc-5015	40	12	of	of	ADP
dpc-5015	40	13	the	the	DET
dpc-5015	40	14	molecules	molecule	NOUN
dpc-5015	40	15	endocan	endocan	ADJ
dpc-5015	40	16	and	and	CCONJ
dpc-5015	40	17	endoglin	endoglin	NOUN
dpc-5015	40	18	in	in	ADP
dpc-5015	40	19	the	the	DET
dpc-5015	40	20	pathogenesis	pathogenesis	NOUN
dpc-5015	40	21	of	of	ADP
dpc-5015	40	22	rosacea	rosacea	NOUN
dpc-5015	40	23	.	.	PUNCT
dpc-5015	41	1	furthermore	furthermore	ADV
dpc-5015	41	2	,	,	PUNCT
dpc-5015	41	3	this	this	DET
dpc-5015	41	4	study	study	NOUN
dpc-5015	41	5	assessed	assess	VERB
dpc-5015	41	6	the	the	DET
dpc-5015	41	7	potential	potential	NOUN
dpc-5015	41	8	of	of	ADP
dpc-5015	41	9	endocan	endocan	ADJ
dpc-5015	41	10	and	and	CCONJ
dpc-5015	41	11	endoglin	endoglin	NOUN
dpc-5015	41	12	levels	level	NOUN
dpc-5015	41	13	as	as	ADP
dpc-5015	41	14	biomarkers	biomarker	NOUN
dpc-5015	41	15	for	for	ADP
dpc-5015	41	16	predicting	predict	VERB
dpc-5015	41	17	cardiovascular	cardiovascular	ADJ
dpc-5015	41	18	disease	disease	NOUN
dpc-5015	41	19	risk	risk	NOUN
dpc-5015	41	20	in	in	ADP
dpc-5015	41	21	patients	patient	NOUN
dpc-5015	41	22	with	with	ADP
dpc-5015	41	23	rosacea	rosacea	NOUN
dpc-5015	41	24	.	.	PUNCT
dpc-5015	42	1	methods	method	NOUN
dpc-5015	42	2	study	study	NOUN
dpc-5015	42	3	design	design	VERB
dpc-5015	42	4	this	this	DET
dpc-5015	42	5	16	16	NUM
dpc-5015	42	6	-	-	PUNCT
dpc-5015	42	7	week	week	NOUN
dpc-5015	42	8	case	case	NOUN
dpc-5015	42	9	-	-	PUNCT
dpc-5015	42	10	control	control	NOUN
dpc-5015	42	11	study	study	NOUN
dpc-5015	42	12	included	include	VERB
dpc-5015	42	13	44	44	NUM
dpc-5015	42	14	patients	patient	NOUN
dpc-5015	42	15	in	in	ADP
dpc-5015	42	16	the	the	DET
dpc-5015	42	17	patient	patient	NOUN
dpc-5015	42	18	group	group	NOUN
dpc-5015	42	19	,	,	PUNCT
dpc-5015	42	20	aged	aged	ADJ
dpc-5015	42	21	28	28	NUM
dpc-5015	42	22	-	-	SYM
dpc-5015	42	23	74	74	NUM
dpc-5015	42	24	years	year	NOUN
dpc-5015	42	25	,	,	PUNCT
dpc-5015	42	26	who	who	PRON
dpc-5015	42	27	were	be	AUX
dpc-5015	42	28	diagnosed	diagnose	VERB
dpc-5015	42	29	with	with	ADP
dpc-5015	42	30	rosacea	rosacea	NOUN
dpc-5015	42	31	based	base	VERB
dpc-5015	42	32	on	on	ADP
dpc-5015	42	33	the	the	DET
dpc-5015	42	34	2017	2017	NUM
dpc-5015	42	35	national	national	PROPN
dpc-5015	42	36	rosacea	rosacea	PROPN
dpc-5015	42	37	society	society	PROPN
dpc-5015	42	38	expert	expert	PROPN
dpc-5015	42	39	committee	committee	PROPN
dpc-5015	42	40	criteria	criterion	NOUN
dpc-5015	43	1	[	[	X
dpc-5015	43	2	34	34	NUM
dpc-5015	43	3	]	]	PUNCT
dpc-5015	43	4	.	.	PUNCT
dpc-5015	44	1	the	the	DET
dpc-5015	44	2	control	control	PROPN
dpc-5015	44	3	group	group	NOUN
dpc-5015	44	4	consisted	consist	VERB
dpc-5015	44	5	of	of	ADP
dpc-5015	44	6	33	33	NUM
dpc-5015	44	7	adults	adult	NOUN
dpc-5015	44	8	who	who	PRON
dpc-5015	44	9	were	be	AUX
dpc-5015	44	10	examined	examine	VERB
dpc-5015	44	11	for	for	ADP
dpc-5015	44	12	dermatological	dermatological	ADJ
dpc-5015	44	13	diseases	disease	NOUN
dpc-5015	44	14	other	other	ADJ
dpc-5015	44	15	than	than	ADP
dpc-5015	44	16	rosacea	rosacea	NOUN
dpc-5015	44	17	.	.	PUNCT
dpc-5015	45	1	exclusion	exclusion	NOUN
dpc-5015	45	2	criteria	criterion	NOUN
dpc-5015	45	3	included	include	VERB
dpc-5015	45	4	individuals	individual	NOUN
dpc-5015	45	5	under	under	ADP
dpc-5015	45	6	18	18	NUM
dpc-5015	45	7	years	year	NOUN
dpc-5015	45	8	of	of	ADP
dpc-5015	45	9	age	age	NOUN
dpc-5015	45	10	,	,	PUNCT
dpc-5015	45	11	pregnant	pregnant	ADJ
dpc-5015	45	12	or	or	CCONJ
dpc-5015	45	13	lactating	lactate	VERB
dpc-5015	45	14	women	woman	NOUN
dpc-5015	45	15	,	,	PUNCT
dpc-5015	45	16	active	active	ADJ
dpc-5015	45	17	infections	infection	NOUN
dpc-5015	45	18	,	,	PUNCT
dpc-5015	45	19	concomitant	concomitant	ADJ
dpc-5015	45	20	inflammatory	inflammatory	ADJ
dpc-5015	45	21	skin	skin	NOUN
dpc-5015	45	22	diseases	disease	NOUN
dpc-5015	45	23	,	,	PUNCT
dpc-5015	45	24	smoking	smoking	NOUN
dpc-5015	45	25	,	,	PUNCT
dpc-5015	45	26	anemia	anemia	NOUN
dpc-5015	45	27	,	,	PUNCT
dpc-5015	45	28	obstructive	obstructive	ADJ
dpc-5015	45	29	lung	lung	NOUN
dpc-5015	45	30	disease	disease	NOUN
dpc-5015	45	31	,	,	PUNCT
dpc-5015	45	32	atrial	atrial	ADJ
dpc-5015	45	33	fibrillation	fibrillation	NOUN
dpc-5015	45	34	and	and	CCONJ
dpc-5015	45	35	arrhythmia	arrhythmia	NOUN
dpc-5015	45	36	,	,	PUNCT
dpc-5015	45	37	anomalies	anomaly	NOUN
dpc-5015	45	38	in	in	ADP
dpc-5015	45	39	thyroid	thyroid	NOUN
dpc-5015	45	40	function	function	NOUN
dpc-5015	45	41	tests	test	NOUN
dpc-5015	45	42	,	,	PUNCT
dpc-5015	45	43	left	leave	VERB
dpc-5015	45	44	ventricular	ventricular	ADJ
dpc-5015	45	45	dysfunction	dysfunction	NOUN
dpc-5015	45	46	,	,	PUNCT
dpc-5015	45	47	malignancy	malignancy	NOUN
dpc-5015	45	48	,	,	PUNCT
dpc-5015	45	49	coronary	coronary	ADJ
dpc-5015	45	50	artery	artery	NOUN
dpc-5015	45	51	disease	disease	NOUN
dpc-5015	45	52	,	,	PUNCT
dpc-5015	45	53	valvular	valvular	ADJ
dpc-5015	45	54	heart	heart	NOUN
dpc-5015	45	55	disease	disease	NOUN
dpc-5015	45	56	,	,	PUNCT
dpc-5015	45	57	diabetes	diabetes	NOUN
dpc-5015	45	58	,	,	PUNCT
dpc-5015	45	59	arterial	arterial	ADJ
dpc-5015	45	60	hypertension	hypertension	NOUN
dpc-5015	45	61	,	,	PUNCT
dpc-5015	45	62	renal	renal	ADJ
dpc-5015	45	63	-	-	PUNCT
dpc-5015	45	64	hepatic	hepatic	NOUN
dpc-5015	45	65	insufficiency	insufficiency	NOUN
dpc-5015	45	66	,	,	PUNCT
dpc-5015	45	67	obesity	obesity	NOUN
dpc-5015	45	68	,	,	PUNCT
dpc-5015	45	69	hyperlipidemia	hyperlipidemia	NOUN
dpc-5015	45	70	,	,	PUNCT
dpc-5015	45	71	autoimmune	autoimmune	ADJ
dpc-5015	45	72	diseases	disease	NOUN
dpc-5015	45	73	,	,	PUNCT
dpc-5015	45	74	individuals	individual	NOUN
dpc-5015	45	75	who	who	PRON
dpc-5015	45	76	received	receive	VERB
dpc-5015	45	77	systemic	systemic	ADJ
dpc-5015	45	78	treatment	treatment	NOUN
dpc-5015	45	79	for	for	ADP
dpc-5015	45	80	rosacea	rosacea	NOUN
dpc-5015	45	81	within	within	ADP
dpc-5015	45	82	the	the	DET
dpc-5015	45	83	previous	previous	ADJ
dpc-5015	45	84	six	six	NUM
dpc-5015	45	85	months	month	NOUN
dpc-5015	45	86	,	,	PUNCT
dpc-5015	45	87	and	and	CCONJ
dpc-5015	45	88	individuals	individual	NOUN
dpc-5015	45	89	taking	take	VERB
dpc-5015	45	90	drugs	drug	NOUN
dpc-5015	45	91	such	such	ADJ
dpc-5015	45	92	as	as	ADP
dpc-5015	45	93	amlodipine	amlodipine	NOUN
dpc-5015	45	94	and	and	CCONJ
dpc-5015	45	95	valsartan	valsartan	PROPN
dpc-5015	45	96	that	that	PRON
dpc-5015	45	97	could	could	AUX
dpc-5015	45	98	affect	affect	VERB
dpc-5015	45	99	endocan	endocan	ADJ
dpc-5015	45	100	levels	level	NOUN
dpc-5015	45	101	[	[	X
dpc-5015	45	102	33	33	NUM
dpc-5015	45	103	]	]	PUNCT
dpc-5015	45	104	.	.	PUNCT
dpc-5015	46	1	study	study	NOUN
dpc-5015	46	2	protocol	protocol	VERB
dpc-5015	46	3	the	the	DET
dpc-5015	46	4	study	study	NOUN
dpc-5015	46	5	was	be	AUX
dpc-5015	46	6	conducted	conduct	VERB
dpc-5015	46	7	in	in	ADP
dpc-5015	46	8	accordance	accordance	NOUN
dpc-5015	46	9	with	with	ADP
dpc-5015	46	10	the	the	DET
dpc-5015	46	11	principles	principle	NOUN
dpc-5015	46	12	outlined	outline	VERB
dpc-5015	46	13	in	in	ADP
dpc-5015	46	14	the	the	DET
dpc-5015	46	15	helsinki	helsinki	PROPN
dpc-5015	46	16	declaration	declaration	PROPN
dpc-5015	46	17	.	.	PUNCT
dpc-5015	47	1	the	the	DET
dpc-5015	47	2	study	study	NOUN
dpc-5015	47	3	protocol	protocol	NOUN
dpc-5015	47	4	was	be	AUX
dpc-5015	47	5	approved	approve	VERB
dpc-5015	47	6	by	by	ADP
dpc-5015	47	7	the	the	DET
dpc-5015	47	8	local	local	ADJ
dpc-5015	47	9	ethics	ethic	NOUN
dpc-5015	47	10	committee	committee	PROPN
dpc-5015	47	11	(	(	PUNCT
dpc-5015	47	12	mersin	mersin	PROPN
dpc-5015	47	13	university	university	PROPN
dpc-5015	47	14	)	)	PUNCT
dpc-5015	47	15	on	on	ADP
dpc-5015	47	16	30	30	NUM
dpc-5015	47	17	september	september	PROPN
dpc-5015	47	18	2020	2020	NUM
dpc-5015	47	19	,	,	PUNCT
dpc-5015	47	20	under	under	ADP
dpc-5015	47	21	decision	decision	NOUN
dpc-5015	47	22	number	number	NOUN
dpc-5015	47	23	663	663	NUM
dpc-5015	47	24	.	.	PUNCT
dpc-5015	48	1	prior	prior	ADV
dpc-5015	48	2	to	to	ADP
dpc-5015	48	3	the	the	DET
dpc-5015	48	4	commencement	commencement	NOUN
dpc-5015	48	5	of	of	ADP
dpc-5015	48	6	the	the	DET
dpc-5015	48	7	study	study	NOUN
dpc-5015	48	8	,	,	PUNCT
dpc-5015	48	9	all	all	DET
dpc-5015	48	10	patients	patient	NOUN
dpc-5015	48	11	were	be	AUX
dpc-5015	48	12	adequately	adequately	ADV
dpc-5015	48	13	informed	inform	VERB
dpc-5015	48	14	about	about	ADP
dpc-5015	48	15	the	the	DET
dpc-5015	48	16	research	research	NOUN
dpc-5015	48	17	and	and	CCONJ
dpc-5015	48	18	provided	provide	VERB
dpc-5015	48	19	their	their	PRON
dpc-5015	48	20	written	write	VERB
dpc-5015	48	21	informed	inform	VERB
dpc-5015	48	22	consent	consent	NOUN
dpc-5015	48	23	.	.	PUNCT
dpc-5015	49	1	data	datum	NOUN
dpc-5015	49	2	collection	collection	NOUN
dpc-5015	49	3	demographic	demographic	ADJ
dpc-5015	49	4	data	datum	NOUN
dpc-5015	49	5	,	,	PUNCT
dpc-5015	49	6	height	height	NOUN
dpc-5015	49	7	,	,	PUNCT
dpc-5015	49	8	weight	weight	NOUN
dpc-5015	49	9	,	,	PUNCT
dpc-5015	49	10	waist	waist	NOUN
dpc-5015	49	11	circumference	circumference	NOUN
dpc-5015	49	12	,	,	PUNCT
dpc-5015	49	13	body	body	NOUN
dpc-5015	49	14	mass	mass	NOUN
dpc-5015	49	15	index	index	NOUN
dpc-5015	49	16	(	(	PUNCT
dpc-5015	49	17	bmi	bmi	PROPN
dpc-5015	49	18	)	)	PUNCT
dpc-5015	49	19	,	,	PUNCT
dpc-5015	49	20	alcohol	alcohol	NOUN
dpc-5015	49	21	and	and	CCONJ
dpc-5015	49	22	smoking	smoking	NOUN
dpc-5015	49	23	history	history	NOUN
dpc-5015	49	24	,	,	PUNCT
dpc-5015	49	25	and	and	CCONJ
dpc-5015	49	26	presence	presence	NOUN
dpc-5015	49	27	of	of	ADP
dpc-5015	49	28	metabolic	metabolic	NOUN
dpc-5015	49	29	syndrome	syndrome	NOUN
dpc-5015	49	30	were	be	AUX
dpc-5015	49	31	obtained	obtain	VERB
dpc-5015	49	32	from	from	ADP
dpc-5015	49	33	the	the	DET
dpc-5015	49	34	patients	patient	NOUN
dpc-5015	49	35	and	and	CCONJ
dpc-5015	49	36	the	the	DET
dpc-5015	49	37	control	control	NOUN
dpc-5015	49	38	group	group	NOUN
dpc-5015	49	39	participants	participant	NOUN
dpc-5015	49	40	.	.	PUNCT
dpc-5015	50	1	systolic	systolic	ADJ
dpc-5015	50	2	and	and	CCONJ
dpc-5015	50	3	diastolic	diastolic	ADJ
dpc-5015	50	4	blood	blood	NOUN
dpc-5015	50	5	pressures	pressure	NOUN
dpc-5015	50	6	(	(	PUNCT
dpc-5015	50	7	sbp	sbp	PROPN
dpc-5015	50	8	,	,	PUNCT
dpc-5015	50	9	dbp	dbp	PROPN
dpc-5015	50	10	)	)	PUNCT
dpc-5015	50	11	were	be	AUX
dpc-5015	50	12	measured	measure	VERB
dpc-5015	50	13	by	by	ADP
dpc-5015	50	14	the	the	DET
dpc-5015	50	15	same	same	ADJ
dpc-5015	50	16	investigator	investigator	NOUN
dpc-5015	50	17	using	use	VERB
dpc-5015	50	18	a	a	DET
dpc-5015	50	19	mercury	mercury	NOUN
dpc-5015	50	20	sphygmomanometer	sphygmomanometer	NOUN
dpc-5015	50	21	after	after	ADP
dpc-5015	50	22	a	a	DET
dpc-5015	50	23	20	20	NUM
dpc-5015	50	24	-	-	PUNCT
dpc-5015	50	25	minute	minute	NOUN
dpc-5015	50	26	rest	rest	NOUN
dpc-5015	50	27	in	in	ADP
dpc-5015	50	28	a	a	DET
dpc-5015	50	29	seated	seated	ADJ
dpc-5015	50	30	position	position	NOUN
dpc-5015	50	31	.	.	PUNCT
dpc-5015	51	1	hypertension	hypertension	NOUN
dpc-5015	51	2	was	be	AUX
dpc-5015	51	3	defined	define	VERB
dpc-5015	51	4	as	as	ADP
dpc-5015	51	5	sbp	sbp	PROPN
dpc-5015	51	6	≥140	≥140	PROPN
dpc-5015	51	7	mmhg	mmhg	PROPN
dpc-5015	51	8	and	and	CCONJ
dpc-5015	51	9	dbp	dbp	PROPN
dpc-5015	51	10	≥90	≥90	PROPN
dpc-5015	51	11	mmhg	mmhg	PROPN
dpc-5015	51	12	.	.	PUNCT
dpc-5015	52	1	clinical	clinical	ADJ
dpc-5015	52	2	assessment	assessment	NOUN
dpc-5015	52	3	in	in	ADP
dpc-5015	52	4	this	this	DET
dpc-5015	52	5	study	study	NOUN
dpc-5015	52	6	,	,	PUNCT
dpc-5015	52	7	we	we	PRON
dpc-5015	52	8	evaluated	evaluate	VERB
dpc-5015	52	9	various	various	ADJ
dpc-5015	52	10	clinical	clinical	ADJ
dpc-5015	52	11	aspects	aspect	NOUN
dpc-5015	52	12	in	in	ADP
dpc-5015	52	13	the	the	DET
dpc-5015	52	14	patient	patient	NOUN
dpc-5015	52	15	group	group	NOUN
dpc-5015	52	16	,	,	PUNCT
dpc-5015	52	17	including	include	VERB
dpc-5015	52	18	skin	skin	NOUN
dpc-5015	52	19	phototype	phototype	NOUN
dpc-5015	52	20	,	,	PUNCT
dpc-5015	52	21	rosacea	rosacea	NOUN
dpc-5015	52	22	subtype	subtype	NOUN
dpc-5015	52	23	,	,	PUNCT
dpc-5015	52	24	symptoms	symptom	NOUN
dpc-5015	52	25	,	,	PUNCT
dpc-5015	52	26	triggering	trigger	VERB
dpc-5015	52	27	factors	factor	NOUN
dpc-5015	52	28	,	,	PUNCT
dpc-5015	52	29	flushing	flush	VERB
dpc-5015	52	30	,	,	PUNCT
dpc-5015	52	31	persistent	persistent	ADJ
dpc-5015	52	32	erythema	erythema	NOUN
dpc-5015	52	33	,	,	PUNCT
dpc-5015	52	34	papulopustular	papulopustular	ADJ
dpc-5015	52	35	lesion	lesion	NOUN
dpc-5015	52	36	count	count	NOUN
dpc-5015	52	37	,	,	PUNCT
dpc-5015	52	38	telangiectasia	telangiectasia	NOUN
dpc-5015	52	39	,	,	PUNCT
dpc-5015	52	40	phymatous	phymatous	ADJ
dpc-5015	52	41	changes	change	NOUN
dpc-5015	52	42	,	,	PUNCT
dpc-5015	52	43	edema	edema	NOUN
dpc-5015	52	44	,	,	PUNCT
dpc-5015	52	45	extra	extra	ADJ
dpc-5015	52	46	facial	facial	ADJ
dpc-5015	52	47	involvement	involvement	NOUN
dpc-5015	52	48	,	,	PUNCT
dpc-5015	52	49	ocular	ocular	ADJ
dpc-5015	52	50	symptoms	symptom	NOUN
dpc-5015	52	51	,	,	PUNCT
dpc-5015	52	52	and	and	CCONJ
dpc-5015	52	53	disease	disease	NOUN
dpc-5015	52	54	severity	severity	NOUN
dpc-5015	52	55	.	.	PUNCT
dpc-5015	53	1	we	we	PRON
dpc-5015	53	2	also	also	ADV
dpc-5015	53	3	examined	examine	VERB
dpc-5015	53	4	the	the	DET
dpc-5015	53	5	presence	presence	NOUN
dpc-5015	53	6	of	of	ADP
dpc-5015	53	7	demodex	demodex	NOUN
dpc-5015	53	8	mites	mite	NOUN
dpc-5015	53	9	and	and	CCONJ
dpc-5015	53	10	assessed	assess	VERB
dpc-5015	53	11	past	past	NOUN
dpc-5015	53	12	and	and	CCONJ
dpc-5015	53	13	current	current	ADJ
dpc-5015	53	14	rosacea	rosacea	NOUN
dpc-5015	53	15	treatments	treatment	NOUN
dpc-5015	53	16	.	.	PUNCT
dpc-5015	54	1	parameter	parameter	NOUN
dpc-5015	54	2	severity	severity	NOUN
dpc-5015	54	3	scoring	scoring	NOUN
dpc-5015	54	4	was	be	AUX
dpc-5015	54	5	performed	perform	VERB
dpc-5015	54	6	according	accord	VERB
dpc-5015	54	7	to	to	ADP
dpc-5015	54	8	the	the	DET
dpc-5015	54	9	grading	grade	VERB
dpc-5015	54	10	system	system	NOUN
dpc-5015	54	11	established	establish	VERB
dpc-5015	54	12	by	by	ADP
dpc-5015	54	13	the	the	DET
dpc-5015	54	14	national	national	PROPN
dpc-5015	54	15	rosacea	rosacea	PROPN
dpc-5015	54	16	society	society	NOUN
dpc-5015	54	17	in	in	ADP
dpc-5015	54	18	2004	2004	NUM
dpc-5015	54	19	:	:	PUNCT
dpc-5015	54	20	0	0	NUM
dpc-5015	55	1	–	–	PUNCT
dpc-5015	55	2	absent	absent	ADJ
dpc-5015	55	3	,	,	PUNCT
dpc-5015	55	4	1	1	NUM
dpc-5015	55	5	–	–	PUNCT
dpc-5015	55	6	mild	mild	ADJ
dpc-5015	55	7	,	,	PUNCT
dpc-5015	55	8	2	2	NUM
dpc-5015	55	9	–	–	PUNCT
dpc-5015	55	10	moderate	moderate	ADJ
dpc-5015	55	11	,	,	PUNCT
dpc-5015	55	12	3	3	NUM
dpc-5015	55	13	–	–	PUNCT
dpc-5015	55	14	severe	severe	ADJ
dpc-5015	55	15	[	[	X
dpc-5015	55	16	35	35	NUM
dpc-5015	55	17	]	]	PUNCT
dpc-5015	55	18	.	.	PUNCT
dpc-5015	56	1	in	in	ADP
dpc-5015	56	2	this	this	DET
dpc-5015	56	3	study	study	NOUN
dpc-5015	56	4	,	,	PUNCT
dpc-5015	56	5	demodex	demodex	NOUN
dpc-5015	56	6	mites	mite	NOUN
dpc-5015	56	7	were	be	AUX
dpc-5015	56	8	detected	detect	VERB
dpc-5015	56	9	using	use	VERB
dpc-5015	56	10	the	the	DET
dpc-5015	56	11	standardized	standardized	ADJ
dpc-5015	56	12	skin	skin	NOUN
dpc-5015	56	13	surface	surface	NOUN
dpc-5015	56	14	biopsy	biopsy	NOUN
dpc-5015	56	15	method	method	NOUN
dpc-5015	56	16	.	.	PUNCT
dpc-5015	57	1	cases	case	NOUN
dpc-5015	57	2	in	in	ADP
dpc-5015	57	3	which	which	PRON
dpc-5015	57	4	more	more	ADJ
dpc-5015	57	5	than	than	ADP
dpc-5015	57	6	five	five	NUM
dpc-5015	57	7	demodex	demodex	NOUN
dpc-5015	57	8	mites	mite	NOUN
dpc-5015	57	9	were	be	AUX
dpc-5015	57	10	observed	observe	VERB
dpc-5015	57	11	in	in	ADP
dpc-5015	57	12	the	the	DET
dpc-5015	57	13	1	1	NUM
dpc-5015	57	14	cm2	cm2	NOUN
dpc-5015	57	15	area	area	NOUN
dpc-5015	57	16	were	be	AUX
dpc-5015	57	17	classified	classify	VERB
dpc-5015	57	18	as	as	ADP
dpc-5015	57	19	positive	positive	ADJ
dpc-5015	57	20	for	for	ADP
dpc-5015	57	21	demodex	demodex	NOUN
dpc-5015	57	22	infestation	infestation	NOUN
dpc-5015	57	23	[	[	X
dpc-5015	57	24	36	36	NUM
dpc-5015	57	25	]	]	PUNCT
dpc-5015	57	26	.	.	PUNCT
dpc-5015	58	1	measurement	measurement	NOUN
dpc-5015	58	2	of	of	ADP
dpc-5015	58	3	biochemical	biochemical	ADJ
dpc-5015	58	4	measurements	measurement	NOUN
dpc-5015	58	5	peripheral	peripheral	ADJ
dpc-5015	58	6	venous	venous	ADJ
dpc-5015	58	7	blood	blood	NOUN
dpc-5015	58	8	samples	sample	NOUN
dpc-5015	58	9	were	be	AUX
dpc-5015	58	10	taken	take	VERB
dpc-5015	58	11	from	from	ADP
dpc-5015	58	12	the	the	DET
dpc-5015	58	13	patient	patient	ADJ
dpc-5015	58	14	and	and	CCONJ
dpc-5015	58	15	control	control	NOUN
dpc-5015	58	16	groups	group	NOUN
dpc-5015	58	17	in	in	ADP
dpc-5015	58	18	vacutainer	vacutainer	ADJ
dpc-5015	58	19	tubes	tube	NOUN
dpc-5015	58	20	without	without	ADP
dpc-5015	58	21	additives	additive	NOUN
dpc-5015	58	22	after	after	ADP
dpc-5015	58	23	a	a	DET
dpc-5015	58	24	12	12	NUM
dpc-5015	58	25	-	-	PUNCT
dpc-5015	58	26	hour	hour	NOUN
dpc-5015	58	27	fast	fast	ADV
dpc-5015	58	28	between	between	ADP
dpc-5015	58	29	07:00	07:00	NUM
dpc-5015	58	30	-	-	SYM
dpc-5015	58	31	08:00	08:00	NUM
dpc-5015	58	32	am	am	NOUN
dpc-5015	58	33	,	,	PUNCT
dpc-5015	58	34	without	without	ADP
dpc-5015	58	35	original	original	ADJ
dpc-5015	58	36	article	article	NOUN
dpc-5015	58	37	|	|	ADV
dpc-5015	58	38	dermatol	dermatol	ADJ
dpc-5015	58	39	pract	pract	NOUN
dpc-5015	58	40	concept	concept	NOUN
dpc-5015	58	41	.	.	PUNCT
dpc-5015	59	1	2025;15(3):5015	2025;15(3):5015	NUM
dpc-5015	59	2	3	3	NUM
dpc-5015	59	3	stasis	stasis	NOUN
dpc-5015	59	4	,	,	PUNCT
dpc-5015	59	5	following	follow	VERB
dpc-5015	59	6	at	at	ADP
dpc-5015	59	7	least	least	ADV
dpc-5015	59	8	20	20	NUM
dpc-5015	59	9	minutes	minute	NOUN
dpc-5015	59	10	of	of	ADP
dpc-5015	59	11	rest	rest	NOUN
dpc-5015	59	12	.	.	PUNCT
dpc-5015	60	1	care	care	NOUN
dpc-5015	60	2	was	be	AUX
dpc-5015	60	3	taken	take	VERB
dpc-5015	60	4	to	to	PART
dpc-5015	60	5	ensure	ensure	VERB
dpc-5015	60	6	that	that	SCONJ
dpc-5015	60	7	participants	participant	NOUN
dpc-5015	60	8	did	do	AUX
dpc-5015	60	9	not	not	PART
dpc-5015	60	10	use	use	VERB
dpc-5015	60	11	medications	medication	NOUN
dpc-5015	60	12	,	,	PUNCT
dpc-5015	60	13	smoke	smoke	NOUN
dpc-5015	60	14	,	,	PUNCT
dpc-5015	60	15	or	or	CCONJ
dpc-5015	60	16	consume	consume	VERB
dpc-5015	60	17	alcohol	alcohol	NOUN
dpc-5015	60	18	before	before	ADP
dpc-5015	60	19	blood	blood	NOUN
dpc-5015	60	20	collection	collection	NOUN
dpc-5015	60	21	.	.	PUNCT
dpc-5015	61	1	after	after	ADP
dpc-5015	61	2	15	15	NUM
dpc-5015	61	3	minutes	minute	NOUN
dpc-5015	61	4	,	,	PUNCT
dpc-5015	61	5	the	the	DET
dpc-5015	61	6	blood	blood	NOUN
dpc-5015	61	7	samples	sample	NOUN
dpc-5015	61	8	were	be	AUX
dpc-5015	61	9	centrifuged	centrifuge	VERB
dpc-5015	61	10	at	at	ADP
dpc-5015	61	11	4000	4000	NUM
dpc-5015	61	12	rpm	rpm	NOUN
dpc-5015	61	13	for	for	ADP
dpc-5015	61	14	10	10	NUM
dpc-5015	61	15	minutes	minute	NOUN
dpc-5015	61	16	.	.	PUNCT
dpc-5015	62	1	after	after	ADP
dpc-5015	62	2	centrifugation	centrifugation	NOUN
dpc-5015	62	3	,	,	PUNCT
dpc-5015	62	4	serum	serum	NOUN
dpc-5015	62	5	aliquots	aliquot	NOUN
dpc-5015	62	6	were	be	AUX
dpc-5015	62	7	stored	store	VERB
dpc-5015	62	8	at	at	ADP
dpc-5015	62	9	-80	-80	NUM
dpc-5015	62	10	°	°	NOUN
dpc-5015	62	11	c	c	NOUN
dpc-5015	62	12	until	until	ADP
dpc-5015	62	13	analysis	analysis	NOUN
dpc-5015	62	14	.	.	PUNCT
dpc-5015	63	1	endocan	endocan	ADJ
dpc-5015	63	2	,	,	PUNCT
dpc-5015	63	3	endoglin	endoglin	NOUN
dpc-5015	63	4	,	,	PUNCT
dpc-5015	63	5	insulin	insulin	NOUN
dpc-5015	63	6	,	,	PUNCT
dpc-5015	63	7	glucose	glucose	NOUN
dpc-5015	63	8	,	,	PUNCT
dpc-5015	63	9	total	total	ADJ
dpc-5015	63	10	cholesterol	cholesterol	NOUN
dpc-5015	63	11	,	,	PUNCT
dpc-5015	63	12	high	high	ADJ
dpc-5015	63	13	-	-	PUNCT
dpc-5015	63	14	density	density	NOUN
dpc-5015	63	15	lipoprotein	lipoprotein	ADJ
dpc-5015	63	16	(	(	PUNCT
dpc-5015	63	17	hdl	hdl	NOUN
dpc-5015	63	18	)	)	PUNCT
dpc-5015	63	19	,	,	PUNCT
dpc-5015	63	20	triglyceride	triglyceride	INTJ
dpc-5015	63	21	(	(	PUNCT
dpc-5015	63	22	tg	tg	INTJ
dpc-5015	63	23	)	)	PUNCT
dpc-5015	63	24	,	,	PUNCT
dpc-5015	63	25	and	and	CCONJ
dpc-5015	63	26	c	c	X
dpc-5015	63	27	-	-	PUNCT
dpc-5015	63	28	reactive	reactive	ADJ
dpc-5015	63	29	protein	protein	NOUN
dpc-5015	63	30	(	(	PUNCT
dpc-5015	63	31	crp	crp	NOUN
dpc-5015	63	32	)	)	PUNCT
dpc-5015	63	33	levels	level	NOUN
dpc-5015	63	34	were	be	AUX
dpc-5015	63	35	measured	measure	VERB
dpc-5015	63	36	on	on	ADP
dpc-5015	63	37	the	the	DET
dpc-5015	63	38	same	same	ADJ
dpc-5015	63	39	day	day	NOUN
dpc-5015	63	40	.	.	PUNCT
dpc-5015	64	1	insulin	insulin	NOUN
dpc-5015	64	2	levels	level	NOUN
dpc-5015	64	3	were	be	AUX
dpc-5015	64	4	measured	measure	VERB
dpc-5015	64	5	by	by	ADP
dpc-5015	64	6	chemiluminescence	chemiluminescence	NOUN
dpc-5015	64	7	immunoassay	immunoassay	PROPN
dpc-5015	64	8	,	,	PUNCT
dpc-5015	64	9	glucose	glucose	NOUN
dpc-5015	64	10	and	and	CCONJ
dpc-5015	64	11	total	total	ADJ
dpc-5015	64	12	cholesterol	cholesterol	NOUN
dpc-5015	64	13	levels	level	NOUN
dpc-5015	64	14	by	by	ADP
dpc-5015	64	15	enzymatic	enzymatic	ADJ
dpc-5015	64	16	assays	assay	NOUN
dpc-5015	64	17	,	,	PUNCT
dpc-5015	64	18	hdl	hdl	PROPN
dpc-5015	64	19	and	and	CCONJ
dpc-5015	64	20	tg	tg	PROPN
dpc-5015	64	21	levels	level	NOUN
dpc-5015	64	22	by	by	ADP
dpc-5015	64	23	enzymatic	enzymatic	ADJ
dpc-5015	64	24	calorimetric	calorimetric	ADJ
dpc-5015	64	25	assays	assay	NOUN
dpc-5015	64	26	,	,	PUNCT
dpc-5015	64	27	crp	crp	PROPN
dpc-5015	64	28	levels	level	NOUN
dpc-5015	64	29	by	by	ADP
dpc-5015	64	30	an	an	DET
dpc-5015	64	31	immunoturbidimetric	immunoturbidimetric	ADJ
dpc-5015	64	32	assay	assay	NOUN
dpc-5015	64	33	,	,	PUNCT
dpc-5015	64	34	and	and	CCONJ
dpc-5015	64	35	sedimentation	sedimentation	NOUN
dpc-5015	64	36	levels	level	NOUN
dpc-5015	64	37	by	by	ADP
dpc-5015	64	38	the	the	DET
dpc-5015	64	39	westergren	westergren	PROPN
dpc-5015	64	40	method	method	PROPN
dpc-5015	64	41	.	.	PUNCT
dpc-5015	65	1	low	low	ADJ
dpc-5015	65	2	-	-	PUNCT
dpc-5015	65	3	density	density	NOUN
dpc-5015	65	4	lipoprotein	lipoprotein	ADJ
dpc-5015	65	5	(	(	PUNCT
dpc-5015	65	6	ldl	ldl	NOUN
dpc-5015	65	7	)	)	PUNCT
dpc-5015	65	8	levels	level	NOUN
dpc-5015	65	9	were	be	AUX
dpc-5015	65	10	calculated	calculate	VERB
dpc-5015	65	11	using	use	VERB
dpc-5015	65	12	the	the	DET
dpc-5015	65	13	friedwaid	friedwaid	ADJ
dpc-5015	65	14	formula	formula	NOUN
dpc-5015	65	15	.	.	PUNCT
dpc-5015	66	1	insulin	insulin	NOUN
dpc-5015	66	2	resistance	resistance	NOUN
dpc-5015	66	3	was	be	AUX
dpc-5015	66	4	assessed	assess	VERB
dpc-5015	66	5	utilizing	utilize	VERB
dpc-5015	66	6	the	the	DET
dpc-5015	66	7	homeostasis	homeostasis	NOUN
dpc-5015	66	8	model	model	NOUN
dpc-5015	66	9	assessment	assessment	NOUN
dpc-5015	66	10	of	of	ADP
dpc-5015	66	11	insulin	insulin	NOUN
dpc-5015	66	12	resistance	resistance	NOUN
dpc-5015	66	13	(	(	PUNCT
dpc-5015	66	14	homa	homa	NOUN
dpc-5015	66	15	-	-	PUNCT
dpc-5015	66	16	ir	ir	NOUN
dpc-5015	66	17	)	)	PUNCT
dpc-5015	66	18	,	,	PUNCT
dpc-5015	66	19	employing	employ	VERB
dpc-5015	66	20	the	the	DET
dpc-5015	66	21	following	follow	VERB
dpc-5015	66	22	formula	formula	NOUN
dpc-5015	66	23	:	:	PUNCT
dpc-5015	66	24	homa	homa	NOUN
dpc-5015	66	25	-	-	PUNCT
dpc-5015	66	26	ir	ir	NOUN
dpc-5015	66	27	=	=	NOUN
dpc-5015	66	28	fasting	fast	VERB
dpc-5015	66	29	insulin	insulin	NOUN
dpc-5015	66	30	level	level	NOUN
dpc-5015	66	31	(	(	PUNCT
dpc-5015	66	32	uiu	uiu	PROPN
dpc-5015	66	33	/	/	SYM
dpc-5015	66	34	ml	ml	NOUN
dpc-5015	66	35	)	)	PUNCT
dpc-5015	66	36	×	×	NOUN
dpc-5015	66	37	fasting	fast	VERB
dpc-5015	66	38	glucose	glucose	NOUN
dpc-5015	66	39	level	level	NOUN
dpc-5015	66	40	(	(	PUNCT
dpc-5015	66	41	mg	mg	PROPN
dpc-5015	66	42	/	/	SYM
dpc-5015	66	43	dl	dl	PROPN
dpc-5015	66	44	)	)	PUNCT
dpc-5015	66	45	/405	/405	PUNCT
dpc-5015	66	46	.	.	PUNCT
dpc-5015	67	1	a	a	DET
dpc-5015	67	2	homa	homa	NOUN
dpc-5015	67	3	-	-	PUNCT
dpc-5015	67	4	ir	ir	NOUN
dpc-5015	67	5	value	value	NOUN
dpc-5015	67	6	exceeding	exceed	VERB
dpc-5015	67	7	2	2	NUM
dpc-5015	67	8	was	be	AUX
dpc-5015	67	9	indicative	indicative	ADJ
dpc-5015	67	10	of	of	ADP
dpc-5015	67	11	insulin	insulin	NOUN
dpc-5015	67	12	resistance	resistance	NOUN
dpc-5015	67	13	.	.	PUNCT
dpc-5015	68	1	on	on	ADP
dpc-5015	68	2	the	the	DET
dpc-5015	68	3	analysis	analysis	NOUN
dpc-5015	68	4	day	day	NOUN
dpc-5015	68	5	,	,	PUNCT
dpc-5015	68	6	the	the	DET
dpc-5015	68	7	serum	serum	NOUN
dpc-5015	68	8	samples	sample	NOUN
dpc-5015	68	9	stored	store	VERB
dpc-5015	68	10	at	at	ADP
dpc-5015	68	11	-80	-80	NUM
dpc-5015	68	12	°	°	ADP
dpc-5015	68	13	c	c	NOUN
dpc-5015	68	14	were	be	AUX
dpc-5015	68	15	brought	bring	VERB
dpc-5015	68	16	to	to	ADP
dpc-5015	68	17	room	room	NOUN
dpc-5015	68	18	temperature	temperature	NOUN
dpc-5015	68	19	,	,	PUNCT
dpc-5015	68	20	and	and	CCONJ
dpc-5015	68	21	serum	serum	NOUN
dpc-5015	68	22	endocan	endocan	PROPN
dpc-5015	68	23	(	(	PUNCT
dpc-5015	68	24	bioassay	bioassay	NOUN
dpc-5015	68	25	technology	technology	PROPN
dpc-5015	68	26	laboratory	laboratory	NOUN
dpc-5015	68	27	,	,	PUNCT
dpc-5015	68	28	e3160hu	e3160hu	PROPN
dpc-5015	68	29	)	)	PUNCT
dpc-5015	68	30	and	and	CCONJ
dpc-5015	68	31	endoglin	endoglin	NOUN
dpc-5015	68	32	(	(	PUNCT
dpc-5015	68	33	bioassay	bioassay	NOUN
dpc-5015	68	34	technology	technology	PROPN
dpc-5015	68	35	laboratory	laboratory	NOUN
dpc-5015	68	36	,	,	PUNCT
dpc-5015	68	37	e3407hu	e3407hu	NOUN
dpc-5015	68	38	)	)	PUNCT
dpc-5015	68	39	levels	level	NOUN
dpc-5015	68	40	were	be	AUX
dpc-5015	68	41	measured	measure	VERB
dpc-5015	68	42	according	accord	VERB
dpc-5015	68	43	to	to	ADP
dpc-5015	68	44	the	the	DET
dpc-5015	68	45	manufacturer	manufacturer	NOUN
dpc-5015	68	46	’s	’s	PART
dpc-5015	68	47	recommended	recommend	VERB
dpc-5015	68	48	protocol	protocol	NOUN
dpc-5015	68	49	using	use	VERB
dpc-5015	68	50	the	the	DET
dpc-5015	68	51	dsx	dsx	PROPN
dpc-5015	68	52	4	4	NUM
dpc-5015	68	53	-	-	PUNCT
dpc-5015	68	54	plate	plate	NOUN
dpc-5015	68	55	automated	automate	VERB
dpc-5015	68	56	enzyme	enzyme	NOUN
dpc-5015	68	57	-	-	PUNCT
dpc-5015	68	58	linked	link	VERB
dpc-5015	68	59	immunosorbent	immunosorbent	NOUN
dpc-5015	68	60	assay	assay	PROPN
dpc-5015	68	61	(	(	PUNCT
dpc-5015	68	62	elisa	elisa	NOUN
dpc-5015	68	63	)	)	PUNCT
dpc-5015	68	64	processing	processing	NOUN
dpc-5015	68	65	system	system	NOUN
dpc-5015	68	66	.	.	PUNCT
dpc-5015	69	1	the	the	DET
dpc-5015	69	2	concentration	concentration	NOUN
dpc-5015	69	3	of	of	ADP
dpc-5015	69	4	each	each	DET
dpc-5015	69	5	sample	sample	NOUN
dpc-5015	69	6	was	be	AUX
dpc-5015	69	7	calculated	calculate	VERB
dpc-5015	69	8	using	use	VERB
dpc-5015	69	9	the	the	DET
dpc-5015	69	10	equation	equation	NOUN
dpc-5015	69	11	and	and	CCONJ
dpc-5015	69	12	curve	curve	NOUN
dpc-5015	69	13	drawn	draw	VERB
dpc-5015	69	14	with	with	ADP
dpc-5015	69	15	optical	optical	ADJ
dpc-5015	69	16	density	density	NOUN
dpc-5015	69	17	(	(	PUNCT
dpc-5015	69	18	od	od	NOUN
dpc-5015	69	19	)	)	PUNCT
dpc-5015	69	20	values	value	NOUN
dpc-5015	69	21	corresponding	correspond	VERB
dpc-5015	69	22	to	to	ADP
dpc-5015	69	23	known	know	VERB
dpc-5015	69	24	standards	standard	NOUN
dpc-5015	69	25	for	for	ADP
dpc-5015	69	26	each	each	DET
dpc-5015	69	27	analysis	analysis	NOUN
dpc-5015	69	28	.	.	PUNCT
dpc-5015	70	1	statistical	statistical	ADJ
dpc-5015	70	2	analysis	analysis	NOUN
dpc-5015	70	3	the	the	DET
dpc-5015	70	4	analyses	analysis	NOUN
dpc-5015	70	5	were	be	AUX
dpc-5015	70	6	performed	perform	VERB
dpc-5015	70	7	using	use	VERB
dpc-5015	70	8	statistica	statistica	PROPN
dpc-5015	70	9	v.13.3.1	v.13.3.1	PROPN
dpc-5015	70	10	software	software	NOUN
dpc-5015	70	11	.	.	PUNCT
dpc-5015	71	1	a	a	DET
dpc-5015	71	2	p	p	NOUN
dpc-5015	71	3	-	-	PUNCT
dpc-5015	71	4	value	value	NOUN
dpc-5015	71	5	of	of	ADP
dpc-5015	71	6	<	<	NOUN
dpc-5015	71	7	0.05	0.05	NUM
dpc-5015	71	8	was	be	AUX
dpc-5015	71	9	considered	consider	VERB
dpc-5015	71	10	statistically	statistically	ADV
dpc-5015	71	11	significant	significant	ADJ
dpc-5015	71	12	.	.	PUNCT
dpc-5015	72	1	the	the	DET
dpc-5015	72	2	normal	normal	ADJ
dpc-5015	72	3	distribution	distribution	NOUN
dpc-5015	72	4	of	of	ADP
dpc-5015	72	5	variables	variable	NOUN
dpc-5015	72	6	was	be	AUX
dpc-5015	72	7	assessed	assess	VERB
dpc-5015	72	8	using	use	VERB
dpc-5015	72	9	the	the	DET
dpc-5015	72	10	shapiro	shapiro	PROPN
dpc-5015	72	11	-	-	PUNCT
dpc-5015	72	12	wilk	wilk	NOUN
dpc-5015	72	13	test	test	NOUN
dpc-5015	72	14	.	.	PUNCT
dpc-5015	73	1	normally	normally	ADV
dpc-5015	73	2	distributed	distribute	VERB
dpc-5015	73	3	continuous	continuous	ADJ
dpc-5015	73	4	variables	variable	NOUN
dpc-5015	73	5	were	be	AUX
dpc-5015	73	6	summarized	summarize	VERB
dpc-5015	73	7	as	as	ADP
dpc-5015	73	8	mean	mean	NOUN
dpc-5015	73	9	±	±	NUM
dpc-5015	73	10	standard	standard	ADJ
dpc-5015	73	11	deviation	deviation	NOUN
dpc-5015	73	12	,	,	PUNCT
dpc-5015	73	13	and	and	CCONJ
dpc-5015	73	14	non	non	ADJ
dpc-5015	73	15	-	-	ADJ
dpc-5015	73	16	normally	normally	ADV
dpc-5015	73	17	distributed	distribute	VERB
dpc-5015	73	18	variables	variable	NOUN
dpc-5015	73	19	were	be	AUX
dpc-5015	73	20	summarized	summarize	VERB
dpc-5015	73	21	as	as	ADP
dpc-5015	73	22	median	median	PROPN
dpc-5015	73	23	[	[	X
dpc-5015	73	24	25th-75th	25th-75th	NUM
dpc-5015	73	25	percentile	percentile	NOUN
dpc-5015	73	26	]	]	PUNCT
dpc-5015	73	27	.	.	PUNCT
dpc-5015	74	1	categorical	categorical	ADJ
dpc-5015	74	2	variables	variable	NOUN
dpc-5015	74	3	were	be	AUX
dpc-5015	74	4	summarized	summarize	VERB
dpc-5015	74	5	as	as	ADP
dpc-5015	74	6	numbers	number	NOUN
dpc-5015	74	7	and	and	CCONJ
dpc-5015	74	8	percentages	percentage	NOUN
dpc-5015	74	9	.	.	PUNCT
dpc-5015	75	1	independent	independent	ADJ
dpc-5015	75	2	samples	sample	NOUN
dpc-5015	75	3	t	t	NOUN
dpc-5015	75	4	-	-	PUNCT
dpc-5015	75	5	test	test	NOUN
dpc-5015	75	6	was	be	AUX
dpc-5015	75	7	used	use	VERB
dpc-5015	75	8	for	for	ADP
dpc-5015	75	9	group	group	NOUN
dpc-5015	75	10	comparisons	comparison	NOUN
dpc-5015	75	11	when	when	SCONJ
dpc-5015	75	12	the	the	DET
dpc-5015	75	13	assumptions	assumption	NOUN
dpc-5015	75	14	were	be	AUX
dpc-5015	75	15	met	meet	VERB
dpc-5015	75	16	;	;	PUNCT
dpc-5015	75	17	otherwise	otherwise	ADV
dpc-5015	75	18	,	,	PUNCT
dpc-5015	75	19	the	the	DET
dpc-5015	75	20	mann	mann	PROPN
dpc-5015	75	21	-	-	PUNCT
dpc-5015	75	22	whitney	whitney	PROPN
dpc-5015	75	23	u	u	PROPN
dpc-5015	75	24	test	test	NOUN
dpc-5015	75	25	and	and	CCONJ
dpc-5015	75	26	kruskal	kruskal	PROPN
dpc-5015	75	27	-	-	PUNCT
dpc-5015	75	28	wallis	wallis	PROPN
dpc-5015	75	29	test	test	NOUN
dpc-5015	75	30	were	be	AUX
dpc-5015	75	31	used	use	VERB
dpc-5015	75	32	for	for	ADP
dpc-5015	75	33	multiple	multiple	ADJ
dpc-5015	75	34	group	group	NOUN
dpc-5015	75	35	comparisons	comparison	NOUN
dpc-5015	75	36	,	,	PUNCT
dpc-5015	75	37	followed	follow	VERB
dpc-5015	75	38	by	by	ADP
dpc-5015	75	39	the	the	DET
dpc-5015	75	40	dunn	dunn	PROPN
dpc-5015	75	41	test	test	NOUN
dpc-5015	75	42	as	as	ADP
dpc-5015	75	43	the	the	DET
dpc-5015	75	44	post	post	X
dpc-5015	75	45	hoc	hoc	X
dpc-5015	75	46	test	test	NOUN
dpc-5015	75	47	.	.	PUNCT
dpc-5015	76	1	spearman	spearman	NOUN
dpc-5015	76	2	’s	’s	PART
dpc-5015	76	3	correlation	correlation	NOUN
dpc-5015	76	4	coefficient	coefficient	NOUN
dpc-5015	76	5	was	be	AUX
dpc-5015	76	6	used	use	VERB
dpc-5015	76	7	to	to	PART
dpc-5015	76	8	investigate	investigate	VERB
dpc-5015	76	9	the	the	DET
dpc-5015	76	10	relationship	relationship	NOUN
dpc-5015	76	11	between	between	ADP
dpc-5015	76	12	continuous	continuous	ADJ
dpc-5015	76	13	variables	variable	NOUN
dpc-5015	76	14	,	,	PUNCT
dpc-5015	76	15	while	while	SCONJ
dpc-5015	76	16	the	the	DET
dpc-5015	76	17	chisquared	chisquared	ADJ
dpc-5015	76	18	test	test	NOUN
dpc-5015	76	19	and	and	CCONJ
dpc-5015	76	20	fisher	fisher	PROPN
dpc-5015	76	21	’s	’s	PART
dpc-5015	76	22	exact	exact	ADJ
dpc-5015	76	23	test	test	NOUN
dpc-5015	76	24	were	be	AUX
dpc-5015	76	25	used	use	VERB
dpc-5015	76	26	to	to	PART
dpc-5015	76	27	investigate	investigate	VERB
dpc-5015	76	28	the	the	DET
dpc-5015	76	29	relationship	relationship	NOUN
dpc-5015	76	30	between	between	ADP
dpc-5015	76	31	categorical	categorical	ADJ
dpc-5015	76	32	variables	variable	NOUN
dpc-5015	76	33	when	when	SCONJ
dpc-5015	76	34	the	the	DET
dpc-5015	76	35	expected	expect	VERB
dpc-5015	76	36	frequency	frequency	NOUN
dpc-5015	76	37	was	be	AUX
dpc-5015	76	38	less	less	ADJ
dpc-5015	76	39	than	than	ADP
dpc-5015	76	40	five	five	NUM
dpc-5015	76	41	and	and	CCONJ
dpc-5015	76	42	the	the	DET
dpc-5015	76	43	percentage	percentage	NOUN
dpc-5015	76	44	was	be	AUX
dpc-5015	76	45	greater	great	ADJ
dpc-5015	76	46	than	than	ADP
dpc-5015	76	47	20	20	NUM
dpc-5015	76	48	%	%	NOUN
dpc-5015	76	49	.	.	PUNCT
dpc-5015	77	1	bonferroni	bonferroni	PROPN
dpc-5015	77	2	correction	correction	NOUN
dpc-5015	77	3	was	be	AUX
dpc-5015	77	4	applied	apply	VERB
dpc-5015	77	5	for	for	ADP
dpc-5015	77	6	pairwise	pairwise	NOUN
dpc-5015	77	7	comparisons	comparison	NOUN
dpc-5015	77	8	.	.	PUNCT
dpc-5015	78	1	results	result	VERB
dpc-5015	78	2	the	the	DET
dpc-5015	78	3	study	study	NOUN
dpc-5015	78	4	included	include	VERB
dpc-5015	78	5	44	44	NUM
dpc-5015	78	6	rosacea	rosacea	NOUN
dpc-5015	78	7	patients	patient	NOUN
dpc-5015	78	8	and	and	CCONJ
dpc-5015	78	9	33	33	NUM
dpc-5015	78	10	individuals	individual	NOUN
dpc-5015	78	11	in	in	ADP
dpc-5015	78	12	the	the	DET
dpc-5015	78	13	control	control	NOUN
dpc-5015	78	14	group	group	NOUN
dpc-5015	78	15	.	.	PUNCT
dpc-5015	79	1	the	the	DET
dpc-5015	79	2	mean	mean	ADJ
dpc-5015	79	3	age	age	NOUN
dpc-5015	79	4	of	of	ADP
dpc-5015	79	5	the	the	DET
dpc-5015	79	6	patients	patient	NOUN
dpc-5015	79	7	was	be	AUX
dpc-5015	79	8	45.05	45.05	NUM
dpc-5015	79	9	±	±	NUM
dpc-5015	79	10	10.9	10.9	NUM
dpc-5015	79	11	years	year	NOUN
dpc-5015	79	12	,	,	PUNCT
dpc-5015	79	13	whereas	whereas	SCONJ
dpc-5015	79	14	the	the	DET
dpc-5015	79	15	mean	mean	ADJ
dpc-5015	79	16	age	age	NOUN
dpc-5015	79	17	of	of	ADP
dpc-5015	79	18	the	the	DET
dpc-5015	79	19	control	control	NOUN
dpc-5015	79	20	group	group	NOUN
dpc-5015	79	21	was	be	AUX
dpc-5015	79	22	45.21	45.21	NUM
dpc-5015	79	23	±	±	NUM
dpc-5015	79	24	8.70	8.70	NUM
dpc-5015	79	25	years	year	NOUN
dpc-5015	79	26	.	.	PUNCT
dpc-5015	80	1	among	among	ADP
dpc-5015	80	2	the	the	DET
dpc-5015	80	3	patients	patient	NOUN
dpc-5015	80	4	,	,	PUNCT
dpc-5015	80	5	77.3	77.3	NUM
dpc-5015	80	6	%	%	NOUN
dpc-5015	80	7	(	(	PUNCT
dpc-5015	80	8	n=34	n=34	NOUN
dpc-5015	80	9	)	)	PUNCT
dpc-5015	80	10	were	be	AUX
dpc-5015	80	11	female	female	ADJ
dpc-5015	80	12	,	,	PUNCT
dpc-5015	80	13	while	while	SCONJ
dpc-5015	80	14	22.7	22.7	NUM
dpc-5015	80	15	%	%	NOUN
dpc-5015	80	16	(	(	PUNCT
dpc-5015	80	17	n=10	n=10	NOUN
dpc-5015	80	18	)	)	PUNCT
dpc-5015	80	19	were	be	AUX
dpc-5015	80	20	male	male	ADJ
dpc-5015	80	21	.	.	PUNCT
dpc-5015	81	1	no	no	DET
dpc-5015	81	2	significant	significant	ADJ
dpc-5015	81	3	difference	difference	NOUN
dpc-5015	81	4	was	be	AUX
dpc-5015	81	5	observed	observe	VERB
dpc-5015	81	6	in	in	ADP
dpc-5015	81	7	sex	sex	NOUN
dpc-5015	81	8	and	and	CCONJ
dpc-5015	81	9	age	age	NOUN
dpc-5015	81	10	distribution	distribution	NOUN
dpc-5015	81	11	between	between	ADP
dpc-5015	81	12	the	the	DET
dpc-5015	81	13	control	control	NOUN
dpc-5015	81	14	and	and	CCONJ
dpc-5015	81	15	patient	patient	ADJ
dpc-5015	81	16	groups	group	NOUN
dpc-5015	81	17	(	(	PUNCT
dpc-5015	81	18	p=1	p=1	NOUN
dpc-5015	81	19	,	,	PUNCT
dpc-5015	81	20	p=0.983	p=0.983	NOUN
dpc-5015	81	21	,	,	PUNCT
dpc-5015	81	22	respectively	respectively	ADV
dpc-5015	81	23	)	)	PUNCT
dpc-5015	81	24	.	.	PUNCT
dpc-5015	82	1	the	the	DET
dpc-5015	82	2	mean	mean	ADJ
dpc-5015	82	3	body	body	NOUN
dpc-5015	82	4	mass	mass	NOUN
dpc-5015	82	5	index	index	NOUN
dpc-5015	82	6	of	of	ADP
dpc-5015	82	7	the	the	DET
dpc-5015	82	8	patient	patient	NOUN
dpc-5015	82	9	group	group	NOUN
dpc-5015	82	10	was	be	AUX
dpc-5015	82	11	26.8	26.8	NUM
dpc-5015	82	12	±	±	NUM
dpc-5015	82	13	3.8	3.8	NUM
dpc-5015	82	14	kg	kg	NOUN
dpc-5015	82	15	/	/	SYM
dpc-5015	82	16	m²	m²	PROPN
dpc-5015	82	17	,	,	PUNCT
dpc-5015	82	18	and	and	CCONJ
dpc-5015	82	19	the	the	DET
dpc-5015	82	20	mean	mean	ADJ
dpc-5015	82	21	waist	waist	NOUN
dpc-5015	82	22	circumference	circumference	NOUN
dpc-5015	82	23	was	be	AUX
dpc-5015	82	24	92.07	92.07	NUM
dpc-5015	82	25	±	±	NUM
dpc-5015	82	26	12.1	12.1	NUM
dpc-5015	82	27	cm	cm	NOUN
dpc-5015	82	28	.	.	PUNCT
dpc-5015	83	1	the	the	DET
dpc-5015	83	2	two	two	NUM
dpc-5015	83	3	groups	group	NOUN
dpc-5015	83	4	had	have	VERB
dpc-5015	83	5	no	no	DET
dpc-5015	83	6	significant	significant	ADJ
dpc-5015	83	7	differences	difference	NOUN
dpc-5015	83	8	in	in	ADP
dpc-5015	83	9	bmi	bmi	NOUN
dpc-5015	83	10	and	and	CCONJ
dpc-5015	83	11	waist	waist	NOUN
dpc-5015	83	12	circumference	circumference	NOUN
dpc-5015	83	13	(	(	PUNCT
dpc-5015	83	14	p=0.735	p=0.735	NOUN
dpc-5015	83	15	,	,	PUNCT
dpc-5015	83	16	p=0.336	p=0.336	NOUN
dpc-5015	83	17	,	,	PUNCT
dpc-5015	83	18	respectively	respectively	ADV
dpc-5015	83	19	)	)	PUNCT
dpc-5015	83	20	.	.	PUNCT
dpc-5015	84	1	regarding	regard	VERB
dpc-5015	84	2	hdl	hdl	PROPN
dpc-5015	84	3	,	,	PUNCT
dpc-5015	84	4	ldl	ldl	NOUN
dpc-5015	84	5	,	,	PUNCT
dpc-5015	84	6	sbp	sbp	NOUN
dpc-5015	84	7	,	,	PUNCT
dpc-5015	84	8	total	total	ADJ
dpc-5015	84	9	cholesterol	cholesterol	NOUN
dpc-5015	84	10	,	,	PUNCT
dpc-5015	84	11	crp	crp	PROPN
dpc-5015	84	12	,	,	PUNCT
dpc-5015	84	13	tg	tg	PROPN
dpc-5015	84	14	,	,	PUNCT
dpc-5015	84	15	insulin	insulin	NOUN
dpc-5015	84	16	,	,	PUNCT
dpc-5015	84	17	homa	homa	NOUN
dpc-5015	84	18	-	-	PUNCT
dpc-5015	84	19	ir	ir	PROPN
dpc-5015	84	20	,	,	PUNCT
dpc-5015	84	21	fasting	fast	VERB
dpc-5015	84	22	blood	blood	NOUN
dpc-5015	84	23	glucose	glucose	NOUN
dpc-5015	84	24	,	,	PUNCT
dpc-5015	84	25	and	and	CCONJ
dpc-5015	84	26	metabolic	metabolic	NOUN
dpc-5015	84	27	syndrome	syndrome	NOUN
dpc-5015	84	28	,	,	PUNCT
dpc-5015	84	29	no	no	DET
dpc-5015	84	30	statistically	statistically	ADV
dpc-5015	84	31	significant	significant	ADJ
dpc-5015	84	32	variance	variance	NOUN
dpc-5015	84	33	was	be	AUX
dpc-5015	84	34	noted	note	VERB
dpc-5015	84	35	between	between	ADP
dpc-5015	84	36	the	the	DET
dpc-5015	84	37	patient	patient	ADJ
dpc-5015	84	38	and	and	CCONJ
dpc-5015	84	39	control	control	NOUN
dpc-5015	84	40	groups	group	NOUN
dpc-5015	84	41	(	(	PUNCT
dpc-5015	84	42	p=0.73	p=0.73	NOUN
dpc-5015	84	43	,	,	PUNCT
dpc-5015	84	44	p=0.589	p=0.589	NOUN
dpc-5015	84	45	,	,	PUNCT
dpc-5015	84	46	p=0.13	p=0.13	NOUN
dpc-5015	84	47	,	,	PUNCT
dpc-5015	84	48	p=0.69	p=0.69	NOUN
dpc-5015	84	49	,	,	PUNCT
dpc-5015	84	50	p=0.32	p=0.32	NOUN
dpc-5015	84	51	,	,	PUNCT
dpc-5015	84	52	p=0.26	p=0.26	NOUN
dpc-5015	84	53	,	,	PUNCT
dpc-5015	84	54	p=0.35	p=0.35	NOUN
dpc-5015	84	55	,	,	PUNCT
dpc-5015	84	56	p=0.22	p=0.22	NOUN
dpc-5015	84	57	,	,	PUNCT
dpc-5015	84	58	p=0.45	p=0.45	NOUN
dpc-5015	84	59	,	,	PUNCT
dpc-5015	84	60	p=1	p=1	PROPN
dpc-5015	84	61	,	,	PUNCT
dpc-5015	84	62	respectively	respectively	ADV
dpc-5015	84	63	)	)	PUNCT
dpc-5015	84	64	.	.	PUNCT
dpc-5015	85	1	the	the	DET
dpc-5015	85	2	demographic	demographic	ADJ
dpc-5015	85	3	and	and	CCONJ
dpc-5015	85	4	clinical	clinical	ADJ
dpc-5015	85	5	characteristics	characteristic	NOUN
dpc-5015	85	6	of	of	ADP
dpc-5015	85	7	rosacea	rosacea	NOUN
dpc-5015	85	8	patients	patient	NOUN
dpc-5015	85	9	and	and	CCONJ
dpc-5015	85	10	healthy	healthy	ADJ
dpc-5015	85	11	controls	control	NOUN
dpc-5015	85	12	are	be	AUX
dpc-5015	85	13	presented	present	VERB
dpc-5015	85	14	in	in	ADP
dpc-5015	85	15	table	table	NOUN
dpc-5015	85	16	1	1	NUM
dpc-5015	85	17	,	,	PUNCT
dpc-5015	85	18	and	and	CCONJ
dpc-5015	85	19	the	the	DET
dpc-5015	85	20	significant	significant	ADJ
dpc-5015	85	21	biochemical	biochemical	ADJ
dpc-5015	85	22	parameters	parameter	NOUN
dpc-5015	85	23	in	in	ADP
dpc-5015	85	24	rosacea	rosacea	NOUN
dpc-5015	85	25	patients	patient	NOUN
dpc-5015	85	26	and	and	CCONJ
dpc-5015	85	27	the	the	DET
dpc-5015	85	28	control	control	NOUN
dpc-5015	85	29	group	group	NOUN
dpc-5015	85	30	are	be	AUX
dpc-5015	85	31	presented	present	VERB
dpc-5015	85	32	in	in	ADP
dpc-5015	85	33	table	table	NOUN
dpc-5015	85	34	2	2	NUM
dpc-5015	85	35	.	.	PUNCT
dpc-5015	85	36	fitzpatrick	fitzpatrick	PROPN
dpc-5015	85	37	skin	skin	PROPN
dpc-5015	85	38	type	type	PROPN
dpc-5015	85	39	ii	ii	PROPN
dpc-5015	85	40	was	be	AUX
dpc-5015	85	41	observed	observe	VERB
dpc-5015	85	42	in	in	ADP
dpc-5015	85	43	23	23	NUM
dpc-5015	85	44	%	%	NOUN
dpc-5015	85	45	of	of	ADP
dpc-5015	85	46	the	the	DET
dpc-5015	85	47	patients	patient	NOUN
dpc-5015	85	48	,	,	PUNCT
dpc-5015	85	49	type	type	NOUN
dpc-5015	85	50	iii	iii	NUM
dpc-5015	85	51	in	in	ADP
dpc-5015	85	52	63	63	NUM
dpc-5015	85	53	%	%	NOUN
dpc-5015	85	54	,	,	PUNCT
dpc-5015	85	55	and	and	CCONJ
dpc-5015	85	56	type	type	NOUN
dpc-5015	85	57	iv	iv	NUM
dpc-5015	85	58	in	in	ADP
dpc-5015	85	59	14	14	NUM
dpc-5015	85	60	%	%	NOUN
dpc-5015	85	61	.	.	PUNCT
dpc-5015	86	1	a	a	DET
dpc-5015	86	2	family	family	NOUN
dpc-5015	86	3	history	history	NOUN
dpc-5015	86	4	of	of	ADP
dpc-5015	86	5	rosacea	rosacea	NOUN
dpc-5015	86	6	was	be	AUX
dpc-5015	86	7	present	present	ADJ
dpc-5015	86	8	in	in	ADP
dpc-5015	86	9	43.2	43.2	NUM
dpc-5015	86	10	%	%	NOUN
dpc-5015	86	11	of	of	ADP
dpc-5015	86	12	the	the	DET
dpc-5015	86	13	patients	patient	NOUN
dpc-5015	86	14	.	.	PUNCT
dpc-5015	87	1	the	the	DET
dpc-5015	87	2	average	average	ADJ
dpc-5015	87	3	disease	disease	NOUN
dpc-5015	87	4	duration	duration	NOUN
dpc-5015	87	5	was	be	AUX
dpc-5015	87	6	5.6	5.6	NUM
dpc-5015	87	7	±	±	NUM
dpc-5015	87	8	4.53	4.53	NUM
dpc-5015	87	9	years	year	NOUN
dpc-5015	87	10	.	.	PUNCT
dpc-5015	88	1	among	among	ADP
dpc-5015	88	2	the	the	DET
dpc-5015	88	3	patients	patient	NOUN
dpc-5015	88	4	,	,	PUNCT
dpc-5015	88	5	the	the	DET
dpc-5015	88	6	most	most	ADV
dpc-5015	88	7	common	common	ADJ
dpc-5015	88	8	subtype	subtype	NOUN
dpc-5015	88	9	was	be	AUX
dpc-5015	88	10	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-5015	88	11	(	(	PUNCT
dpc-5015	88	12	et	et	NOUN
dpc-5015	88	13	)	)	PUNCT
dpc-5015	88	14	rosacea	rosacea	NOUN
dpc-5015	88	15	(	(	PUNCT
dpc-5015	88	16	61.4	61.4	NUM
dpc-5015	88	17	%	%	NOUN
dpc-5015	88	18	)	)	PUNCT
dpc-5015	88	19	,	,	PUNCT
dpc-5015	88	20	followed	follow	VERB
dpc-5015	88	21	by	by	ADP
dpc-5015	88	22	papulopustular	papulopustular	ADJ
dpc-5015	88	23	(	(	PUNCT
dpc-5015	88	24	pp	pp	ADJ
dpc-5015	88	25	)	)	PUNCT
dpc-5015	88	26	rosacea	rosacea	NOUN
dpc-5015	88	27	(	(	PUNCT
dpc-5015	88	28	34.2	34.2	NUM
dpc-5015	88	29	%	%	NOUN
dpc-5015	88	30	)	)	PUNCT
dpc-5015	88	31	,	,	PUNCT
dpc-5015	88	32	and	and	CCONJ
dpc-5015	88	33	phymatous	phymatous	ADJ
dpc-5015	88	34	rosacea	rosacea	NOUN
dpc-5015	88	35	(	(	PUNCT
dpc-5015	88	36	4.4	4.4	NUM
dpc-5015	88	37	%	%	NOUN
dpc-5015	88	38	)	)	PUNCT
dpc-5015	88	39	.	.	PUNCT
dpc-5015	89	1	disease	disease	NOUN
dpc-5015	89	2	severity	severity	NOUN
dpc-5015	89	3	assessment	assessment	NOUN
dpc-5015	89	4	revealed	reveal	VERB
dpc-5015	89	5	that	that	SCONJ
dpc-5015	89	6	20.5	20.5	NUM
dpc-5015	89	7	%	%	NOUN
dpc-5015	89	8	(	(	PUNCT
dpc-5015	89	9	n=9	n=9	NOUN
dpc-5015	89	10	)	)	PUNCT
dpc-5015	89	11	of	of	ADP
dpc-5015	89	12	the	the	DET
dpc-5015	89	13	patients	patient	NOUN
dpc-5015	89	14	had	have	VERB
dpc-5015	89	15	mild	mild	ADJ
dpc-5015	89	16	disease	disease	NOUN
dpc-5015	89	17	,	,	PUNCT
dpc-5015	89	18	41	41	NUM
dpc-5015	89	19	%	%	NOUN
dpc-5015	89	20	(	(	PUNCT
dpc-5015	89	21	n=18	n=18	NOUN
dpc-5015	89	22	)	)	PUNCT
dpc-5015	89	23	had	have	VERB
dpc-5015	89	24	moderate	moderate	ADJ
dpc-5015	89	25	disease	disease	NOUN
dpc-5015	89	26	,	,	PUNCT
dpc-5015	89	27	and	and	CCONJ
dpc-5015	89	28	38.5	38.5	NUM
dpc-5015	89	29	%	%	NOUN
dpc-5015	89	30	(	(	PUNCT
dpc-5015	89	31	n=17	n=17	NOUN
dpc-5015	89	32	)	)	PUNCT
dpc-5015	89	33	had	have	VERB
dpc-5015	89	34	severe	severe	ADJ
dpc-5015	89	35	disease	disease	NOUN
dpc-5015	89	36	.	.	PUNCT
dpc-5015	90	1	demodicosis	demodicosis	PROPN
dpc-5015	90	2	was	be	AUX
dpc-5015	90	3	detected	detect	VERB
dpc-5015	90	4	in	in	ADP
dpc-5015	90	5	63.6	63.6	NUM
dpc-5015	90	6	%	%	NOUN
dpc-5015	90	7	of	of	ADP
dpc-5015	90	8	the	the	DET
dpc-5015	90	9	patients	patient	NOUN
dpc-5015	90	10	.	.	PUNCT
dpc-5015	91	1	the	the	DET
dpc-5015	91	2	median	median	ADJ
dpc-5015	91	3	level	level	NOUN
dpc-5015	91	4	of	of	ADP
dpc-5015	91	5	endocan	endocan	PROPN
dpc-5015	91	6	in	in	ADP
dpc-5015	91	7	patients	patient	NOUN
dpc-5015	91	8	was	be	AUX
dpc-5015	91	9	176	176	NUM
dpc-5015	91	10	ng	ng	PROPN
dpc-5015	91	11	/	/	SYM
dpc-5015	91	12	l	l	PROPN
dpc-5015	91	13	,	,	PUNCT
dpc-5015	91	14	with	with	ADP
dpc-5015	91	15	a	a	DET
dpc-5015	91	16	mean	mean	NOUN
dpc-5015	91	17	of	of	ADP
dpc-5015	91	18	371.1	371.1	NUM
dpc-5015	91	19	ng	ng	PROPN
dpc-5015	91	20	/	/	SYM
dpc-5015	91	21	l	l	PROPN
dpc-5015	91	22	and	and	CCONJ
dpc-5015	91	23	in	in	ADP
dpc-5015	91	24	the	the	DET
dpc-5015	91	25	control	control	NOUN
dpc-5015	91	26	group	group	NOUN
dpc-5015	91	27	;	;	PUNCT
dpc-5015	91	28	the	the	DET
dpc-5015	91	29	median	median	ADJ
dpc-5015	91	30	value	value	NOUN
dpc-5015	91	31	was	be	AUX
dpc-5015	91	32	194	194	NUM
dpc-5015	91	33	(	(	PUNCT
dpc-5015	91	34	142	142	NUM
dpc-5015	91	35	-	-	SYM
dpc-5015	91	36	692	692	NUM
dpc-5015	91	37	)	)	PUNCT
dpc-5015	91	38	ng	ng	PROPN
dpc-5015	91	39	/	/	SYM
dpc-5015	91	40	l	l	PROPN
dpc-5015	91	41	with	with	ADP
dpc-5015	91	42	a	a	DET
dpc-5015	91	43	mean	mean	NOUN
dpc-5015	91	44	of	of	ADP
dpc-5015	91	45	280.7	280.7	NUM
dpc-5015	91	46	ng	ng	PROPN
dpc-5015	91	47	/	/	SYM
dpc-5015	91	48	l.	l.	PROPN
dpc-5015	91	49	we	we	PRON
dpc-5015	91	50	did	do	AUX
dpc-5015	91	51	not	not	PART
dpc-5015	91	52	find	find	VERB
dpc-5015	91	53	any	any	DET
dpc-5015	91	54	difference	difference	NOUN
dpc-5015	91	55	between	between	ADP
dpc-5015	91	56	these	these	DET
dpc-5015	91	57	groups	group	NOUN
dpc-5015	91	58	(	(	PUNCT
dpc-5015	91	59	p=0.765	p=0.765	NOUN
dpc-5015	91	60	)	)	PUNCT
dpc-5015	91	61	.	.	PUNCT
dpc-5015	92	1	the	the	DET
dpc-5015	92	2	median	median	ADJ
dpc-5015	92	3	level	level	NOUN
dpc-5015	92	4	of	of	ADP
dpc-5015	92	5	endoglin	endoglin	NOUN
dpc-5015	92	6	in	in	ADP
dpc-5015	92	7	patients	patient	NOUN
dpc-5015	92	8	was	be	AUX
dpc-5015	92	9	5.4	5.4	NUM
dpc-5015	92	10	ng	ng	NOUN
dpc-5015	92	11	/	/	SYM
dpc-5015	92	12	ml	ml	PROPN
dpc-5015	92	13	,	,	PUNCT
dpc-5015	92	14	with	with	ADP
dpc-5015	92	15	a	a	DET
dpc-5015	92	16	mean	mean	NOUN
dpc-5015	92	17	of	of	ADP
dpc-5015	92	18	8.6	8.6	NUM
dpc-5015	92	19	ng	ng	NOUN
dpc-5015	92	20	/	/	SYM
dpc-5015	92	21	ml	ml	PROPN
dpc-5015	92	22	;	;	PUNCT
dpc-5015	92	23	in	in	ADP
dpc-5015	92	24	the	the	DET
dpc-5015	92	25	control	control	NOUN
dpc-5015	92	26	group	group	NOUN
dpc-5015	92	27	,	,	PUNCT
dpc-5015	92	28	the	the	DET
dpc-5015	92	29	median	median	ADJ
dpc-5015	92	30	value	value	NOUN
dpc-5015	92	31	was	be	AUX
dpc-5015	92	32	6.8	6.8	NUM
dpc-5015	92	33	ng	ng	NOUN
dpc-5015	92	34	/	/	SYM
dpc-5015	92	35	ml	ml	PROPN
dpc-5015	92	36	,	,	PUNCT
dpc-5015	92	37	with	with	ADP
dpc-5015	92	38	a	a	DET
dpc-5015	92	39	mean	mean	NOUN
dpc-5015	92	40	of	of	ADP
dpc-5015	92	41	8.6	8.6	NUM
dpc-5015	92	42	ng/	ng/	VERB
dpc-5015	92	43	ml	ml	NOUN
dpc-5015	92	44	.	.	PUNCT
dpc-5015	93	1	no	no	DET
dpc-5015	93	2	discernible	discernible	ADJ
dpc-5015	93	3	difference	difference	NOUN
dpc-5015	93	4	was	be	AUX
dpc-5015	93	5	observed	observe	VERB
dpc-5015	93	6	between	between	ADP
dpc-5015	93	7	the	the	DET
dpc-5015	93	8	groups	group	NOUN
dpc-5015	93	9	(	(	PUNCT
dpc-5015	93	10	p=0.111	p=0.111	NOUN
dpc-5015	93	11	)	)	PUNCT
dpc-5015	93	12	.	.	PUNCT
dpc-5015	94	1	no	no	DET
dpc-5015	94	2	statistically	statistically	ADV
dpc-5015	94	3	significant	significant	ADJ
dpc-5015	94	4	correlation	correlation	NOUN
dpc-5015	94	5	was	be	AUX
dpc-5015	94	6	found	find	VERB
dpc-5015	94	7	between	between	ADP
dpc-5015	94	8	age	age	NOUN
dpc-5015	94	9	or	or	CCONJ
dpc-5015	94	10	sex	sex	NOUN
dpc-5015	94	11	with	with	ADP
dpc-5015	94	12	endocan	endocan	ADJ
dpc-5015	94	13	and	and	CCONJ
dpc-5015	94	14	endoglin	endoglin	NOUN
dpc-5015	94	15	levels	level	NOUN
dpc-5015	94	16	(	(	PUNCT
dpc-5015	94	17	p=0.154	p=0.154	NOUN
dpc-5015	94	18	,	,	PUNCT
dpc-5015	94	19	p=0.382	p=0.382	NOUN
dpc-5015	94	20	,	,	PUNCT
dpc-5015	94	21	p=0.836	p=0.836	ADV
dpc-5015	94	22	,	,	PUNCT
dpc-5015	94	23	p=0.286	p=0.286	NUM
dpc-5015	94	24	,	,	PUNCT
dpc-5015	94	25	respectively	respectively	ADV
dpc-5015	94	26	)	)	PUNCT
dpc-5015	94	27	.	.	PUNCT
dpc-5015	95	1	the	the	DET
dpc-5015	95	2	levels	level	NOUN
dpc-5015	95	3	of	of	ADP
dpc-5015	95	4	endoglin	endoglin	NOUN
dpc-5015	95	5	and	and	CCONJ
dpc-5015	95	6	endocan	endocan	ADJ
dpc-5015	95	7	in	in	ADP
dpc-5015	95	8	the	the	DET
dpc-5015	95	9	patient	patient	ADJ
dpc-5015	95	10	and	and	CCONJ
dpc-5015	95	11	control	control	NOUN
dpc-5015	95	12	groups	group	NOUN
dpc-5015	95	13	are	be	AUX
dpc-5015	95	14	shown	show	VERB
dpc-5015	95	15	in	in	ADP
dpc-5015	95	16	figures	figure	NOUN
dpc-5015	95	17	1a	1a	PROPN
dpc-5015	95	18	and	and	CCONJ
dpc-5015	95	19	1b	1b	NUM
dpc-5015	95	20	.	.	PUNCT
dpc-5015	96	1	no	no	DET
dpc-5015	96	2	significant	significant	ADJ
dpc-5015	96	3	association	association	NOUN
dpc-5015	96	4	was	be	AUX
dpc-5015	96	5	identified	identify	VERB
dpc-5015	96	6	between	between	ADP
dpc-5015	96	7	hdl	hdl	PROPN
dpc-5015	96	8	,	,	PUNCT
dpc-5015	96	9	ldl	ldl	NOUN
dpc-5015	96	10	,	,	PUNCT
dpc-5015	96	11	sbp	sbp	PROPN
dpc-5015	96	12	,	,	PUNCT
dpc-5015	96	13	dbp	dbp	PROPN
dpc-5015	96	14	,	,	PUNCT
dpc-5015	96	15	total	total	ADJ
dpc-5015	96	16	cholesterol	cholesterol	NOUN
dpc-5015	96	17	,	,	PUNCT
dpc-5015	96	18	crp	crp	PROPN
dpc-5015	96	19	,	,	PUNCT
dpc-5015	96	20	tg	tg	PROPN
dpc-5015	96	21	,	,	PUNCT
dpc-5015	96	22	insulin	insulin	NOUN
dpc-5015	96	23	,	,	PUNCT
dpc-5015	96	24	homa	homa	NOUN
dpc-5015	96	25	-	-	PUNCT
dpc-5015	96	26	ir	ir	PROPN
dpc-5015	96	27	,	,	PUNCT
dpc-5015	96	28	or	or	CCONJ
dpc-5015	96	29	fasting	fast	VERB
dpc-5015	96	30	blood	blood	NOUN
dpc-5015	96	31	glucose	glucose	NOUN
dpc-5015	96	32	levels	level	NOUN
dpc-5015	96	33	with	with	ADP
dpc-5015	96	34	endocan	endocan	PROPN
dpc-5015	96	35	and	and	CCONJ
dpc-5015	96	36	endoglin	endoglin	NOUN
dpc-5015	96	37	.	.	PUNCT
dpc-5015	97	1	statistically	statistically	ADV
dpc-5015	97	2	significant	significant	ADJ
dpc-5015	97	3	relationships	relationship	NOUN
dpc-5015	97	4	were	be	AUX
dpc-5015	97	5	identified	identify	VERB
dpc-5015	97	6	between	between	ADP
dpc-5015	97	7	waist	waist	NOUN
dpc-5015	97	8	circumference	circumference	NOUN
dpc-5015	97	9	and	and	CCONJ
dpc-5015	97	10	bmi	bmi	NOUN
dpc-5015	97	11	and	and	CCONJ
dpc-5015	97	12	levels	level	NOUN
dpc-5015	97	13	of	of	ADP
dpc-5015	97	14	endoglin	endoglin	NOUN
dpc-5015	97	15	4	4	NUM
dpc-5015	97	16	original	original	ADJ
dpc-5015	97	17	article	article	NOUN
dpc-5015	97	18	|	|	ADV
dpc-5015	97	19	dermatol	dermatol	ADJ
dpc-5015	97	20	pract	pract	NOUN
dpc-5015	97	21	concept	concept	NOUN
dpc-5015	97	22	.	.	PUNCT
dpc-5015	98	1	2025;15(3):5015	2025;15(3):5015	NUM
dpc-5015	98	2	table	table	NOUN
dpc-5015	98	3	2	2	NUM
dpc-5015	98	4	.	.	PUNCT
dpc-5015	98	5	laboratory	laboratory	NOUN
dpc-5015	98	6	values	value	NOUN
dpc-5015	98	7	in	in	ADP
dpc-5015	98	8	the	the	DET
dpc-5015	98	9	patient	patient	NOUN
dpc-5015	98	10	and	and	CCONJ
dpc-5015	98	11	control	control	NOUN
dpc-5015	98	12	groups	group	NOUN
dpc-5015	98	13	.	.	PUNCT
dpc-5015	99	1	control	control	NOUN
dpc-5015	99	2	group	group	PROPN
dpc-5015	99	3	,	,	PUNCT
dpc-5015	99	4	na=33	na=33	ADJ
dpc-5015	99	5	patient	patient	NOUN
dpc-5015	99	6	group	group	NOUN
dpc-5015	99	7	,	,	PUNCT
dpc-5015	99	8	na=44	na=44	PROPN
dpc-5015	99	9	median	median	PROPN
dpc-5015	99	10	min	min	PROPN
dpc-5015	99	11	max	max	PROPN
dpc-5015	99	12	median	median	PROPN
dpc-5015	99	13	min	min	PROPN
dpc-5015	99	14	max	max	PROPN
dpc-5015	99	15	pb	pb	ADP
dpc-5015	99	16	crpc	crpc	ADJ
dpc-5015	99	17	2	2	NUM
dpc-5015	99	18	1	1	NUM
dpc-5015	99	19	13	13	NUM
dpc-5015	99	20	3	3	NUM
dpc-5015	99	21	1	1	NUM
dpc-5015	99	22	15	15	NUM
dpc-5015	99	23	0.26	0.26	NUM
dpc-5015	99	24	tgd	tgd	PROPN
dpc-5015	99	25	110	110	NUM
dpc-5015	99	26	45	45	NUM
dpc-5015	99	27	483	483	NUM
dpc-5015	99	28	121	121	NUM
dpc-5015	99	29	47	47	NUM
dpc-5015	99	30	414	414	NUM
dpc-5015	99	31	0.27	0.27	NUM
dpc-5015	99	32	insulin	insulin	NOUN
dpc-5015	99	33	6.8	6.8	NUM
dpc-5015	99	34	2.3	2.3	NUM
dpc-5015	99	35	23	23	NUM
dpc-5015	99	36	7.5	7.5	NUM
dpc-5015	99	37	3	3	NUM
dpc-5015	99	38	38	38	NUM
dpc-5015	99	39	0.41	0.41	NUM
dpc-5015	99	40	homa	homa	NOUN
dpc-5015	99	41	-	-	PUNCT
dpc-5015	99	42	ire	ire	NOUN
dpc-5015	99	43	1.7	1.7	NUM
dpc-5015	99	44	0.5	0.5	NUM
dpc-5015	99	45	5.8	5.8	NUM
dpc-5015	99	46	1.9	1.9	NUM
dpc-5015	99	47	0.7	0.7	NUM
dpc-5015	99	48	9.3	9.3	NUM
dpc-5015	99	49	0.28	0.28	NUM
dpc-5015	99	50	fbgf	fbgf	NOUN
dpc-5015	99	51	98	98	NUM
dpc-5015	99	52	77	77	NUM
dpc-5015	99	53	116	116	NUM
dpc-5015	99	54	99.5	99.5	NUM
dpc-5015	99	55	82	82	NUM
dpc-5015	99	56	155	155	NUM
dpc-5015	99	57	0.50	0.50	NUM
dpc-5015	99	58	a	a	DET
dpc-5015	99	59	:	:	PUNCT
dpc-5015	99	60	number	number	NOUN
dpc-5015	99	61	of	of	ADP
dpc-5015	99	62	samples	sample	NOUN
dpc-5015	99	63	;	;	PUNCT
dpc-5015	99	64	b	b	X
dpc-5015	99	65	:	:	PUNCT
dpc-5015	99	66	values	value	NOUN
dpc-5015	99	67	of	of	ADP
dpc-5015	99	68	significance	significance	NOUN
dpc-5015	99	69	with	with	ADP
dpc-5015	99	70	difference	difference	NOUN
dpc-5015	99	71	of	of	ADP
dpc-5015	99	72	each	each	DET
dpc-5015	99	73	group	group	NOUN
dpc-5015	99	74	;	;	PUNCT
dpc-5015	99	75	c	c	X
dpc-5015	99	76	:	:	PUNCT
dpc-5015	99	77	c	c	NOUN
dpc-5015	99	78	reactive	reactive	ADJ
dpc-5015	99	79	protein	protein	NOUN
dpc-5015	99	80	;	;	PUNCT
dpc-5015	100	1	d	d	X
dpc-5015	100	2	:	:	PUNCT
dpc-5015	100	3	triglyceride	triglyceride	ADJ
dpc-5015	100	4	;	;	PUNCT
dpc-5015	100	5	e	e	NOUN
dpc-5015	100	6	:	:	PUNCT
dpc-5015	100	7	homeostasis	homeostasis	NOUN
dpc-5015	100	8	model	model	NOUN
dpc-5015	100	9	assessment	assessment	NOUN
dpc-5015	100	10	of	of	ADP
dpc-5015	100	11	insulin	insulin	NOUN
dpc-5015	100	12	resistance	resistance	NOUN
dpc-5015	100	13	.	.	PUNCT
dpc-5015	101	1	f	f	X
dpc-5015	101	2	:	:	PUNCT
dpc-5015	101	3	fasting	fast	VERB
dpc-5015	101	4	blood	blood	NOUN
dpc-5015	101	5	glucose	glucose	NOUN
dpc-5015	101	6	.	.	PUNCT
dpc-5015	102	1	table	table	NOUN
dpc-5015	102	2	1	1	NUM
dpc-5015	102	3	.	.	PUNCT
dpc-5015	102	4	demographic	demographic	ADJ
dpc-5015	102	5	and	and	CCONJ
dpc-5015	102	6	clinical	clinical	ADJ
dpc-5015	102	7	characteristics	characteristic	NOUN
dpc-5015	102	8	of	of	ADP
dpc-5015	102	9	rosacea	rosacea	NOUN
dpc-5015	102	10	patients	patient	NOUN
dpc-5015	102	11	and	and	CCONJ
dpc-5015	102	12	healthy	healthy	ADJ
dpc-5015	102	13	controls	control	NOUN
dpc-5015	102	14	.	.	PUNCT
dpc-5015	103	1	characteristics	characteristics	PROPN
dpc-5015	103	2	control	control	PROPN
dpc-5015	103	3	group	group	PROPN
dpc-5015	103	4	na=33	na=33	PROPN
dpc-5015	103	5	rosacea	rosacea	PROPN
dpc-5015	103	6	group	group	PROPN
dpc-5015	103	7	na=44	na=44	PROPN
dpc-5015	103	8	female	female	NOUN
dpc-5015	103	9	,	,	PUNCT
dpc-5015	103	10	n	n	CCONJ
dpc-5015	103	11	(	(	PUNCT
dpc-5015	103	12	%	%	INTJ
dpc-5015	103	13	)	)	PUNCT
dpc-5015	103	14	25	25	NUM
dpc-5015	103	15	(	(	PUNCT
dpc-5015	103	16	75.7	75.7	NUM
dpc-5015	103	17	%	%	NOUN
dpc-5015	103	18	)	)	PUNCT
dpc-5015	103	19	34	34	NUM
dpc-5015	103	20	(	(	PUNCT
dpc-5015	103	21	77.3	77.3	NUM
dpc-5015	103	22	%	%	NOUN
dpc-5015	103	23	)	)	PUNCT
dpc-5015	103	24	male	male	NOUN
dpc-5015	103	25	,	,	PUNCT
dpc-5015	103	26	n	n	CCONJ
dpc-5015	103	27	(	(	PUNCT
dpc-5015	103	28	%	%	INTJ
dpc-5015	103	29	)	)	PUNCT
dpc-5015	103	30	8	8	NUM
dpc-5015	103	31	(	(	PUNCT
dpc-5015	103	32	24.3	24.3	NUM
dpc-5015	103	33	%	%	NOUN
dpc-5015	103	34	)	)	PUNCT
dpc-5015	103	35	10	10	NUM
dpc-5015	103	36	(	(	PUNCT
dpc-5015	103	37	22.7	22.7	NUM
dpc-5015	103	38	%	%	NOUN
dpc-5015	103	39	)	)	PUNCT
dpc-5015	103	40	age	age	NOUN
dpc-5015	103	41	,	,	PUNCT
dpc-5015	103	42	years	year	NOUN
dpc-5015	103	43	,	,	PUNCT
dpc-5015	103	44	mean	mean	INTJ
dpc-5015	103	45	(	(	PUNCT
dpc-5015	103	46	sd	sd	NOUN
dpc-5015	103	47	)	)	PUNCT
dpc-5015	103	48	45.21	45.21	NUM
dpc-5015	103	49	(	(	PUNCT
dpc-5015	103	50	8.70	8.70	NUM
dpc-5015	103	51	)	)	PUNCT
dpc-5015	103	52	45	45	NUM
dpc-5015	103	53	(	(	PUNCT
dpc-5015	103	54	10.9	10.9	NUM
dpc-5015	103	55	)	)	PUNCT
dpc-5015	103	56	bmib	bmib	ADV
dpc-5015	103	57	,	,	PUNCT
dpc-5015	103	58	mean	mean	INTJ
dpc-5015	103	59	(	(	PUNCT
dpc-5015	103	60	sd	sd	NOUN
dpc-5015	103	61	)	)	PUNCT
dpc-5015	103	62	,	,	PUNCT
dpc-5015	103	63	kg	kg	PROPN
dpc-5015	103	64	/	/	SYM
dpc-5015	103	65	m2	m2	PROPN
dpc-5015	103	66	27.03	27.03	NUM
dpc-5015	103	67	(	(	PUNCT
dpc-5015	103	68	3.77	3.77	NUM
dpc-5015	103	69	)	)	PUNCT
dpc-5015	103	70	26.8	26.8	NUM
dpc-5015	103	71	(	(	PUNCT
dpc-5015	103	72	3.8	3.8	NUM
dpc-5015	103	73	)	)	PUNCT
dpc-5015	103	74	weight	weight	NOUN
dpc-5015	103	75	,	,	PUNCT
dpc-5015	103	76	mean	mean	NOUN
dpc-5015	103	77	(	(	PUNCT
dpc-5015	103	78	sd	sd	NOUN
dpc-5015	103	79	)	)	PUNCT
dpc-5015	103	80	,	,	PUNCT
dpc-5015	103	81	kg	kg	PROPN
dpc-5015	103	82	75.21	75.21	NUM
dpc-5015	103	83	(	(	PUNCT
dpc-5015	103	84	12.61	12.61	NUM
dpc-5015	103	85	)	)	PUNCT
dpc-5015	103	86	73.3	73.3	NUM
dpc-5015	103	87	(	(	PUNCT
dpc-5015	103	88	12.5	12.5	NUM
dpc-5015	103	89	)	)	PUNCT
dpc-5015	103	90	waist	waist	NOUN
dpc-5015	103	91	circumference	circumference	NOUN
dpc-5015	103	92	,	,	PUNCT
dpc-5015	103	93	mean	mean	NOUN
dpc-5015	103	94	(	(	PUNCT
dpc-5015	103	95	sd	sd	NOUN
dpc-5015	103	96	)	)	PUNCT
dpc-5015	103	97	,	,	PUNCT
dpc-5015	103	98	cm	cm	PROPN
dpc-5015	103	99	89.48	89.48	NUM
dpc-5015	103	100	(	(	PUNCT
dpc-5015	103	101	11.74	11.74	NUM
dpc-5015	103	102	)	)	PUNCT
dpc-5015	103	103	92	92	NUM
dpc-5015	103	104	(	(	PUNCT
dpc-5015	103	105	12.1	12.1	NUM
dpc-5015	103	106	)	)	PUNCT
dpc-5015	103	107	family	family	NOUN
dpc-5015	103	108	comorbidity	comorbidity	NOUN
dpc-5015	103	109	,	,	PUNCT
dpc-5015	103	110	n(%	n(%	PROPN
dpc-5015	103	111	)	)	PUNCT
dpc-5015	103	112	27	27	NUM
dpc-5015	103	113	(	(	PUNCT
dpc-5015	103	114	81.8	81.8	NUM
dpc-5015	103	115	)	)	PUNCT
dpc-5015	103	116	36	36	NUM
dpc-5015	103	117	(	(	PUNCT
dpc-5015	103	118	81.8	81.8	NUM
dpc-5015	103	119	)	)	PUNCT
dpc-5015	103	120	disease	disease	NOUN
dpc-5015	103	121	duration	duration	NOUN
dpc-5015	103	122	,	,	PUNCT
dpc-5015	103	123	years	year	NOUN
dpc-5015	103	124	,	,	PUNCT
dpc-5015	103	125	mean	mean	INTJ
dpc-5015	103	126	(	(	PUNCT
dpc-5015	103	127	sd	sd	NOUN
dpc-5015	103	128	)	)	PUNCT
dpc-5015	103	129	5.6	5.6	NUM
dpc-5015	103	130	(	(	PUNCT
dpc-5015	103	131	4	4	NUM
dpc-5015	103	132	.	.	PUNCT
dpc-5015	103	133	)	)	PUNCT
dpc-5015	103	134	subtype	subtype	NOUN
dpc-5015	103	135	,	,	PUNCT
dpc-5015	103	136	n(%	n(%	PROPN
dpc-5015	103	137	)	)	PUNCT
dpc-5015	103	138	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-5015	103	139	27	27	NUM
dpc-5015	103	140	(	(	PUNCT
dpc-5015	103	141	61.4	61.4	NUM
dpc-5015	103	142	)	)	PUNCT
dpc-5015	103	143	papulopustular	papulopustular	ADJ
dpc-5015	103	144	15	15	NUM
dpc-5015	103	145	(	(	PUNCT
dpc-5015	103	146	34.2	34.2	NUM
dpc-5015	103	147	)	)	PUNCT
dpc-5015	103	148	phymatous	phymatous	ADJ
dpc-5015	103	149	2	2	NUM
dpc-5015	103	150	(	(	PUNCT
dpc-5015	103	151	4.4	4.4	NUM
dpc-5015	103	152	)	)	PUNCT
dpc-5015	103	153	disease	disease	NOUN
dpc-5015	103	154	severity	severity	NOUN
dpc-5015	103	155	mild	mild	ADJ
dpc-5015	103	156	n(%	n(%	NOUN
dpc-5015	103	157	)	)	PUNCT
dpc-5015	103	158	9	9	NUM
dpc-5015	103	159	(	(	PUNCT
dpc-5015	103	160	20.5	20.5	NUM
dpc-5015	103	161	)	)	PUNCT
dpc-5015	103	162	moderate	moderate	ADJ
dpc-5015	103	163	n(%	n(%	PROPN
dpc-5015	103	164	)	)	PUNCT
dpc-5015	103	165	18	18	NUM
dpc-5015	103	166	(	(	PUNCT
dpc-5015	103	167	41	41	NUM
dpc-5015	103	168	)	)	PUNCT
dpc-5015	103	169	severe	severe	ADJ
dpc-5015	103	170	n(%	n(%	PROPN
dpc-5015	103	171	)	)	PUNCT
dpc-5015	103	172	17	17	NUM
dpc-5015	103	173	(	(	PUNCT
dpc-5015	103	174	38.5	38.5	NUM
dpc-5015	103	175	)	)	PUNCT
dpc-5015	103	176	a	a	DET
dpc-5015	103	177	:	:	PUNCT
dpc-5015	103	178	number	number	NOUN
dpc-5015	103	179	of	of	ADP
dpc-5015	103	180	samples	sample	NOUN
dpc-5015	103	181	;	;	PUNCT
dpc-5015	103	182	b	b	X
dpc-5015	103	183	:	:	PUNCT
dpc-5015	103	184	body	body	NOUN
dpc-5015	103	185	mass	mass	PROPN
dpc-5015	103	186	index	index	NOUN
dpc-5015	103	187	.	.	PUNCT
dpc-5015	104	1	(	(	PUNCT
dpc-5015	104	2	p=0.005	p=0.005	NOUN
dpc-5015	104	3	,	,	PUNCT
dpc-5015	104	4	p=0.014	p=0.014	ADV
dpc-5015	104	5	,	,	PUNCT
dpc-5015	104	6	respectively	respectively	ADV
dpc-5015	104	7	)	)	PUNCT
dpc-5015	104	8	.	.	PUNCT
dpc-5015	105	1	no	no	DET
dpc-5015	105	2	substantial	substantial	ADJ
dpc-5015	105	3	association	association	NOUN
dpc-5015	105	4	was	be	AUX
dpc-5015	105	5	found	find	VERB
dpc-5015	105	6	between	between	ADP
dpc-5015	105	7	rosacea	rosacea	NOUN
dpc-5015	105	8	subtypes	subtype	NOUN
dpc-5015	105	9	and	and	CCONJ
dpc-5015	105	10	levels	level	NOUN
dpc-5015	105	11	of	of	ADP
dpc-5015	105	12	endocan	endocan	PROPN
dpc-5015	105	13	and	and	CCONJ
dpc-5015	105	14	endoglin	endoglin	NOUN
dpc-5015	105	15	(	(	PUNCT
dpc-5015	105	16	p=0.730	p=0.730	PROPN
dpc-5015	105	17	,	,	PUNCT
dpc-5015	105	18	p=0.527	p=0.527	X
dpc-5015	105	19	,	,	PUNCT
dpc-5015	105	20	respectively	respectively	ADV
dpc-5015	105	21	)	)	PUNCT
dpc-5015	105	22	.	.	PUNCT
dpc-5015	106	1	a	a	DET
dpc-5015	106	2	notable	notable	ADJ
dpc-5015	106	3	correlation	correlation	NOUN
dpc-5015	106	4	was	be	AUX
dpc-5015	106	5	observed	observe	VERB
dpc-5015	106	6	between	between	ADP
dpc-5015	106	7	the	the	DET
dpc-5015	106	8	presence	presence	NOUN
dpc-5015	106	9	of	of	ADP
dpc-5015	106	10	symptoms	symptom	NOUN
dpc-5015	106	11	(	(	PUNCT
dpc-5015	106	12	p<0.001	p<0.001	ADJ
dpc-5015	106	13	,	,	PUNCT
dpc-5015	106	14	p<0.001	p<0.001	PROPN
dpc-5015	106	15	)	)	PUNCT
dpc-5015	106	16	,	,	PUNCT
dpc-5015	106	17	erythema	erythema	ADJ
dpc-5015	106	18	severity	severity	NOUN
dpc-5015	106	19	(	(	PUNCT
dpc-5015	106	20	p<0.001	p<0.001	NOUN
dpc-5015	106	21	,	,	PUNCT
dpc-5015	106	22	p=0.004	p=0.004	PROPN
dpc-5015	106	23	)	)	PUNCT
dpc-5015	106	24	,	,	PUNCT
dpc-5015	106	25	disease	disease	NOUN
dpc-5015	106	26	severity	severity	NOUN
dpc-5015	106	27	(	(	PUNCT
dpc-5015	106	28	p<0.001	p<0.001	ADJ
dpc-5015	106	29	,	,	PUNCT
dpc-5015	106	30	p=0.007	p=0.007	VERB
dpc-5015	106	31	)	)	PUNCT
dpc-5015	106	32	and	and	CCONJ
dpc-5015	106	33	endocan	endocan	ADJ
dpc-5015	106	34	and	and	CCONJ
dpc-5015	106	35	endoglin	endoglin	NOUN
dpc-5015	106	36	levels	level	NOUN
dpc-5015	106	37	.	.	PUNCT
dpc-5015	107	1	the	the	DET
dpc-5015	107	2	intensity	intensity	NOUN
dpc-5015	107	3	of	of	ADP
dpc-5015	107	4	telangiectasia	telangiectasia	NOUN
dpc-5015	107	5	was	be	AUX
dpc-5015	107	6	found	find	VERB
dpc-5015	107	7	to	to	PART
dpc-5015	107	8	have	have	VERB
dpc-5015	107	9	a	a	DET
dpc-5015	107	10	strong	strong	ADJ
dpc-5015	107	11	correlation	correlation	NOUN
dpc-5015	107	12	with	with	ADP
dpc-5015	107	13	endocan	endocan	ADJ
dpc-5015	107	14	levels	level	NOUN
dpc-5015	107	15	(	(	PUNCT
dpc-5015	107	16	p=0.007	p=0.007	ADP
dpc-5015	107	17	)	)	PUNCT
dpc-5015	107	18	.	.	PUNCT
dpc-5015	108	1	a	a	DET
dpc-5015	108	2	significant	significant	ADJ
dpc-5015	108	3	association	association	NOUN
dpc-5015	108	4	was	be	AUX
dpc-5015	108	5	also	also	ADV
dpc-5015	108	6	noted	note	VERB
dpc-5015	108	7	between	between	ADP
dpc-5015	108	8	endoglin	endoglin	NOUN
dpc-5015	108	9	levels	level	NOUN
dpc-5015	108	10	and	and	CCONJ
dpc-5015	108	11	the	the	DET
dpc-5015	108	12	occurrence	occurrence	NOUN
dpc-5015	108	13	of	of	ADP
dpc-5015	108	14	flushing	flush	VERB
dpc-5015	108	15	attacks	attack	NOUN
dpc-5015	108	16	(	(	PUNCT
dpc-5015	108	17	p=0.003	p=0.003	NOUN
dpc-5015	108	18	)	)	PUNCT
dpc-5015	108	19	,	,	PUNCT
dpc-5015	108	20	the	the	DET
dpc-5015	108	21	number	number	NOUN
dpc-5015	108	22	of	of	ADP
dpc-5015	108	23	papulopustular	papulopustular	ADJ
dpc-5015	108	24	lesions	lesion	NOUN
dpc-5015	108	25	(	(	PUNCT
dpc-5015	108	26	p=0.045	p=0.045	NUM
dpc-5015	108	27	)	)	PUNCT
dpc-5015	108	28	,	,	PUNCT
dpc-5015	108	29	and	and	CCONJ
dpc-5015	108	30	demodicosis	demodicosis	NOUN
dpc-5015	108	31	(	(	PUNCT
dpc-5015	108	32	p=0.040	p=0.040	PROPN
dpc-5015	108	33	)	)	PUNCT
dpc-5015	108	34	.	.	PUNCT
dpc-5015	109	1	the	the	DET
dpc-5015	109	2	levels	level	NOUN
dpc-5015	109	3	of	of	ADP
dpc-5015	109	4	endocan	endocan	PROPN
dpc-5015	109	5	and	and	CCONJ
dpc-5015	109	6	endoglin	endoglin	NOUN
dpc-5015	109	7	in	in	ADP
dpc-5015	109	8	mild	mild	ADJ
dpc-5015	109	9	,	,	PUNCT
dpc-5015	109	10	moderate	moderate	ADJ
dpc-5015	109	11	,	,	PUNCT
dpc-5015	109	12	and	and	CCONJ
dpc-5015	109	13	severe	severe	ADJ
dpc-5015	109	14	rosacea	rosacea	NOUN
dpc-5015	109	15	patients	patient	NOUN
dpc-5015	109	16	are	be	AUX
dpc-5015	109	17	shown	show	VERB
dpc-5015	109	18	in	in	ADP
dpc-5015	109	19	figures	figure	NOUN
dpc-5015	109	20	2a	2a	NUM
dpc-5015	109	21	and	and	CCONJ
dpc-5015	109	22	2b	2b	NOUN
dpc-5015	109	23	.	.	PUNCT
dpc-5015	110	1	conclusions	conclusion	NOUN
dpc-5015	110	2	endocan	endocan	PROPN
dpc-5015	110	3	is	be	AUX
dpc-5015	110	4	a	a	DET
dpc-5015	110	5	proteoglycan	proteoglycan	NOUN
dpc-5015	110	6	being	be	AUX
dpc-5015	110	7	investigated	investigate	VERB
dpc-5015	110	8	for	for	ADP
dpc-5015	110	9	its	its	PRON
dpc-5015	110	10	role	role	NOUN
dpc-5015	110	11	in	in	ADP
dpc-5015	110	12	many	many	ADJ
dpc-5015	110	13	inflammatory	inflammatory	ADJ
dpc-5015	110	14	diseases	disease	NOUN
dpc-5015	110	15	where	where	SCONJ
dpc-5015	110	16	angiogenesis	angiogenesis	NOUN
dpc-5015	110	17	is	be	AUX
dpc-5015	110	18	increased	increase	VERB
dpc-5015	110	19	,	,	PUNCT
dpc-5015	110	20	such	such	ADJ
dpc-5015	110	21	as	as	ADP
dpc-5015	110	22	coronary	coronary	ADJ
dpc-5015	110	23	artery	artery	NOUN
dpc-5015	110	24	disease	disease	NOUN
dpc-5015	110	25	,	,	PUNCT
dpc-5015	110	26	hypertension	hypertension	NOUN
dpc-5015	110	27	,	,	PUNCT
dpc-5015	110	28	and	and	CCONJ
dpc-5015	110	29	psoriasis	psoriasis	NOUN
dpc-5015	110	30	[	[	X
dpc-5015	110	31	29,31,37,38	29,31,37,38	NUM
dpc-5015	110	32	]	]	PUNCT
dpc-5015	110	33	.	.	PUNCT
dpc-5015	111	1	the	the	DET
dpc-5015	111	2	endoglin	endoglin	PROPN
dpc-5015	111	3	molecule	molecule	NOUN
dpc-5015	111	4	also	also	ADV
dpc-5015	111	5	plays	play	VERB
dpc-5015	111	6	a	a	DET
dpc-5015	111	7	role	role	NOUN
dpc-5015	111	8	in	in	ADP
dpc-5015	111	9	many	many	ADJ
dpc-5015	111	10	angiogenesis	angiogenesis	NOUN
dpc-5015	111	11	-	-	PUNCT
dpc-5015	111	12	related	relate	VERB
dpc-5015	111	13	pathways	pathway	NOUN
dpc-5015	111	14	where	where	SCONJ
dpc-5015	111	15	vegf	vegf	PROPN
dpc-5015	111	16	,	,	PUNCT
dpc-5015	111	17	tgfbeta	tgfbeta	PROPN
dpc-5015	111	18	,	,	PUNCT
dpc-5015	111	19	and	and	CCONJ
dpc-5015	111	20	similar	similar	ADJ
dpc-5015	111	21	angiogenic	angiogenic	ADJ
dpc-5015	111	22	molecules	molecule	NOUN
dpc-5015	111	23	are	be	AUX
dpc-5015	111	24	involved	involve	VERB
dpc-5015	111	25	[	[	PUNCT
dpc-5015	111	26	23,39	23,39	NUM
dpc-5015	111	27	]	]	PUNCT
dpc-5015	111	28	.	.	PUNCT
dpc-5015	112	1	our	our	PRON
dpc-5015	112	2	study	study	NOUN
dpc-5015	112	3	explored	explore	VERB
dpc-5015	112	4	the	the	DET
dpc-5015	112	5	association	association	NOUN
dpc-5015	112	6	between	between	ADP
dpc-5015	112	7	rosacea	rosacea	NOUN
dpc-5015	112	8	and	and	CCONJ
dpc-5015	112	9	endocan	endocan	ADJ
dpc-5015	112	10	and	and	CCONJ
dpc-5015	112	11	endoglin	endoglin	NOUN
dpc-5015	112	12	molecules	molecule	NOUN
dpc-5015	112	13	,	,	PUNCT
dpc-5015	112	14	which	which	PRON
dpc-5015	112	15	are	be	AUX
dpc-5015	112	16	known	know	VERB
dpc-5015	112	17	to	to	PART
dpc-5015	112	18	play	play	VERB
dpc-5015	112	19	significant	significant	ADJ
dpc-5015	112	20	roles	role	NOUN
dpc-5015	112	21	in	in	ADP
dpc-5015	112	22	pathways	pathway	NOUN
dpc-5015	112	23	such	such	ADJ
dpc-5015	112	24	as	as	ADP
dpc-5015	112	25	angiogenesis	angiogenesis	NOUN
dpc-5015	112	26	,	,	PUNCT
dpc-5015	112	27	vasodilation	vasodilation	NOUN
dpc-5015	112	28	,	,	PUNCT
dpc-5015	112	29	and	and	CCONJ
dpc-5015	112	30	inflammation	inflammation	NOUN
dpc-5015	112	31	.	.	PUNCT
dpc-5015	113	1	we	we	PRON
dpc-5015	113	2	also	also	ADV
dpc-5015	113	3	investigated	investigate	VERB
dpc-5015	113	4	the	the	DET
dpc-5015	113	5	relationship	relationship	NOUN
dpc-5015	113	6	between	between	ADP
dpc-5015	113	7	these	these	DET
dpc-5015	113	8	molecules	molecule	NOUN
dpc-5015	113	9	and	and	CCONJ
dpc-5015	113	10	cardiovascular	cardiovascular	ADJ
dpc-5015	113	11	risk	risk	NOUN
dpc-5015	113	12	factors	factor	NOUN
dpc-5015	113	13	[	[	X
dpc-5015	113	14	9,14	9,14	X
dpc-5015	113	15	]	]	PUNCT
dpc-5015	113	16	.	.	PUNCT
dpc-5015	114	1	in	in	ADP
dpc-5015	114	2	this	this	DET
dpc-5015	114	3	study	study	NOUN
dpc-5015	114	4	,	,	PUNCT
dpc-5015	114	5	we	we	PRON
dpc-5015	114	6	hypothesized	hypothesize	VERB
dpc-5015	114	7	that	that	SCONJ
dpc-5015	114	8	in	in	ADP
dpc-5015	114	9	rosacea	rosacea	NOUN
dpc-5015	114	10	patients	patient	NOUN
dpc-5015	114	11	with	with	ADP
dpc-5015	114	12	high	high	ADJ
dpc-5015	114	13	levels	level	NOUN
dpc-5015	114	14	of	of	ADP
dpc-5015	114	15	endocan	endocan	ADJ
dpc-5015	114	16	and	and	CCONJ
dpc-5015	114	17	endoglin	endoglin	NOUN
dpc-5015	114	18	molecules	molecule	NOUN
dpc-5015	114	19	,	,	PUNCT
dpc-5015	114	20	original	original	ADJ
dpc-5015	114	21	article	article	NOUN
dpc-5015	114	22	|	|	ADV
dpc-5015	114	23	dermatol	dermatol	ADJ
dpc-5015	114	24	pract	pract	NOUN
dpc-5015	114	25	concept	concept	NOUN
dpc-5015	114	26	.	.	PUNCT
dpc-5015	115	1	2025;15(3):5015	2025;15(3):5015	NUM
dpc-5015	115	2	5	5	NUM
dpc-5015	115	3	not	not	PART
dpc-5015	115	4	identify	identify	VERB
dpc-5015	115	5	an	an	DET
dpc-5015	115	6	association	association	NOUN
dpc-5015	115	7	between	between	ADP
dpc-5015	115	8	endocan	endocan	ADJ
dpc-5015	115	9	levels	level	NOUN
dpc-5015	115	10	and	and	CCONJ
dpc-5015	115	11	metabolic	metabolic	NOUN
dpc-5015	115	12	parameters	parameter	NOUN
dpc-5015	115	13	such	such	ADJ
dpc-5015	115	14	as	as	ADP
dpc-5015	115	15	lipid	lipid	ADJ
dpc-5015	115	16	levels	level	NOUN
dpc-5015	115	17	,	,	PUNCT
dpc-5015	115	18	fasting	fast	VERB
dpc-5015	115	19	blood	blood	NOUN
dpc-5015	115	20	glucose	glucose	NOUN
dpc-5015	115	21	,	,	PUNCT
dpc-5015	115	22	or	or	CCONJ
dpc-5015	115	23	insulin	insulin	NOUN
dpc-5015	115	24	resistance	resistance	NOUN
dpc-5015	115	25	.	.	PUNCT
dpc-5015	116	1	this	this	DET
dpc-5015	116	2	result	result	NOUN
dpc-5015	116	3	could	could	AUX
dpc-5015	116	4	be	be	AUX
dpc-5015	116	5	attributed	attribute	VERB
dpc-5015	116	6	to	to	ADP
dpc-5015	116	7	the	the	DET
dpc-5015	116	8	selection	selection	NOUN
dpc-5015	116	9	of	of	ADP
dpc-5015	116	10	patients	patient	NOUN
dpc-5015	116	11	and	and	CCONJ
dpc-5015	116	12	control	control	NOUN
dpc-5015	116	13	group	group	NOUN
dpc-5015	116	14	without	without	ADP
dpc-5015	116	15	comorbidities	comorbiditie	NOUN
dpc-5015	116	16	and	and	CCONJ
dpc-5015	116	17	not	not	PART
dpc-5015	116	18	using	use	VERB
dpc-5015	116	19	systemic	systemic	ADJ
dpc-5015	116	20	medication	medication	NOUN
dpc-5015	116	21	.	.	PUNCT
dpc-5015	117	1	to	to	ADP
dpc-5015	117	2	our	our	PRON
dpc-5015	117	3	knowledge	knowledge	NOUN
dpc-5015	117	4	,	,	PUNCT
dpc-5015	117	5	only	only	ADV
dpc-5015	117	6	one	one	NUM
dpc-5015	117	7	study	study	NOUN
dpc-5015	117	8	has	have	AUX
dpc-5015	117	9	investigated	investigate	VERB
dpc-5015	117	10	the	the	DET
dpc-5015	117	11	relationship	relationship	NOUN
dpc-5015	117	12	between	between	ADP
dpc-5015	117	13	endocan	endocan	PROPN
dpc-5015	117	14	and	and	CCONJ
dpc-5015	117	15	rosacea	rosacea	NOUN
dpc-5015	117	16	.	.	PUNCT
dpc-5015	118	1	that	that	DET
dpc-5015	118	2	study	study	NOUN
dpc-5015	118	3	reported	report	VERB
dpc-5015	118	4	that	that	SCONJ
dpc-5015	118	5	elevated	elevated	ADJ
dpc-5015	118	6	endocan	endocan	ADJ
dpc-5015	118	7	levels	level	NOUN
dpc-5015	118	8	were	be	AUX
dpc-5015	118	9	detected	detect	VERB
dpc-5015	118	10	in	in	ADP
dpc-5015	118	11	patients	patient	NOUN
dpc-5015	118	12	with	with	ADP
dpc-5015	118	13	rosacea	rosacea	NOUN
dpc-5015	118	14	,	,	PUNCT
dpc-5015	118	15	suggesting	suggest	VERB
dpc-5015	118	16	a	a	DET
dpc-5015	118	17	potential	potential	ADJ
dpc-5015	118	18	association	association	NOUN
dpc-5015	118	19	with	with	ADP
dpc-5015	118	20	increased	increase	VERB
dpc-5015	118	21	levels	level	NOUN
dpc-5015	118	22	of	of	ADP
dpc-5015	118	23	vegf	vegf	PROPN
dpc-5015	119	1	[	[	X
dpc-5015	119	2	40	40	NUM
dpc-5015	119	3	]	]	PUNCT
dpc-5015	119	4	.	.	PUNCT
dpc-5015	120	1	according	accord	VERB
dpc-5015	120	2	to	to	ADP
dpc-5015	120	3	our	our	PRON
dpc-5015	120	4	findings	finding	NOUN
dpc-5015	120	5	,	,	PUNCT
dpc-5015	120	6	endocan	endocan	PROPN
dpc-5015	120	7	alone	alone	ADV
dpc-5015	120	8	is	be	AUX
dpc-5015	120	9	not	not	PART
dpc-5015	120	10	causative	causative	ADJ
dpc-5015	120	11	in	in	ADP
dpc-5015	120	12	the	the	DET
dpc-5015	120	13	development	development	NOUN
dpc-5015	120	14	of	of	ADP
dpc-5015	120	15	rosacea	rosacea	NOUN
dpc-5015	120	16	,	,	PUNCT
dpc-5015	120	17	but	but	CCONJ
dpc-5015	120	18	its	its	PRON
dpc-5015	120	19	levels	level	NOUN
dpc-5015	120	20	increase	increase	VERB
dpc-5015	120	21	in	in	ADP
dpc-5015	120	22	severe	severe	ADJ
dpc-5015	120	23	cases	case	NOUN
dpc-5015	120	24	.	.	PUNCT
dpc-5015	121	1	it	it	PRON
dpc-5015	121	2	is	be	AUX
dpc-5015	121	3	not	not	PART
dpc-5015	121	4	possible	possible	ADJ
dpc-5015	121	5	to	to	AUX
dpc-5015	121	6	definitively	definitively	ADV
dpc-5015	121	7	state	state	VERB
dpc-5015	121	8	from	from	ADP
dpc-5015	121	9	the	the	DET
dpc-5015	121	10	existing	exist	VERB
dpc-5015	121	11	literature	literature	NOUN
dpc-5015	121	12	that	that	PRON
dpc-5015	121	13	endocan	endocan	PROPN
dpc-5015	121	14	is	be	AUX
dpc-5015	121	15	involved	involve	VERB
dpc-5015	121	16	in	in	ADP
dpc-5015	121	17	the	the	DET
dpc-5015	121	18	pathogenesis	pathogenesis	NOUN
dpc-5015	121	19	of	of	ADP
dpc-5015	121	20	rosacea	rosacea	NOUN
dpc-5015	121	21	.	.	PUNCT
dpc-5015	122	1	in	in	ADP
dpc-5015	122	2	a	a	DET
dpc-5015	122	3	study	study	NOUN
dpc-5015	122	4	conducted	conduct	VERB
dpc-5015	122	5	by	by	ADP
dpc-5015	122	6	sánchez	sánchez	NOUN
dpc-5015	122	7	-	-	PUNCT
dpc-5015	122	8	elsner	elsner	NOUN
dpc-5015	122	9	et	et	PROPN
dpc-5015	122	10	al	al	PROPN
dpc-5015	122	11	.	.	PROPN
dpc-5015	122	12	,	,	PUNCT
dpc-5015	122	13	it	it	PRON
dpc-5015	122	14	was	be	AUX
dpc-5015	122	15	reported	report	VERB
dpc-5015	122	16	that	that	SCONJ
dpc-5015	122	17	hypoxia	hypoxia	NOUN
dpc-5015	122	18	and	and	CCONJ
dpc-5015	122	19	tgf	tgf	PROPN
dpc-5015	122	20	-	-	PUNCT
dpc-5015	122	21	beta	beta	NOUN
dpc-5015	122	22	release	release	NOUN
dpc-5015	122	23	increase	increase	VERB
dpc-5015	122	24	the	the	DET
dpc-5015	122	25	secretion	secretion	NOUN
dpc-5015	122	26	of	of	ADP
dpc-5015	122	27	endoglin	endoglin	NOUN
dpc-5015	122	28	and	and	CCONJ
dpc-5015	122	29	vegf	vegf	PROPN
dpc-5015	123	1	[	[	X
dpc-5015	123	2	41	41	NUM
dpc-5015	123	3	]	]	PUNCT
dpc-5015	123	4	.	.	PUNCT
dpc-5015	124	1	in	in	ADP
dpc-5015	124	2	another	another	DET
dpc-5015	124	3	study	study	NOUN
dpc-5015	124	4	,	,	PUNCT
dpc-5015	124	5	by	by	ADP
dpc-5015	124	6	furuya	furuya	PROPN
dpc-5015	124	7	et	et	PROPN
dpc-5015	124	8	al	al	PROPN
dpc-5015	124	9	.	.	PROPN
dpc-5015	124	10	,	,	PUNCT
dpc-5015	124	11	vegfr-2	vegfr-2	NUM
dpc-5015	124	12	and	and	CCONJ
dpc-5015	124	13	endoglin	endoglin	NOUN
dpc-5015	124	14	were	be	AUX
dpc-5015	124	15	identified	identify	VERB
dpc-5015	124	16	as	as	ADP
dpc-5015	124	17	markers	marker	NOUN
dpc-5015	124	18	for	for	ADP
dpc-5015	124	19	tumor	tumor	NOUN
dpc-5015	124	20	-	-	PUNCT
dpc-5015	124	21	derived	derive	VERB
dpc-5015	124	22	endothelial	endothelial	NOUN
dpc-5015	124	23	cells	cell	NOUN
dpc-5015	124	24	in	in	ADP
dpc-5015	124	25	investigating	investigate	VERB
dpc-5015	124	26	molecules	molecule	NOUN
dpc-5015	124	27	related	relate	VERB
dpc-5015	124	28	to	to	ADP
dpc-5015	124	29	tumor	tumor	NOUN
dpc-5015	124	30	neovascularization	neovascularization	NOUN
dpc-5015	124	31	.	.	PUNCT
dpc-5015	125	1	endoglin	endoglin	NOUN
dpc-5015	125	2	is	be	AUX
dpc-5015	125	3	typically	typically	ADV
dpc-5015	125	4	released	release	VERB
dpc-5015	125	5	at	at	ADP
dpc-5015	125	6	low	low	ADJ
dpc-5015	125	7	levels	level	NOUN
dpc-5015	125	8	from	from	ADP
dpc-5015	125	9	normal	normal	ADJ
dpc-5015	125	10	endothelium	endothelium	NOUN
dpc-5015	125	11	,	,	PUNCT
dpc-5015	125	12	but	but	CCONJ
dpc-5015	125	13	its	its	PRON
dpc-5015	125	14	levels	level	NOUN
dpc-5015	125	15	in	in	ADP
dpc-5015	125	16	serum	serum	NOUN
dpc-5015	125	17	increase	increase	NOUN
dpc-5015	125	18	during	during	ADP
dpc-5015	125	19	embryogenesis	embryogenesis	NOUN
dpc-5015	125	20	,	,	PUNCT
dpc-5015	125	21	inflammatory	inflammatory	ADJ
dpc-5015	125	22	diseases	disease	NOUN
dpc-5015	125	23	,	,	PUNCT
dpc-5015	125	24	and	and	CCONJ
dpc-5015	125	25	tumorigenesis	tumorigenesis	NOUN
dpc-5015	125	26	[	[	X
dpc-5015	125	27	42	42	NUM
dpc-5015	125	28	]	]	PUNCT
dpc-5015	125	29	.	.	PUNCT
dpc-5015	126	1	research	research	NOUN
dpc-5015	126	2	conducted	conduct	VERB
dpc-5015	126	3	by	by	ADP
dpc-5015	126	4	wladis	wladis	PROPN
dpc-5015	126	5	et	et	PROPN
dpc-5015	126	6	al	al	PROPN
dpc-5015	126	7	.	.	PROPN
dpc-5015	126	8	demonstrated	demonstrate	VERB
dpc-5015	126	9	elevated	elevated	ADJ
dpc-5015	126	10	endoglin	endoglin	NOUN
dpc-5015	126	11	levels	level	NOUN
dpc-5015	126	12	in	in	ADP
dpc-5015	126	13	ocular	ocular	ADJ
dpc-5015	126	14	rosacea	rosacea	NOUN
dpc-5015	126	15	,	,	PUNCT
dpc-5015	126	16	indicating	indicate	VERB
dpc-5015	126	17	heightened	heightened	ADJ
dpc-5015	126	18	vegf	vegf	NOUN
dpc-5015	126	19	-	-	PUNCT
dpc-5015	126	20	mediated	mediate	VERB
dpc-5015	126	21	angiogenesis	angiogenesis	NOUN
dpc-5015	126	22	,	,	PUNCT
dpc-5015	126	23	inflammation	inflammation	NOUN
dpc-5015	126	24	,	,	PUNCT
dpc-5015	126	25	and	and	CCONJ
dpc-5015	126	26	increased	increase	VERB
dpc-5015	126	27	vasodilation	vasodilation	NOUN
dpc-5015	126	28	through	through	ADP
dpc-5015	126	29	molecules	molecule	NOUN
dpc-5015	126	30	such	such	ADJ
dpc-5015	126	31	as	as	ADP
dpc-5015	126	32	tnf	tnf	PROPN
dpc-5015	126	33	-	-	PUNCT
dpc-5015	126	34	alpha	alpha	NOUN
dpc-5015	126	35	and	and	CCONJ
dpc-5015	126	36	il17	il17	PROPN
dpc-5015	126	37	could	could	AUX
dpc-5015	126	38	lead	lead	VERB
dpc-5015	126	39	to	to	ADP
dpc-5015	126	40	more	more	ADV
dpc-5015	126	41	severe	severe	ADJ
dpc-5015	126	42	symptoms	symptom	NOUN
dpc-5015	126	43	,	,	PUNCT
dpc-5015	126	44	more	more	ADV
dpc-5015	126	45	severe	severe	ADJ
dpc-5015	126	46	telangiectasia	telangiectasia	NOUN
dpc-5015	126	47	,	,	PUNCT
dpc-5015	126	48	persistent	persistent	ADJ
dpc-5015	126	49	erythema	erythema	NOUN
dpc-5015	126	50	,	,	PUNCT
dpc-5015	126	51	and	and	CCONJ
dpc-5015	126	52	flushing	flush	VERB
dpc-5015	126	53	attacks	attack	NOUN
dpc-5015	126	54	.	.	PUNCT
dpc-5015	127	1	the	the	DET
dpc-5015	127	2	study	study	NOUN
dpc-5015	127	3	undertaken	undertake	VERB
dpc-5015	127	4	by	by	ADP
dpc-5015	127	5	buhl	buhl	PROPN
dpc-5015	127	6	et	et	PROPN
dpc-5015	127	7	al	al	PROPN
dpc-5015	127	8	.	.	PROPN
dpc-5015	127	9	demonstrated	demonstrate	VERB
dpc-5015	127	10	the	the	DET
dpc-5015	127	11	involvement	involvement	NOUN
dpc-5015	127	12	of	of	ADP
dpc-5015	127	13	immune	immune	ADJ
dpc-5015	127	14	dysregulation	dysregulation	NOUN
dpc-5015	127	15	in	in	ADP
dpc-5015	127	16	the	the	DET
dpc-5015	127	17	pathogenesis	pathogenesis	NOUN
dpc-5015	127	18	of	of	ADP
dpc-5015	127	19	rosacea	rosacea	NOUN
dpc-5015	127	20	,	,	PUNCT
dpc-5015	127	21	with	with	ADP
dpc-5015	127	22	th1	th1	PROPN
dpc-5015	127	23	and	and	CCONJ
dpc-5015	127	24	th17	th17	PROPN
dpc-5015	127	25	cells	cell	NOUN
dpc-5015	127	26	,	,	PUNCT
dpc-5015	127	27	tnf	tnf	PROPN
dpc-5015	127	28	-	-	PUNCT
dpc-5015	127	29	alpha	alpha	NOUN
dpc-5015	127	30	,	,	PUNCT
dpc-5015	127	31	il-1	il-1	ADP
dpc-5015	127	32	,	,	PUNCT
dpc-5015	127	33	il-6	il-6	NOUN
dpc-5015	127	34	,	,	PUNCT
dpc-5015	127	35	il-8	il-8	NOUN
dpc-5015	127	36	,	,	PUNCT
dpc-5015	127	37	il-17	il-17	ADV
dpc-5015	127	38	cytokines	cytokine	NOUN
dpc-5015	127	39	,	,	PUNCT
dpc-5015	127	40	increased	increase	VERB
dpc-5015	127	41	tlr-2	tlr-2	PRON
dpc-5015	127	42	expression	expression	NOUN
dpc-5015	127	43	,	,	PUNCT
dpc-5015	127	44	mmps	mmp	NOUN
dpc-5015	127	45	,	,	PUNCT
dpc-5015	127	46	and	and	CCONJ
dpc-5015	127	47	the	the	DET
dpc-5015	127	48	inflammasome	inflammasome	NOUN
dpc-5015	127	49	complex	complex	ADJ
dpc-5015	127	50	playing	play	VERB
dpc-5015	127	51	crucial	crucial	ADJ
dpc-5015	127	52	roles	role	NOUN
dpc-5015	127	53	[	[	X
dpc-5015	127	54	11	11	NUM
dpc-5015	127	55	]	]	PUNCT
dpc-5015	127	56	.	.	PUNCT
dpc-5015	128	1	a	a	DET
dpc-5015	128	2	study	study	NOUN
dpc-5015	128	3	by	by	ADP
dpc-5015	128	4	schwab	schwab	PROPN
dpc-5015	128	5	et	et	PROPN
dpc-5015	128	6	al	al	PROPN
dpc-5015	128	7	.	.	PROPN
dpc-5015	128	8	also	also	ADV
dpc-5015	128	9	demonstrated	demonstrate	VERB
dpc-5015	128	10	the	the	DET
dpc-5015	128	11	importance	importance	NOUN
dpc-5015	128	12	of	of	ADP
dpc-5015	128	13	molecules	molecule	NOUN
dpc-5015	128	14	such	such	ADJ
dpc-5015	128	15	as	as	ADP
dpc-5015	128	16	vegf	vegf	PROPN
dpc-5015	128	17	and	and	CCONJ
dpc-5015	128	18	ll-37	ll-37	PROPN
dpc-5015	128	19	in	in	ADP
dpc-5015	128	20	angiogenesis	angiogenesis	NOUN
dpc-5015	128	21	,	,	PUNCT
dpc-5015	128	22	as	as	ADV
dpc-5015	128	23	well	well	ADV
dpc-5015	128	24	as	as	ADP
dpc-5015	128	25	factors	factor	NOUN
dpc-5015	128	26	like	like	ADP
dpc-5015	128	27	cathelicidin	cathelicidin	VERB
dpc-5015	128	28	,	,	PUNCT
dpc-5015	128	29	nitric	nitric	ADJ
dpc-5015	128	30	oxide	oxide	NOUN
dpc-5015	128	31	(	(	PUNCT
dpc-5015	128	32	no	no	NOUN
dpc-5015	128	33	)	)	PUNCT
dpc-5015	128	34	,	,	PUNCT
dpc-5015	128	35	and	and	CCONJ
dpc-5015	128	36	pro	pro	ADJ
dpc-5015	128	37	-	-	ADJ
dpc-5015	128	38	inflammatory	inflammatory	ADJ
dpc-5015	128	39	pathways	pathway	NOUN
dpc-5015	128	40	in	in	ADP
dpc-5015	128	41	vasodilation	vasodilation	NOUN
dpc-5015	128	42	in	in	ADP
dpc-5015	128	43	the	the	DET
dpc-5015	128	44	development	development	NOUN
dpc-5015	128	45	of	of	ADP
dpc-5015	128	46	rosacea	rosacea	NOUN
dpc-5015	128	47	[	[	X
dpc-5015	128	48	21	21	NUM
dpc-5015	128	49	]	]	PUNCT
dpc-5015	128	50	.	.	PUNCT
dpc-5015	129	1	endocan	endocan	ADJ
dpc-5015	129	2	,	,	PUNCT
dpc-5015	129	3	on	on	ADP
dpc-5015	129	4	the	the	DET
dpc-5015	129	5	other	other	ADJ
dpc-5015	129	6	hand	hand	NOUN
dpc-5015	129	7	,	,	PUNCT
dpc-5015	129	8	is	be	AUX
dpc-5015	129	9	a	a	DET
dpc-5015	129	10	vital	vital	ADJ
dpc-5015	129	11	proteoglycan	proteoglycan	NOUN
dpc-5015	129	12	involved	involve	VERB
dpc-5015	129	13	in	in	ADP
dpc-5015	129	14	both	both	DET
dpc-5015	129	15	angiogenesis	angiogenesis	NOUN
dpc-5015	129	16	and	and	CCONJ
dpc-5015	129	17	inflammation	inflammation	NOUN
dpc-5015	129	18	,	,	PUNCT
dpc-5015	129	19	and	and	CCONJ
dpc-5015	129	20	these	these	DET
dpc-5015	129	21	mechanisms	mechanism	NOUN
dpc-5015	129	22	have	have	AUX
dpc-5015	129	23	been	be	AUX
dpc-5015	129	24	investigated	investigate	VERB
dpc-5015	129	25	in	in	ADP
dpc-5015	129	26	numerous	numerous	ADJ
dpc-5015	129	27	studies	study	NOUN
dpc-5015	129	28	.	.	PUNCT
dpc-5015	130	1	sarrazin	sarrazin	PROPN
dpc-5015	130	2	et	et	PROPN
dpc-5015	130	3	al	al	PROPN
dpc-5015	130	4	.	.	PROPN
dpc-5015	130	5	showed	show	VERB
dpc-5015	130	6	that	that	SCONJ
dpc-5015	130	7	its	its	PRON
dpc-5015	130	8	expression	expression	NOUN
dpc-5015	130	9	in	in	ADP
dpc-5015	130	10	vascular	vascular	ADJ
dpc-5015	130	11	endothelial	endothelial	NOUN
dpc-5015	130	12	cells	cell	NOUN
dpc-5015	130	13	is	be	AUX
dpc-5015	130	14	regulated	regulate	VERB
dpc-5015	130	15	by	by	ADP
dpc-5015	130	16	several	several	ADJ
dpc-5015	130	17	cytokines	cytokine	NOUN
dpc-5015	130	18	,	,	PUNCT
dpc-5015	130	19	including	include	VERB
dpc-5015	130	20	tnf	tnf	PROPN
dpc-5015	130	21	-	-	PUNCT
dpc-5015	130	22	α	α	PROPN
dpc-5015	130	23	,	,	PUNCT
dpc-5015	130	24	vegf	vegf	PROPN
dpc-5015	130	25	,	,	PUNCT
dpc-5015	130	26	and	and	CCONJ
dpc-5015	130	27	fibroblast	fibroblast	ADJ
dpc-5015	130	28	growth	growth	NOUN
dpc-5015	130	29	factor	factor	NOUN
dpc-5015	130	30	(	(	PUNCT
dpc-5015	130	31	fgf)-2	fgf)-2	ADV
dpc-5015	130	32	[	[	X
dpc-5015	130	33	29	29	NUM
dpc-5015	130	34	]	]	PUNCT
dpc-5015	130	35	.	.	PUNCT
dpc-5015	131	1	the	the	DET
dpc-5015	131	2	role	role	NOUN
dpc-5015	131	3	of	of	ADP
dpc-5015	131	4	endocan	endocan	PROPN
dpc-5015	131	5	in	in	ADP
dpc-5015	131	6	cardiovascular	cardiovascular	ADJ
dpc-5015	131	7	comorbidities	comorbiditie	NOUN
dpc-5015	131	8	has	have	AUX
dpc-5015	131	9	also	also	ADV
dpc-5015	131	10	been	be	AUX
dpc-5015	131	11	the	the	DET
dpc-5015	131	12	subject	subject	NOUN
dpc-5015	131	13	of	of	ADP
dpc-5015	131	14	many	many	ADJ
dpc-5015	131	15	studies	study	NOUN
dpc-5015	131	16	.	.	PUNCT
dpc-5015	132	1	the	the	DET
dpc-5015	132	2	study	study	NOUN
dpc-5015	132	3	by	by	ADP
dpc-5015	132	4	balta	balta	PROPN
dpc-5015	132	5	et	et	PROPN
dpc-5015	132	6	al	al	PROPN
dpc-5015	132	7	.	.	PROPN
dpc-5015	132	8	found	find	VERB
dpc-5015	132	9	that	that	SCONJ
dpc-5015	132	10	endocan	endocan	PROPN
dpc-5015	132	11	serves	serve	VERB
dpc-5015	132	12	as	as	ADP
dpc-5015	132	13	an	an	DET
dpc-5015	132	14	emerging	emerge	VERB
dpc-5015	132	15	inflammatory	inflammatory	ADJ
dpc-5015	132	16	marker	marker	NOUN
dpc-5015	132	17	among	among	ADP
dpc-5015	132	18	atherosclerotic	atherosclerotic	ADJ
dpc-5015	132	19	patients	patient	NOUN
dpc-5015	132	20	and	and	CCONJ
dpc-5015	132	21	could	could	AUX
dpc-5015	132	22	potentially	potentially	ADV
dpc-5015	132	23	serve	serve	VERB
dpc-5015	132	24	as	as	ADP
dpc-5015	132	25	a	a	DET
dpc-5015	132	26	valuable	valuable	ADJ
dpc-5015	132	27	predictor	predictor	NOUN
dpc-5015	132	28	of	of	ADP
dpc-5015	132	29	cardiovascular	cardiovascular	ADJ
dpc-5015	132	30	events	event	NOUN
dpc-5015	132	31	[	[	X
dpc-5015	132	32	37	37	NUM
dpc-5015	132	33	]	]	PUNCT
dpc-5015	132	34	.	.	PUNCT
dpc-5015	133	1	in	in	ADP
dpc-5015	133	2	contrast	contrast	NOUN
dpc-5015	133	3	to	to	ADP
dpc-5015	133	4	these	these	DET
dpc-5015	133	5	studies	study	NOUN
dpc-5015	133	6	,	,	PUNCT
dpc-5015	133	7	our	our	PRON
dpc-5015	133	8	research	research	NOUN
dpc-5015	133	9	did	do	AUX
dpc-5015	133	10	figure	figure	VERB
dpc-5015	133	11	1	1	NUM
dpc-5015	133	12	.	.	PUNCT
dpc-5015	134	1	endoglin	endoglin	NOUN
dpc-5015	134	2	levels	level	NOUN
dpc-5015	134	3	in	in	ADP
dpc-5015	134	4	the	the	DET
dpc-5015	134	5	patient	patient	ADJ
dpc-5015	134	6	and	and	CCONJ
dpc-5015	134	7	control	control	NOUN
dpc-5015	134	8	groups	group	NOUN
dpc-5015	134	9	(	(	PUNCT
dpc-5015	134	10	a	a	X
dpc-5015	134	11	)	)	PUNCT
dpc-5015	134	12	and	and	CCONJ
dpc-5015	134	13	endocan	endocan	ADJ
dpc-5015	134	14	levels	level	NOUN
dpc-5015	134	15	in	in	ADP
dpc-5015	134	16	the	the	DET
dpc-5015	134	17	patient	patient	ADJ
dpc-5015	134	18	and	and	CCONJ
dpc-5015	134	19	control	control	NOUN
dpc-5015	134	20	groups	group	NOUN
dpc-5015	134	21	(	(	PUNCT
dpc-5015	134	22	b	b	NOUN
dpc-5015	134	23	)	)	PUNCT
dpc-5015	134	24	.	.	PUNCT
dpc-5015	135	1	figure	figure	NOUN
dpc-5015	135	2	2	2	NUM
dpc-5015	135	3	.	.	NOUN
dpc-5015	135	4	level	level	NOUN
dpc-5015	135	5	of	of	ADP
dpc-5015	135	6	endoglin	endoglin	NOUN
dpc-5015	135	7	in	in	ADP
dpc-5015	135	8	mild	mild	ADJ
dpc-5015	135	9	,	,	PUNCT
dpc-5015	135	10	moderate	moderate	ADJ
dpc-5015	135	11	,	,	PUNCT
dpc-5015	135	12	and	and	CCONJ
dpc-5015	135	13	severe	severe	ADJ
dpc-5015	135	14	cases	case	NOUN
dpc-5015	135	15	of	of	ADP
dpc-5015	135	16	rosacea	rosacea	NOUN
dpc-5015	135	17	(	(	PUNCT
dpc-5015	135	18	a	a	NOUN
dpc-5015	135	19	)	)	PUNCT
dpc-5015	135	20	and	and	CCONJ
dpc-5015	135	21	level	level	NOUN
dpc-5015	135	22	of	of	ADP
dpc-5015	135	23	endocan	endocan	ADJ
dpc-5015	135	24	in	in	ADP
dpc-5015	135	25	mild	mild	ADJ
dpc-5015	135	26	,	,	PUNCT
dpc-5015	135	27	moderate	moderate	ADJ
dpc-5015	135	28	,	,	PUNCT
dpc-5015	135	29	and	and	CCONJ
dpc-5015	135	30	severe	severe	ADJ
dpc-5015	135	31	cases	case	NOUN
dpc-5015	135	32	of	of	ADP
dpc-5015	135	33	rosacea	rosacea	NOUN
dpc-5015	135	34	(	(	PUNCT
dpc-5015	135	35	b	b	NOUN
dpc-5015	135	36	)	)	PUNCT
dpc-5015	135	37	.	.	PUNCT
dpc-5015	136	1	6	6	NUM
dpc-5015	136	2	original	original	ADJ
dpc-5015	136	3	article	article	NOUN
dpc-5015	136	4	|	|	ADV
dpc-5015	136	5	dermatol	dermatol	ADJ
dpc-5015	136	6	pract	pract	NOUN
dpc-5015	136	7	concept	concept	NOUN
dpc-5015	136	8	.	.	PUNCT
dpc-5015	137	1	2025;15(3):5015	2025;15(3):5015	NUM
dpc-5015	137	2	research	research	NOUN
dpc-5015	137	3	and	and	CCONJ
dpc-5015	137	4	to	to	ADP
dpc-5015	137	5	dr	dr	PROPN
dpc-5015	137	6	.	.	PROPN
dpc-5015	137	7	nazime	nazime	PROPN
dpc-5015	137	8	bensu	bensu	PROPN
dpc-5015	137	9	önentaşçi	önentaşçi	PROPN
dpc-5015	137	10	demi̇r	demi̇r	PROPN
dpc-5015	137	11	,	,	PUNCT
dpc-5015	137	12	md	md	PROPN
dpc-5015	137	13	,	,	PUNCT
dpc-5015	137	14	for	for	ADP
dpc-5015	137	15	her	her	PRON
dpc-5015	137	16	valuable	valuable	ADJ
dpc-5015	137	17	input	input	NOUN
dpc-5015	137	18	.	.	PUNCT
dpc-5015	138	1	we	we	PRON
dpc-5015	138	2	also	also	ADV
dpc-5015	138	3	extend	extend	VERB
dpc-5015	138	4	our	our	PRON
dpc-5015	138	5	thanks	thank	NOUN
dpc-5015	138	6	to	to	ADP
dpc-5015	138	7	dr	dr	PROPN
dpc-5015	138	8	.	.	PROPN
dpc-5015	138	9	didem	didem	PROPN
dpc-5015	138	10	deri̇ci̇	deri̇ci̇	PROPN
dpc-5015	138	11	yildirim	yildirim	PROPN
dpc-5015	138	12	,	,	PUNCT
dpc-5015	138	13	md	md	PROPN
dpc-5015	138	14	,	,	PUNCT
dpc-5015	138	15	and	and	CCONJ
dpc-5015	138	16	i̇pek	i̇pek	NOUN
dpc-5015	138	17	kivanç	kivanç	NOUN
dpc-5015	138	18	,	,	PUNCT
dpc-5015	138	19	m.sc	m.sc	PROPN
dpc-5015	138	20	.	.	PROPN
dpc-5015	138	21	,	,	PUNCT
dpc-5015	138	22	ph.d.for	ph.d.for	ADP
dpc-5015	138	23	their	their	PRON
dpc-5015	138	24	statistical	statistical	ADJ
dpc-5015	138	25	analysis	analysis	NOUN
dpc-5015	138	26	expertise	expertise	NOUN
dpc-5015	138	27	.	.	PUNCT
dpc-5015	139	1	ethical	ethical	ADJ
dpc-5015	139	2	approval	approval	NOUN
dpc-5015	139	3	:	:	PUNCT
dpc-5015	139	4	the	the	DET
dpc-5015	139	5	study	study	NOUN
dpc-5015	139	6	protocol	protocol	NOUN
dpc-5015	139	7	was	be	AUX
dpc-5015	139	8	approved	approve	VERB
dpc-5015	139	9	by	by	ADP
dpc-5015	139	10	the	the	DET
dpc-5015	139	11	local	local	ADJ
dpc-5015	139	12	ethics	ethic	NOUN
dpc-5015	139	13	committee	committee	PROPN
dpc-5015	139	14	(	(	PUNCT
dpc-5015	139	15	mersin	mersin	PROPN
dpc-5015	139	16	university	university	PROPN
dpc-5015	139	17	)	)	PUNCT
dpc-5015	139	18	on	on	ADP
dpc-5015	139	19	september	september	PROPN
dpc-5015	139	20	30	30	NUM
dpc-5015	139	21	,	,	PUNCT
dpc-5015	139	22	2020	2020	NUM
dpc-5015	139	23	,	,	PUNCT
dpc-5015	139	24	under	under	ADP
dpc-5015	139	25	decision	decision	NOUN
dpc-5015	139	26	number	number	NOUN
dpc-5015	139	27	663	663	NUM
dpc-5015	139	28	.	.	PUNCT
dpc-5015	140	1	ethics	ethic	NOUN
dpc-5015	140	2	statement	statement	NOUN
dpc-5015	140	3	:	:	PUNCT
dpc-5015	140	4	the	the	DET
dpc-5015	140	5	patients	patient	NOUN
dpc-5015	140	6	in	in	ADP
dpc-5015	140	7	this	this	DET
dpc-5015	140	8	manuscript	manuscript	NOUN
dpc-5015	140	9	have	have	AUX
dpc-5015	140	10	given	give	VERB
dpc-5015	140	11	written	write	VERB
dpc-5015	140	12	informed	inform	VERB
dpc-5015	140	13	consent	consent	NOUN
dpc-5015	140	14	to	to	ADP
dpc-5015	140	15	the	the	DET
dpc-5015	140	16	publication	publication	NOUN
dpc-5015	140	17	of	of	ADP
dpc-5015	140	18	their	their	PRON
dpc-5015	140	19	case	case	NOUN
dpc-5015	140	20	details	detail	NOUN
dpc-5015	140	21	.	.	PUNCT
dpc-5015	141	1	patient	patient	ADJ
dpc-5015	141	2	consent	consent	NOUN
dpc-5015	141	3	for	for	ADP
dpc-5015	141	4	publication	publication	NOUN
dpc-5015	141	5	statement	statement	NOUN
dpc-5015	141	6	:	:	PUNCT
dpc-5015	141	7	all	all	DET
dpc-5015	141	8	patients	patient	NOUN
dpc-5015	141	9	were	be	AUX
dpc-5015	141	10	adequately	adequately	ADV
dpc-5015	141	11	informed	inform	VERB
dpc-5015	141	12	about	about	ADP
dpc-5015	141	13	the	the	DET
dpc-5015	141	14	research	research	NOUN
dpc-5015	141	15	and	and	CCONJ
dpc-5015	141	16	provided	provide	VERB
dpc-5015	141	17	their	their	PRON
dpc-5015	141	18	written	write	VERB
dpc-5015	141	19	informed	inform	VERB
dpc-5015	141	20	consent	consent	NOUN
dpc-5015	141	21	.	.	PUNCT
dpc-5015	142	1	references	reference	NOUN
dpc-5015	142	2	1	1	NUM
dpc-5015	142	3	.	.	PUNCT
dpc-5015	142	4	crawford	crawford	PROPN
dpc-5015	142	5	gh	gh	PROPN
dpc-5015	142	6	,	,	PUNCT
dpc-5015	142	7	pelle	pelle	PROPN
dpc-5015	142	8	mt	mt	PROPN
dpc-5015	142	9	,	,	PUNCT
dpc-5015	142	10	james	james	PROPN
dpc-5015	142	11	wd	wd	PROPN
dpc-5015	142	12	.	.	PUNCT
dpc-5015	142	13	rosacea	rosacea	PROPN
dpc-5015	142	14	:	:	PUNCT
dpc-5015	142	15	i.	i.	PROPN
dpc-5015	142	16	etiology	etiology	PROPN
dpc-5015	142	17	,	,	PUNCT
dpc-5015	142	18	pathogenesis	pathogenesis	NOUN
dpc-5015	142	19	,	,	PUNCT
dpc-5015	142	20	and	and	CCONJ
dpc-5015	142	21	subtype	subtype	NOUN
dpc-5015	142	22	classification	classification	NOUN
dpc-5015	142	23	.	.	PUNCT
dpc-5015	143	1	j	j	PROPN
dpc-5015	143	2	am	be	AUX
dpc-5015	143	3	acad	acad	ADJ
dpc-5015	143	4	dermatol	dermatol	NOUN
dpc-5015	143	5	.	.	PUNCT
dpc-5015	144	1	2004;51(3):327	2004;51(3):327	NUM
dpc-5015	144	2	-	-	SYM
dpc-5015	144	3	341	341	NUM
dpc-5015	144	4	.	.	PUNCT
dpc-5015	145	1	doi:10.1016	doi:10.1016	PROPN
dpc-5015	145	2	/	/	SYM
dpc-5015	145	3	j.jaad.2004.03.030	j.jaad.2004.03.030	PROPN
dpc-5015	145	4	.	.	PUNCT
dpc-5015	146	1	pmid	pmid	NOUN
dpc-5015	146	2	:	:	PUNCT
dpc-5015	146	3	15337973	15337973	NUM
dpc-5015	146	4	.	.	PUNCT
dpc-5015	147	1	2	2	X
dpc-5015	147	2	.	.	X
dpc-5015	147	3	powell	powell	PROPN
dpc-5015	147	4	f.	f.	PROPN
dpc-5015	147	5	rosacea	rosacea	PROPN
dpc-5015	147	6	:	:	PUNCT
dpc-5015	147	7	diagnosis	diagnosis	NOUN
dpc-5015	147	8	and	and	CCONJ
dpc-5015	147	9	management	management	NOUN
dpc-5015	147	10	.	.	PUNCT
dpc-5015	148	1	boca	boca	PROPN
dpc-5015	148	2	raton	raton	PROPN
dpc-5015	148	3	,	,	PUNCT
dpc-5015	148	4	fl	fl	PROPN
dpc-5015	148	5	:	:	PUNCT
dpc-5015	148	6	crc	crc	NOUN
dpc-5015	148	7	press	press	NOUN
dpc-5015	148	8	;	;	PUNCT
dpc-5015	148	9	2008	2008	NUM
dpc-5015	148	10	.	.	PUNCT
dpc-5015	149	1	3	3	X
dpc-5015	149	2	.	.	X
dpc-5015	149	3	mcaleer	mcaleer	PROPN
dpc-5015	149	4	ma	ma	PROPN
dpc-5015	149	5	,	,	PUNCT
dpc-5015	149	6	fitzpatrick	fitzpatrick	PROPN
dpc-5015	149	7	p	p	PROPN
dpc-5015	149	8	,	,	PUNCT
dpc-5015	149	9	powell	powell	PROPN
dpc-5015	149	10	fc	fc	PROPN
dpc-5015	149	11	.	.	PUNCT
dpc-5015	150	1	papulopustular	papulopustular	ADJ
dpc-5015	150	2	rosacea	rosacea	NOUN
dpc-5015	150	3	:	:	PUNCT
dpc-5015	150	4	prevalence	prevalence	NOUN
dpc-5015	150	5	and	and	CCONJ
dpc-5015	150	6	relationship	relationship	NOUN
dpc-5015	150	7	to	to	ADP
dpc-5015	150	8	photodamage	photodamage	NOUN
dpc-5015	150	9	.	.	PUNCT
dpc-5015	151	1	j	j	PROPN
dpc-5015	151	2	am	be	AUX
dpc-5015	151	3	acad	acad	ADJ
dpc-5015	151	4	derma‑	derma‑	NOUN
dpc-5015	151	5	tol	tol	NOUN
dpc-5015	151	6	.	.	PUNCT
dpc-5015	152	1	2010;63(1):33	2010;63(1):33	NUM
dpc-5015	152	2	-	-	SYM
dpc-5015	152	3	39	39	NUM
dpc-5015	152	4	.	.	PUNCT
dpc-5015	153	1	doi:10.1016	doi:10.1016	PROPN
dpc-5015	153	2	/	/	SYM
dpc-5015	153	3	j.jaad.2009.04.024	j.jaad.2009.04.024	PROPN
dpc-5015	153	4	.	.	PUNCT
dpc-5015	154	1	pmid	pmid	NOUN
dpc-5015	154	2	:	:	PUNCT
dpc-5015	154	3	20462665	20462665	NUM
dpc-5015	154	4	.	.	PUNCT
dpc-5015	155	1	4	4	X
dpc-5015	155	2	.	.	X
dpc-5015	155	3	spoendlin	spoendlin	PROPN
dpc-5015	155	4	j	j	PROPN
dpc-5015	155	5	,	,	PUNCT
dpc-5015	155	6	voegel	voegel	PROPN
dpc-5015	155	7	j	j	PROPN
dpc-5015	155	8	,	,	PUNCT
dpc-5015	155	9	jick	jick	PROPN
dpc-5015	155	10	s	s	PROPN
dpc-5015	155	11	,	,	PUNCT
dpc-5015	155	12	et	et	PROPN
dpc-5015	155	13	al	al	PROPN
dpc-5015	155	14	.	.	PUNCT
dpc-5015	156	1	a	a	DET
dpc-5015	156	2	study	study	NOUN
dpc-5015	156	3	on	on	ADP
dpc-5015	156	4	the	the	DET
dpc-5015	156	5	epidemiology	epidemiology	NOUN
dpc-5015	156	6	of	of	ADP
dpc-5015	156	7	rosacea	rosacea	NOUN
dpc-5015	156	8	in	in	ADP
dpc-5015	156	9	the	the	DET
dpc-5015	156	10	uk	uk	PROPN
dpc-5015	156	11	.	.	PROPN
dpc-5015	156	12	br	br	PROPN
dpc-5015	157	1	j	j	PROPN
dpc-5015	157	2	dermatol	dermatol	NOUN
dpc-5015	157	3	.	.	PUNCT
dpc-5015	158	1	2012;167(3):598	2012;167(3):598	NUM
dpc-5015	158	2	-	-	PUNCT
dpc-5015	158	3	605	605	NUM
dpc-5015	158	4	.	.	PUNCT
dpc-5015	159	1	doi:10.1111	doi:10.1111	ADJ
dpc-5015	159	2	/	/	SYM
dpc-5015	159	3	j.1365	j.1365	NOUN
dpc-5015	159	4	-	-	PUNCT
dpc-5015	159	5	2133.2012.11018.x	2133.2012.11018.x	NUM
dpc-5015	159	6	.	.	PUNCT
dpc-5015	160	1	pmid:22640409	pmid:22640409	NOUN
dpc-5015	160	2	.	.	PUNCT
dpc-5015	161	1	5	5	X
dpc-5015	161	2	.	.	X
dpc-5015	161	3	emiral	emiral	ADJ
dpc-5015	161	4	go	go	VERB
dpc-5015	161	5	,	,	PUNCT
dpc-5015	161	6	ozay	ozay	ADV
dpc-5015	161	7	o	o	NOUN
dpc-5015	161	8	,	,	PUNCT
dpc-5015	161	9	arslantas	arslantas	PROPN
dpc-5015	162	1	d	d	PROPN
dpc-5015	162	2	,	,	PUNCT
dpc-5015	162	3	et	et	PROPN
dpc-5015	162	4	al	al	PROPN
dpc-5015	162	5	.	.	PROPN
dpc-5015	162	6	assessment	assessment	NOUN
dpc-5015	162	7	of	of	ADP
dpc-5015	162	8	acne	acne	NOUN
dpc-5015	162	9	rosacea	rosacea	NOUN
dpc-5015	162	10	prevalence	prevalence	NOUN
dpc-5015	162	11	and	and	CCONJ
dpc-5015	162	12	quality	quality	NOUN
dpc-5015	162	13	of	of	ADP
dpc-5015	162	14	life	life	NOUN
dpc-5015	162	15	between	between	ADP
dpc-5015	162	16	individuals	individual	NOUN
dpc-5015	162	17	aged	age	VERB
dpc-5015	162	18	18	18	NUM
dpc-5015	162	19	years	year	NOUN
dpc-5015	162	20	and	and	CCONJ
dpc-5015	162	21	over	over	ADP
dpc-5015	162	22	in	in	ADP
dpc-5015	162	23	mahmudiye	mahmudiye	PROPN
dpc-5015	162	24	district	district	PROPN
dpc-5015	162	25	center	center	NOUN
dpc-5015	162	26	,	,	PUNCT
dpc-5015	162	27	eskisehir	eskisehir	ADJ
dpc-5015	162	28	,	,	PUNCT
dpc-5015	162	29	turkey	turkey	NOUN
dpc-5015	162	30	(	(	PUNCT
dpc-5015	162	31	a	a	DET
dpc-5015	162	32	population	population	NOUN
dpc-5015	162	33	-	-	PUNCT
dpc-5015	162	34	based	base	VERB
dpc-5015	162	35	study	study	NOUN
dpc-5015	162	36	)	)	PUNCT
dpc-5015	162	37	.	.	PUNCT
dpc-5015	163	1	turk	turk	PROPN
dpc-5015	163	2	j	j	PROPN
dpc-5015	163	3	dermatol	dermatol	PROPN
dpc-5015	163	4	.	.	PUNCT
dpc-5015	164	1	2020;14(2):48	2020;14(2):48	PROPN
dpc-5015	164	2	-	-	SYM
dpc-5015	164	3	54	54	NUM
dpc-5015	164	4	.	.	PUNCT
dpc-5015	165	1	doi:10.4103	doi:10.4103	ADJ
dpc-5015	165	2	/	/	SYM
dpc-5015	165	3	tjd.tjd_14_20	tjd.tjd_14_20	NOUN
dpc-5015	165	4	.	.	PROPN
dpc-5015	166	1	6	6	NUM
dpc-5015	166	2	.	.	X
dpc-5015	166	3	rainer	rainer	PROPN
dpc-5015	166	4	bm	bm	PROPN
dpc-5015	166	5	,	,	PUNCT
dpc-5015	166	6	fischer	fischer	PROPN
dpc-5015	166	7	ah	ah	INTJ
dpc-5015	166	8	,	,	PUNCT
dpc-5015	166	9	da	da	PROPN
dpc-5015	166	10	silva	silva	PROPN
dpc-5015	166	11	dlf	dlf	PROPN
dpc-5015	166	12	,	,	PUNCT
dpc-5015	166	13	et	et	PROPN
dpc-5015	166	14	al	al	PROPN
dpc-5015	166	15	.	.	PROPN
dpc-5015	167	1	rosacea	rosacea	PROPN
dpc-5015	167	2	is	be	AUX
dpc-5015	167	3	associated	associate	VERB
dpc-5015	167	4	with	with	ADP
dpc-5015	167	5	chronic	chronic	ADJ
dpc-5015	167	6	systemic	systemic	ADJ
dpc-5015	167	7	diseases	disease	NOUN
dpc-5015	167	8	in	in	ADP
dpc-5015	167	9	a	a	DET
dpc-5015	167	10	skin	skin	NOUN
dpc-5015	167	11	severity	severity	NOUN
dpc-5015	167	12	–	–	PUNCT
dpc-5015	167	13	dependent	dependent	ADJ
dpc-5015	167	14	manner	manner	NOUN
dpc-5015	167	15	:	:	PUNCT
dpc-5015	167	16	results	result	NOUN
dpc-5015	167	17	of	of	ADP
dpc-5015	167	18	a	a	DET
dpc-5015	167	19	case	case	NOUN
dpc-5015	167	20	-	-	PUNCT
dpc-5015	167	21	control	control	NOUN
dpc-5015	167	22	study	study	NOUN
dpc-5015	167	23	.	.	PUNCT
dpc-5015	168	1	j	j	PROPN
dpc-5015	168	2	am	be	AUX
dpc-5015	168	3	acad	acad	ADJ
dpc-5015	168	4	dermatol	dermatol	NOUN
dpc-5015	168	5	.	.	PUNCT
dpc-5015	169	1	2015;73(4):604	2015;73(4):604	NUM
dpc-5015	169	2	-	-	SYM
dpc-5015	169	3	608	608	NUM
dpc-5015	169	4	.	.	PUNCT
dpc-5015	170	1	doi:10.1016	doi:10.1016	PROPN
dpc-5015	170	2	/	/	SYM
dpc-5015	170	3	j.jaad.2015.07.023	j.jaad.2015.07.023	PROPN
dpc-5015	170	4	.	.	PUNCT
dpc-5015	171	1	pmid	pmid	NOUN
dpc-5015	171	2	:	:	PUNCT
dpc-5015	171	3	26308532	26308532	NUM
dpc-5015	171	4	7	7	NUM
dpc-5015	171	5	.	.	PUNCT
dpc-5015	172	1	wilkin	wilkin	PROPN
dpc-5015	172	2	j	j	PROPN
dpc-5015	172	3	,	,	PUNCT
dpc-5015	172	4	dahl	dahl	PROPN
dpc-5015	172	5	m	m	PROPN
dpc-5015	172	6	,	,	PUNCT
dpc-5015	172	7	detmar	detmar	PROPN
dpc-5015	172	8	m	m	PROPN
dpc-5015	172	9	,	,	PUNCT
dpc-5015	172	10	et	et	PROPN
dpc-5015	172	11	al	al	PROPN
dpc-5015	172	12	.	.	PROPN
dpc-5015	173	1	standard	standard	ADJ
dpc-5015	173	2	classification	classification	NOUN
dpc-5015	173	3	of	of	ADP
dpc-5015	173	4	rosacea	rosacea	NOUN
dpc-5015	173	5	:	:	PUNCT
dpc-5015	173	6	report	report	NOUN
dpc-5015	173	7	of	of	ADP
dpc-5015	173	8	the	the	DET
dpc-5015	173	9	national	national	PROPN
dpc-5015	173	10	rosacea	rosacea	PROPN
dpc-5015	173	11	society	society	PROPN
dpc-5015	173	12	expert	expert	PROPN
dpc-5015	173	13	committee	committee	PROPN
dpc-5015	173	14	on	on	ADP
dpc-5015	173	15	the	the	DET
dpc-5015	173	16	classification	classification	NOUN
dpc-5015	173	17	and	and	CCONJ
dpc-5015	173	18	staging	staging	NOUN
dpc-5015	173	19	of	of	ADP
dpc-5015	173	20	rosacea	rosacea	NOUN
dpc-5015	173	21	.	.	PUNCT
dpc-5015	174	1	j	j	PROPN
dpc-5015	174	2	am	be	AUX
dpc-5015	174	3	acad	acad	PROPN
dpc-5015	174	4	der‑	der‑	NOUN
dpc-5015	174	5	matol	matol	NOUN
dpc-5015	174	6	.	.	PUNCT
dpc-5015	175	1	2002;46(4):584	2002;46(4):584	NUM
dpc-5015	175	2	-	-	SYM
dpc-5015	175	3	587	587	NUM
dpc-5015	175	4	.	.	PUNCT
dpc-5015	175	5	doi:10.1067	doi:10.1067	NOUN
dpc-5015	175	6	/	/	SYM
dpc-5015	176	1	mjd.2002.120152	mjd.2002.120152	PROPN
dpc-5015	176	2	.	.	PUNCT
dpc-5015	176	3	pmid:11907501	pmid:11907501	NOUN
dpc-5015	176	4	8	8	NUM
dpc-5015	176	5	.	.	PUNCT
dpc-5015	177	1	ghanadan	ghanadan	PROPN
dpc-5015	177	2	a	a	DET
dpc-5015	177	3	,	,	PUNCT
dpc-5015	177	4	kamyab	kamyab	PROPN
dpc-5015	177	5	k	k	PROPN
dpc-5015	177	6	,	,	PUNCT
dpc-5015	177	7	azhari	azhari	PROPN
dpc-5015	177	8	vs	vs	ADP
dpc-5015	177	9	,	,	PUNCT
dpc-5015	177	10	et	et	PROPN
dpc-5015	177	11	al	al	PROPN
dpc-5015	177	12	.	.	PROPN
dpc-5015	177	13	clinicopathological	clinicopathological	ADJ
dpc-5015	177	14	survey	survey	NOUN
dpc-5015	177	15	of	of	ADP
dpc-5015	177	16	204	204	NUM
dpc-5015	177	17	rosacea	rosacea	NOUN
dpc-5015	177	18	patients	patient	NOUN
dpc-5015	177	19	regarding	regard	VERB
dpc-5015	177	20	rosacea	rosacea	NOUN
dpc-5015	177	21	subgroups	subgroup	NOUN
dpc-5015	177	22	and	and	CCONJ
dpc-5015	177	23	severity	severity	NOUN
dpc-5015	177	24	.	.	PUNCT
dpc-5015	178	1	dermatol	dermatol	NOUN
dpc-5015	178	2	pract	pract	PROPN
dpc-5015	178	3	concept	concept	NOUN
dpc-5015	178	4	.	.	PUNCT
dpc-5015	179	1	2023;13(3):e2023182	2023;13(3):e2023182	X
dpc-5015	179	2	.	.	X
dpc-5015	179	3	doi:10.5826	doi:10.5826	PROPN
dpc-5015	179	4	/	/	SYM
dpc-5015	179	5	dpc.1303a182	dpc.1303a182	PROPN
dpc-5015	179	6	.	.	PUNCT
dpc-5015	180	1	pmid:37557115	pmid:37557115	PROPN
dpc-5015	180	2	.	.	PUNCT
dpc-5015	181	1	9	9	NUM
dpc-5015	181	2	.	.	X
dpc-5015	181	3	kang	kang	PROPN
dpc-5015	181	4	s.	s.	PROPN
dpc-5015	181	5	fitzpatrick	fitzpatrick	PROPN
dpc-5015	181	6	’s	’s	PART
dpc-5015	181	7	dermatology	dermatology	NOUN
dpc-5015	181	8	,	,	PUNCT
dpc-5015	181	9	2‑volume	2‑volume	NUM
dpc-5015	181	10	set	set	NOUN
dpc-5015	181	11	.	.	PUNCT
dpc-5015	182	1	new	new	PROPN
dpc-5015	182	2	york	york	PROPN
dpc-5015	182	3	,	,	PUNCT
dpc-5015	182	4	ny	ny	PROPN
dpc-5015	182	5	:	:	PUNCT
dpc-5015	182	6	mcgraw	mcgraw	PROPN
dpc-5015	182	7	-	-	PUNCT
dpc-5015	182	8	hill	hill	NOUN
dpc-5015	182	9	;	;	PUNCT
dpc-5015	182	10	2019	2019	NUM
dpc-5015	182	11	.	.	PUNCT
dpc-5015	183	1	10	10	NUM
dpc-5015	183	2	.	.	X
dpc-5015	183	3	brown	brown	PROPN
dpc-5015	183	4	tt	tt	PROPN
dpc-5015	183	5	,	,	PUNCT
dpc-5015	183	6	choi	choi	PROPN
dpc-5015	183	7	ey	ey	PROPN
dpc-5015	183	8	,	,	PUNCT
dpc-5015	183	9	thomas	thomas	PROPN
dpc-5015	183	10	dg	dg	PROPN
dpc-5015	183	11	,	,	PUNCT
dpc-5015	183	12	et	et	PROPN
dpc-5015	183	13	al	al	PROPN
dpc-5015	183	14	.	.	PROPN
dpc-5015	183	15	comparative	comparative	ADJ
dpc-5015	183	16	analysis	analysis	NOUN
dpc-5015	183	17	of	of	ADP
dpc-5015	183	18	rosacea	rosacea	NOUN
dpc-5015	183	19	and	and	CCONJ
dpc-5015	183	20	cutaneous	cutaneous	ADJ
dpc-5015	183	21	lupus	lupus	PROPN
dpc-5015	183	22	erythematosus	erythematosus	NOUN
dpc-5015	183	23	:	:	PUNCT
dpc-5015	183	24	histopathologic	histopathologic	NOUN
dpc-5015	183	25	features	feature	NOUN
dpc-5015	183	26	,	,	PUNCT
dpc-5015	183	27	t	t	NOUN
dpc-5015	183	28	-	-	PUNCT
dpc-5015	183	29	cell	cell	NOUN
dpc-5015	183	30	subsets	subset	NOUN
dpc-5015	183	31	,	,	PUNCT
dpc-5015	183	32	and	and	CCONJ
dpc-5015	183	33	plasmacytoid	plasmacytoid	VERB
dpc-5015	183	34	dendritic	dendritic	ADJ
dpc-5015	183	35	cells	cell	NOUN
dpc-5015	183	36	.	.	PUNCT
dpc-5015	184	1	levels	level	NOUN
dpc-5015	184	2	in	in	ADP
dpc-5015	184	3	cutaneous	cutaneous	ADJ
dpc-5015	184	4	arterioles	arteriole	NOUN
dpc-5015	184	5	,	,	PUNCT
dpc-5015	184	6	which	which	PRON
dpc-5015	184	7	are	be	AUX
dpc-5015	184	8	associated	associate	VERB
dpc-5015	184	9	with	with	ADP
dpc-5015	184	10	inflammation	inflammation	NOUN
dpc-5015	184	11	and	and	CCONJ
dpc-5015	184	12	vascular	vascular	ADJ
dpc-5015	184	13	remodeling	remodeling	NOUN
dpc-5015	184	14	[	[	X
dpc-5015	184	15	43	43	NUM
dpc-5015	184	16	]	]	PUNCT
dpc-5015	184	17	.	.	PUNCT
dpc-5015	185	1	the	the	DET
dpc-5015	185	2	association	association	NOUN
dpc-5015	185	3	between	between	ADP
dpc-5015	185	4	endoglin	endoglin	NOUN
dpc-5015	185	5	,	,	PUNCT
dpc-5015	185	6	facial	facial	ADJ
dpc-5015	185	7	rosacea	rosacea	NOUN
dpc-5015	185	8	,	,	PUNCT
dpc-5015	185	9	and	and	CCONJ
dpc-5015	185	10	demodicosis	demodicosis	NOUN
dpc-5015	185	11	has	have	AUX
dpc-5015	185	12	not	not	PART
dpc-5015	185	13	been	be	AUX
dpc-5015	185	14	investigated	investigate	VERB
dpc-5015	185	15	in	in	ADP
dpc-5015	185	16	any	any	DET
dpc-5015	185	17	study	study	NOUN
dpc-5015	185	18	to	to	ADP
dpc-5015	185	19	date	date	NOUN
dpc-5015	185	20	.	.	PUNCT
dpc-5015	186	1	given	give	VERB
dpc-5015	186	2	these	these	DET
dpc-5015	186	3	observations	observation	NOUN
dpc-5015	186	4	and	and	CCONJ
dpc-5015	186	5	our	our	PRON
dpc-5015	186	6	findings	finding	NOUN
dpc-5015	186	7	,	,	PUNCT
dpc-5015	186	8	we	we	PRON
dpc-5015	186	9	hypothesize	hypothesize	VERB
dpc-5015	186	10	that	that	SCONJ
dpc-5015	186	11	the	the	DET
dpc-5015	186	12	endoglin	endoglin	NOUN
dpc-5015	186	13	molecule	molecule	NOUN
dpc-5015	186	14	may	may	AUX
dpc-5015	186	15	contribute	contribute	VERB
dpc-5015	186	16	to	to	ADP
dpc-5015	186	17	the	the	DET
dpc-5015	186	18	development	development	NOUN
dpc-5015	186	19	of	of	ADP
dpc-5015	186	20	telangiectasia	telangiectasia	PROPN
dpc-5015	186	21	,	,	PUNCT
dpc-5015	186	22	flushing	flush	VERB
dpc-5015	186	23	,	,	PUNCT
dpc-5015	186	24	and	and	CCONJ
dpc-5015	186	25	erythema	erythema	ADV
dpc-5015	186	26	observed	observe	VERB
dpc-5015	186	27	in	in	ADP
dpc-5015	186	28	rosacea	rosacea	PROPN
dpc-5015	186	29	.	.	PUNCT
dpc-5015	187	1	casas	casas	PROPN
dpc-5015	187	2	et	et	PROPN
dpc-5015	187	3	al	al	PROPN
dpc-5015	187	4	.	.	PROPN
dpc-5015	187	5	performed	perform	VERB
dpc-5015	187	6	a	a	DET
dpc-5015	187	7	study	study	NOUN
dpc-5015	187	8	that	that	PRON
dpc-5015	187	9	found	find	VERB
dpc-5015	187	10	a	a	DET
dpc-5015	187	11	significant	significant	ADJ
dpc-5015	187	12	increase	increase	NOUN
dpc-5015	187	13	in	in	ADP
dpc-5015	187	14	the	the	DET
dpc-5015	187	15	density	density	NOUN
dpc-5015	187	16	of	of	ADP
dpc-5015	187	17	demodex	demodex	NOUN
dpc-5015	187	18	folliculorum	folliculorum	NOUN
dpc-5015	187	19	in	in	ADP
dpc-5015	187	20	patients	patient	NOUN
dpc-5015	187	21	with	with	ADP
dpc-5015	187	22	rosacea	rosacea	NOUN
dpc-5015	187	23	as	as	ADV
dpc-5015	187	24	well	well	ADV
dpc-5015	187	25	as	as	ADP
dpc-5015	187	26	marked	mark	VERB
dpc-5015	187	27	elevations	elevation	NOUN
dpc-5015	187	28	in	in	ADP
dpc-5015	187	29	the	the	DET
dpc-5015	187	30	levels	level	NOUN
dpc-5015	187	31	of	of	ADP
dpc-5015	187	32	tnf	tnf	PROPN
dpc-5015	187	33	-	-	PUNCT
dpc-5015	187	34	alpha	alpha	NOUN
dpc-5015	187	35	,	,	PUNCT
dpc-5015	187	36	il-6	il-6	NOUN
dpc-5015	187	37	,	,	PUNCT
dpc-5015	187	38	il-8	il-8	NOUN
dpc-5015	187	39	,	,	PUNCT
dpc-5015	187	40	and	and	CCONJ
dpc-5015	187	41	vegf	vegf	PROPN
dpc-5015	188	1	[	[	X
dpc-5015	188	2	22	22	NUM
dpc-5015	188	3	]	]	PUNCT
dpc-5015	188	4	.	.	PUNCT
dpc-5015	189	1	we	we	PRON
dpc-5015	189	2	theorized	theorize	VERB
dpc-5015	189	3	that	that	SCONJ
dpc-5015	189	4	the	the	DET
dpc-5015	189	5	increased	increase	VERB
dpc-5015	189	6	endoglin	endoglin	NOUN
dpc-5015	189	7	level	level	NOUN
dpc-5015	189	8	in	in	ADP
dpc-5015	189	9	demodex	demodex	NOUN
dpc-5015	189	10	-	-	PUNCT
dpc-5015	189	11	positive	positive	ADJ
dpc-5015	189	12	patients	patient	NOUN
dpc-5015	189	13	might	might	AUX
dpc-5015	189	14	be	be	AUX
dpc-5015	189	15	associated	associate	VERB
dpc-5015	189	16	with	with	ADP
dpc-5015	189	17	an	an	DET
dpc-5015	189	18	enhanced	enhanced	ADJ
dpc-5015	189	19	inflammatory	inflammatory	ADJ
dpc-5015	189	20	response	response	NOUN
dpc-5015	189	21	,	,	PUNCT
dpc-5015	189	22	but	but	CCONJ
dpc-5015	189	23	this	this	DET
dpc-5015	189	24	relationship	relationship	NOUN
dpc-5015	189	25	was	be	AUX
dpc-5015	189	26	not	not	PART
dpc-5015	189	27	confirmed	confirm	VERB
dpc-5015	189	28	in	in	ADP
dpc-5015	189	29	our	our	PRON
dpc-5015	189	30	study	study	NOUN
dpc-5015	189	31	with	with	ADP
dpc-5015	189	32	endocan	endocan	PROPN
dpc-5015	189	33	.	.	PUNCT
dpc-5015	190	1	beyond	beyond	ADP
dpc-5015	190	2	diseases	disease	NOUN
dpc-5015	190	3	associated	associate	VERB
dpc-5015	190	4	with	with	ADP
dpc-5015	190	5	angiogenesis	angiogenesis	NOUN
dpc-5015	190	6	,	,	PUNCT
dpc-5015	190	7	endoglin	endoglin	PROPN
dpc-5015	190	8	is	be	AUX
dpc-5015	190	9	implicated	implicate	VERB
dpc-5015	190	10	in	in	ADP
dpc-5015	190	11	various	various	ADJ
dpc-5015	190	12	systemic	systemic	ADJ
dpc-5015	190	13	diseases	disease	NOUN
dpc-5015	190	14	.	.	PUNCT
dpc-5015	191	1	li	li	PROPN
dpc-5015	191	2	et	et	PROPN
dpc-5015	191	3	al	al	PROPN
dpc-5015	191	4	.	.	PROPN
dpc-5015	191	5	observed	observe	VERB
dpc-5015	191	6	that	that	SCONJ
dpc-5015	191	7	high	high	ADJ
dpc-5015	191	8	levels	level	NOUN
dpc-5015	191	9	of	of	ADP
dpc-5015	191	10	endoglin	endoglin	NOUN
dpc-5015	191	11	are	be	AUX
dpc-5015	191	12	associated	associate	VERB
dpc-5015	191	13	with	with	ADP
dpc-5015	191	14	high	high	ADJ
dpc-5015	191	15	sbp	sbp	NOUN
dpc-5015	191	16	,	,	PUNCT
dpc-5015	191	17	dbp	dbp	PROPN
dpc-5015	191	18	,	,	PUNCT
dpc-5015	191	19	and	and	CCONJ
dpc-5015	191	20	bmi	bmi	NOUN
dpc-5015	191	21	and	and	CCONJ
dpc-5015	191	22	are	be	AUX
dpc-5015	191	23	correlated	correlate	VERB
dpc-5015	191	24	with	with	ADP
dpc-5015	191	25	carotid	carotid	NOUN
dpc-5015	191	26	intima	intima	ADJ
dpc-5015	191	27	-	-	PUNCT
dpc-5015	191	28	media	medium	NOUN
dpc-5015	191	29	thickness	thickness	NOUN
dpc-5015	192	1	[	[	X
dpc-5015	192	2	44	44	NUM
dpc-5015	192	3	]	]	PUNCT
dpc-5015	192	4	.	.	PUNCT
dpc-5015	193	1	in	in	ADP
dpc-5015	193	2	our	our	PRON
dpc-5015	193	3	study	study	NOUN
dpc-5015	193	4	,	,	PUNCT
dpc-5015	193	5	an	an	DET
dpc-5015	193	6	association	association	NOUN
dpc-5015	193	7	was	be	AUX
dpc-5015	193	8	found	find	VERB
dpc-5015	193	9	between	between	ADP
dpc-5015	193	10	endoglin	endoglin	NOUN
dpc-5015	193	11	,	,	PUNCT
dpc-5015	193	12	increased	increase	VERB
dpc-5015	193	13	waist	waist	NOUN
dpc-5015	193	14	circumference	circumference	NOUN
dpc-5015	193	15	,	,	PUNCT
dpc-5015	193	16	and	and	CCONJ
dpc-5015	193	17	bmi	bmi	PROPN
dpc-5015	193	18	,	,	PUNCT
dpc-5015	193	19	corroborating	corroborate	VERB
dpc-5015	193	20	findings	finding	NOUN
dpc-5015	193	21	from	from	ADP
dpc-5015	193	22	other	other	ADJ
dpc-5015	193	23	studies	study	NOUN
dpc-5015	193	24	.	.	PUNCT
dpc-5015	194	1	endoglin	endoglin	PROPN
dpc-5015	194	2	may	may	AUX
dpc-5015	194	3	be	be	AUX
dpc-5015	194	4	a	a	DET
dpc-5015	194	5	parameter	parameter	NOUN
dpc-5015	194	6	indicating	indicate	VERB
dpc-5015	194	7	the	the	DET
dpc-5015	194	8	development	development	NOUN
dpc-5015	194	9	of	of	ADP
dpc-5015	194	10	comorbidities	comorbiditie	NOUN
dpc-5015	194	11	in	in	ADP
dpc-5015	194	12	rosacea	rosacea	NOUN
dpc-5015	194	13	.	.	PUNCT
dpc-5015	195	1	in	in	ADP
dpc-5015	195	2	the	the	DET
dpc-5015	195	3	present	present	ADJ
dpc-5015	195	4	study	study	NOUN
dpc-5015	195	5	,	,	PUNCT
dpc-5015	195	6	levels	level	NOUN
dpc-5015	195	7	of	of	ADP
dpc-5015	195	8	endocan	endocan	PROPN
dpc-5015	195	9	and	and	CCONJ
dpc-5015	195	10	endoglin	endoglin	NOUN
dpc-5015	195	11	were	be	AUX
dpc-5015	195	12	not	not	PART
dpc-5015	195	13	investigated	investigate	VERB
dpc-5015	195	14	in	in	ADP
dpc-5015	195	15	tissue	tissue	NOUN
dpc-5015	195	16	biopsy	biopsy	NOUN
dpc-5015	195	17	samples	sample	NOUN
dpc-5015	195	18	,	,	PUNCT
dpc-5015	195	19	which	which	PRON
dpc-5015	195	20	is	be	AUX
dpc-5015	195	21	a	a	DET
dpc-5015	195	22	limitation	limitation	NOUN
dpc-5015	195	23	.	.	PUNCT
dpc-5015	196	1	there	there	PRON
dpc-5015	196	2	are	be	VERB
dpc-5015	196	3	many	many	ADJ
dpc-5015	196	4	different	different	ADJ
dpc-5015	196	5	molecular	molecular	ADJ
dpc-5015	196	6	pathways	pathway	NOUN
dpc-5015	196	7	that	that	PRON
dpc-5015	196	8	could	could	AUX
dpc-5015	196	9	affect	affect	VERB
dpc-5015	196	10	serum	serum	NOUN
dpc-5015	196	11	levels	level	NOUN
dpc-5015	196	12	of	of	ADP
dpc-5015	196	13	endocan	endocan	PROPN
dpc-5015	196	14	and	and	CCONJ
dpc-5015	196	15	endoglin	endoglin	NOUN
dpc-5015	196	16	.	.	PUNCT
dpc-5015	197	1	for	for	ADP
dpc-5015	197	2	a	a	DET
dpc-5015	197	3	more	more	ADV
dpc-5015	197	4	specific	specific	ADJ
dpc-5015	197	5	conclusion	conclusion	NOUN
dpc-5015	197	6	,	,	PUNCT
dpc-5015	197	7	future	future	ADJ
dpc-5015	197	8	research	research	NOUN
dpc-5015	197	9	should	should	AUX
dpc-5015	197	10	examine	examine	VERB
dpc-5015	197	11	the	the	DET
dpc-5015	197	12	difference	difference	NOUN
dpc-5015	197	13	in	in	ADP
dpc-5015	197	14	levels	level	NOUN
dpc-5015	197	15	of	of	ADP
dpc-5015	197	16	these	these	DET
dpc-5015	197	17	molecules	molecule	NOUN
dpc-5015	197	18	between	between	ADP
dpc-5015	197	19	rosacea	rosacea	NOUN
dpc-5015	197	20	-	-	PUNCT
dpc-5015	197	21	affected	affect	VERB
dpc-5015	197	22	tissue	tissue	NOUN
dpc-5015	197	23	and	and	CCONJ
dpc-5015	197	24	healthy	healthy	ADJ
dpc-5015	197	25	tissue	tissue	NOUN
dpc-5015	197	26	.	.	PUNCT
dpc-5015	198	1	other	other	ADJ
dpc-5015	198	2	limitations	limitation	NOUN
dpc-5015	198	3	of	of	ADP
dpc-5015	198	4	our	our	PRON
dpc-5015	198	5	study	study	NOUN
dpc-5015	198	6	include	include	VERB
dpc-5015	198	7	the	the	DET
dpc-5015	198	8	examination	examination	NOUN
dpc-5015	198	9	of	of	ADP
dpc-5015	198	10	serum	serum	NOUN
dpc-5015	198	11	endocan	endocan	PROPN
dpc-5015	198	12	and	and	CCONJ
dpc-5015	198	13	endoglin	endoglin	NOUN
dpc-5015	198	14	levels	level	NOUN
dpc-5015	198	15	performed	perform	VERB
dpc-5015	198	16	on	on	ADP
dpc-5015	198	17	a	a	DET
dpc-5015	198	18	limited	limited	ADJ
dpc-5015	198	19	number	number	NOUN
dpc-5015	198	20	of	of	ADP
dpc-5015	198	21	patients	patient	NOUN
dpc-5015	198	22	with	with	ADP
dpc-5015	198	23	rosacea	rosacea	NOUN
dpc-5015	198	24	,	,	PUNCT
dpc-5015	198	25	the	the	DET
dpc-5015	198	26	inability	inability	NOUN
dpc-5015	198	27	to	to	PART
dpc-5015	198	28	conduct	conduct	VERB
dpc-5015	198	29	ocular	ocular	ADJ
dpc-5015	198	30	examinations	examination	NOUN
dpc-5015	198	31	on	on	ADP
dpc-5015	198	32	the	the	DET
dpc-5015	198	33	participants	participant	NOUN
dpc-5015	198	34	,	,	PUNCT
dpc-5015	198	35	and	and	CCONJ
dpc-5015	198	36	restriction	restriction	NOUN
dpc-5015	198	37	to	to	ADP
dpc-5015	198	38	a	a	DET
dpc-5015	198	39	single	single	ADJ
dpc-5015	198	40	center	center	NOUN
dpc-5015	198	41	.	.	PUNCT
dpc-5015	199	1	in	in	ADP
dpc-5015	199	2	conclusion	conclusion	NOUN
dpc-5015	199	3	,	,	PUNCT
dpc-5015	199	4	elevated	elevated	ADJ
dpc-5015	199	5	serum	serum	NOUN
dpc-5015	199	6	levels	level	NOUN
dpc-5015	199	7	of	of	ADP
dpc-5015	199	8	endocan	endocan	PROPN
dpc-5015	199	9	and	and	CCONJ
dpc-5015	199	10	endoglin	endoglin	NOUN
dpc-5015	199	11	have	have	AUX
dpc-5015	199	12	been	be	AUX
dpc-5015	199	13	linked	link	VERB
dpc-5015	199	14	to	to	ADP
dpc-5015	199	15	the	the	DET
dpc-5015	199	16	progression	progression	NOUN
dpc-5015	199	17	of	of	ADP
dpc-5015	199	18	rosacea	rosacea	NOUN
dpc-5015	199	19	to	to	ADP
dpc-5015	199	20	a	a	DET
dpc-5015	199	21	more	more	ADV
dpc-5015	199	22	severe	severe	ADJ
dpc-5015	199	23	stage	stage	NOUN
dpc-5015	199	24	,	,	PUNCT
dpc-5015	199	25	characterized	characterize	VERB
dpc-5015	199	26	by	by	ADP
dpc-5015	199	27	increased	increase	VERB
dpc-5015	199	28	telangiectasia	telangiectasia	NOUN
dpc-5015	199	29	and	and	CCONJ
dpc-5015	199	30	intense	intense	ADJ
dpc-5015	199	31	erythema	erythema	NOUN
dpc-5015	199	32	and	and	CCONJ
dpc-5015	199	33	severe	severe	ADJ
dpc-5015	199	34	symptoms	symptom	NOUN
dpc-5015	199	35	attributed	attribute	VERB
dpc-5015	199	36	to	to	ADP
dpc-5015	199	37	heightened	heighten	VERB
dpc-5015	199	38	inflammation	inflammation	NOUN
dpc-5015	199	39	and	and	CCONJ
dpc-5015	199	40	angiogenesis	angiogenesis	NOUN
dpc-5015	199	41	.	.	PUNCT
dpc-5015	200	1	we	we	PRON
dpc-5015	200	2	believe	believe	VERB
dpc-5015	200	3	that	that	SCONJ
dpc-5015	200	4	these	these	DET
dpc-5015	200	5	molecules	molecule	NOUN
dpc-5015	200	6	could	could	AUX
dpc-5015	200	7	serve	serve	VERB
dpc-5015	200	8	as	as	ADP
dpc-5015	200	9	potential	potential	ADJ
dpc-5015	200	10	target	target	NOUN
dpc-5015	200	11	molecules	molecule	NOUN
dpc-5015	200	12	for	for	ADP
dpc-5015	200	13	future	future	ADJ
dpc-5015	200	14	rosacea	rosacea	NOUN
dpc-5015	200	15	treatments	treatment	NOUN
dpc-5015	200	16	.	.	PUNCT
dpc-5015	201	1	to	to	PART
dpc-5015	201	2	better	well	ADV
dpc-5015	201	3	understand	understand	VERB
dpc-5015	201	4	the	the	DET
dpc-5015	201	5	role	role	NOUN
dpc-5015	201	6	of	of	ADP
dpc-5015	201	7	endocan	endocan	ADJ
dpc-5015	201	8	and	and	CCONJ
dpc-5015	201	9	endoglin	endoglin	NOUN
dpc-5015	201	10	molecules	molecule	NOUN
dpc-5015	201	11	in	in	ADP
dpc-5015	201	12	the	the	DET
dpc-5015	201	13	pathogenesis	pathogenesis	NOUN
dpc-5015	201	14	of	of	ADP
dpc-5015	201	15	rosacea	rosacea	NOUN
dpc-5015	201	16	,	,	PUNCT
dpc-5015	201	17	larger	large	ADJ
dpc-5015	201	18	-	-	PUNCT
dpc-5015	201	19	scale	scale	NOUN
dpc-5015	201	20	studies	study	NOUN
dpc-5015	201	21	involving	involve	VERB
dpc-5015	201	22	more	more	ADJ
dpc-5015	201	23	patients	patient	NOUN
dpc-5015	201	24	and	and	CCONJ
dpc-5015	201	25	control	control	NOUN
dpc-5015	201	26	participants	participant	NOUN
dpc-5015	201	27	are	be	AUX
dpc-5015	201	28	needed	need	VERB
dpc-5015	201	29	.	.	PUNCT
dpc-5015	202	1	additionally	additionally	ADV
dpc-5015	202	2	,	,	PUNCT
dpc-5015	202	3	endoglin	endoglin	NOUN
dpc-5015	202	4	levels	level	NOUN
dpc-5015	202	5	could	could	AUX
dpc-5015	202	6	be	be	AUX
dpc-5015	202	7	utilized	utilize	VERB
dpc-5015	202	8	to	to	PART
dpc-5015	202	9	identify	identify	VERB
dpc-5015	202	10	the	the	DET
dpc-5015	202	11	risk	risk	NOUN
dpc-5015	202	12	of	of	ADP
dpc-5015	202	13	cardiovascular	cardiovascular	ADJ
dpc-5015	202	14	diseases	disease	NOUN
dpc-5015	202	15	in	in	ADP
dpc-5015	202	16	rosacea	rosacea	NOUN
dpc-5015	202	17	groups	group	NOUN
dpc-5015	202	18	.	.	PUNCT
dpc-5015	203	1	furthermore	furthermore	ADV
dpc-5015	203	2	,	,	PUNCT
dpc-5015	203	3	in	in	ADP
dpc-5015	203	4	future	future	ADJ
dpc-5015	203	5	studies	study	NOUN
dpc-5015	203	6	,	,	PUNCT
dpc-5015	203	7	repeated	repeat	VERB
dpc-5015	203	8	measurements	measurement	NOUN
dpc-5015	203	9	of	of	ADP
dpc-5015	203	10	endocan	endocan	ADJ
dpc-5015	203	11	and	and	CCONJ
dpc-5015	203	12	endoglin	endoglin	NOUN
dpc-5015	203	13	before	before	ADP
dpc-5015	203	14	and	and	CCONJ
dpc-5015	203	15	after	after	ADP
dpc-5015	203	16	treatment	treatment	NOUN
dpc-5015	203	17	could	could	AUX
dpc-5015	203	18	provide	provide	VERB
dpc-5015	203	19	us	we	PRON
dpc-5015	203	20	with	with	ADP
dpc-5015	203	21	information	information	NOUN
dpc-5015	203	22	regarding	regard	VERB
dpc-5015	203	23	the	the	DET
dpc-5015	203	24	treatment	treatment	NOUN
dpc-5015	203	25	’s	’s	PART
dpc-5015	203	26	antiangiogenic	antiangiogenic	ADJ
dpc-5015	203	27	and	and	CCONJ
dpc-5015	203	28	anti	anti	ADJ
dpc-5015	203	29	-	-	ADJ
dpc-5015	203	30	inflammatory	inflammatory	ADJ
dpc-5015	203	31	efficacy	efficacy	NOUN
dpc-5015	203	32	.	.	PUNCT
dpc-5015	204	1	acknowledgments	acknowledgment	NOUN
dpc-5015	204	2	:	:	PUNCT
dpc-5015	204	3	we	we	PRON
dpc-5015	204	4	would	would	AUX
dpc-5015	204	5	like	like	VERB
dpc-5015	204	6	to	to	PART
dpc-5015	204	7	express	express	VERB
dpc-5015	204	8	our	our	PRON
dpc-5015	204	9	gratitude	gratitude	NOUN
dpc-5015	204	10	to	to	ADP
dpc-5015	204	11	dr	dr	PROPN
dpc-5015	204	12	.	.	PROPN
dpc-5015	204	13	huseyin	huseyin	PROPN
dpc-5015	204	14	oflaz	oflaz	PROPN
dpc-5015	204	15	,	,	PUNCT
dpc-5015	204	16	md	md	PROPN
dpc-5015	204	17	,	,	PUNCT
dpc-5015	204	18	for	for	ADP
dpc-5015	204	19	his	his	PRON
dpc-5015	204	20	contributions	contribution	NOUN
dpc-5015	204	21	to	to	ADP
dpc-5015	204	22	our	our	PRON
dpc-5015	204	23	original	original	ADJ
dpc-5015	204	24	article	article	NOUN
dpc-5015	204	25	|	|	ADV
dpc-5015	204	26	dermatol	dermatol	ADJ
dpc-5015	204	27	pract	pract	NOUN
dpc-5015	204	28	concept	concept	NOUN
dpc-5015	204	29	.	.	PUNCT
dpc-5015	205	1	2025;15(3):5015	2025;15(3):5015	NUM
dpc-5015	205	2	7	7	NUM
dpc-5015	205	3	26	26	NUM
dpc-5015	205	4	.	.	PUNCT
dpc-5015	206	1	bellón	bellón	PROPN
dpc-5015	206	2	t	t	PROPN
dpc-5015	206	3	,	,	PUNCT
dpc-5015	206	4	corbi	corbi	PROPN
dpc-5015	206	5	a	a	PRON
dpc-5015	206	6	,	,	PUNCT
dpc-5015	206	7	lastres	lastre	VERB
dpc-5015	206	8	p	p	X
dpc-5015	206	9	,	,	PUNCT
dpc-5015	206	10	et	et	PROPN
dpc-5015	206	11	al	al	PROPN
dpc-5015	206	12	.	.	PUNCT
dpc-5015	206	13	identification	identification	NOUN
dpc-5015	206	14	and	and	CCONJ
dpc-5015	206	15	expression	expression	NOUN
dpc-5015	206	16	of	of	ADP
dpc-5015	206	17	two	two	NUM
dpc-5015	206	18	forms	form	NOUN
dpc-5015	206	19	of	of	ADP
dpc-5015	206	20	the	the	DET
dpc-5015	206	21	human	human	ADJ
dpc-5015	206	22	transforming	transform	VERB
dpc-5015	206	23	growth	growth	NOUN
dpc-5015	206	24	factor	factor	NOUN
dpc-5015	206	25	-	-	PUNCT
dpc-5015	206	26	βbinding	βbinde	VERB
dpc-5015	206	27	protein	protein	NOUN
dpc-5015	206	28	endoglin	endoglin	NOUN
dpc-5015	206	29	with	with	ADP
dpc-5015	206	30	distinct	distinct	ADJ
dpc-5015	206	31	cytoplasmic	cytoplasmic	ADJ
dpc-5015	206	32	regions	region	NOUN
dpc-5015	206	33	.	.	PUNCT
dpc-5015	207	1	eur	eur	PROPN
dpc-5015	207	2	j	j	PROPN
dpc-5015	207	3	im‑	im‑	PROPN
dpc-5015	207	4	munol	munol	NOUN
dpc-5015	207	5	.	.	PUNCT
dpc-5015	208	1	1993;23(9):2340–2345	1993;23(9):2340–2345	NUM
dpc-5015	208	2	.	.	PUNCT
dpc-5015	209	1	doi:10.1002	doi:10.1002	NOUN
dpc-5015	209	2	/	/	SYM
dpc-5015	209	3	eji.1830230940	eji.1830230940	PROPN
dpc-5015	209	4	.	.	PUNCT
dpc-5015	210	1	pmid:8403503	pmid:8403503	NOUN
dpc-5015	210	2	.	.	PROPN
dpc-5015	211	1	27	27	NUM
dpc-5015	211	2	.	.	PUNCT
dpc-5015	212	1	mcallister	mcallister	PROPN
dpc-5015	212	2	ka	ka	PROPN
dpc-5015	212	3	,	,	PUNCT
dpc-5015	212	4	grogg	grogg	PROPN
dpc-5015	212	5	km	km	PROPN
dpc-5015	212	6	,	,	PUNCT
dpc-5015	212	7	johnson	johnson	PROPN
dpc-5015	212	8	dw	dw	PROPN
dpc-5015	212	9	,	,	PUNCT
dpc-5015	212	10	et	et	PROPN
dpc-5015	212	11	al	al	PROPN
dpc-5015	212	12	.	.	PUNCT
dpc-5015	213	1	endoglin	endoglin	PROPN
dpc-5015	213	2	,	,	PUNCT
dpc-5015	213	3	a	a	DET
dpc-5015	213	4	tgf	tgf	PROPN
dpc-5015	213	5	-	-	PUNCT
dpc-5015	213	6	β	β	X
dpc-5015	213	7	binding	bind	VERB
dpc-5015	213	8	protein	protein	NOUN
dpc-5015	213	9	of	of	ADP
dpc-5015	213	10	endothelial	endothelial	ADJ
dpc-5015	213	11	cells	cell	NOUN
dpc-5015	213	12	,	,	PUNCT
dpc-5015	213	13	is	be	AUX
dpc-5015	213	14	the	the	DET
dpc-5015	213	15	gene	gene	NOUN
dpc-5015	213	16	for	for	ADP
dpc-5015	213	17	hereditary	hereditary	ADJ
dpc-5015	213	18	haemorrhagic	haemorrhagic	ADJ
dpc-5015	213	19	telangiectasia	telangiectasia	NOUN
dpc-5015	213	20	type	type	VERB
dpc-5015	213	21	1	1	NUM
dpc-5015	213	22	.	.	PUNCT
dpc-5015	214	1	nat	nat	PROPN
dpc-5015	214	2	genet	genet	PROPN
dpc-5015	214	3	.	.	PUNCT
dpc-5015	215	1	1994;8(4	1994;8(4	NUM
dpc-5015	215	2	):	):	PUNCT
dpc-5015	215	3	345–351	345–351	NUM
dpc-5015	215	4	.	.	PUNCT
dpc-5015	215	5	doi:10.1038	doi:10.1038	NOUN
dpc-5015	215	6	/	/	SYM
dpc-5015	215	7	ng1294	ng1294	NOUN
dpc-5015	215	8	-	-	PUNCT
dpc-5015	215	9	345	345	NUM
dpc-5015	215	10	.	.	PUNCT
dpc-5015	216	1	pmid:7894484	pmid:7894484	NOUN
dpc-5015	216	2	.	.	PUNCT
dpc-5015	217	1	28	28	NUM
dpc-5015	217	2	.	.	PUNCT
dpc-5015	218	1	lópez	lópez	NOUN
dpc-5015	218	2	-	-	PUNCT
dpc-5015	218	3	novoa	novoa	NOUN
dpc-5015	218	4	jm	jm	PROPN
dpc-5015	218	5	,	,	PUNCT
dpc-5015	218	6	bernabeu	bernabeu	PROPN
dpc-5015	218	7	c.	c.	NOUN
dpc-5015	219	1	the	the	DET
dpc-5015	219	2	physiological	physiological	ADJ
dpc-5015	219	3	role	role	NOUN
dpc-5015	219	4	of	of	ADP
dpc-5015	219	5	endoglin	endoglin	NOUN
dpc-5015	219	6	in	in	ADP
dpc-5015	219	7	the	the	DET
dpc-5015	219	8	cardiovascular	cardiovascular	ADJ
dpc-5015	219	9	system	system	NOUN
dpc-5015	219	10	.	.	PUNCT
dpc-5015	220	1	am	be	AUX
dpc-5015	220	2	j	j	PROPN
dpc-5015	220	3	physiol	physiol	PROPN
dpc-5015	220	4	heart	heart	PROPN
dpc-5015	220	5	circ	circ	PROPN
dpc-5015	220	6	physiol	physiol	PROPN
dpc-5015	220	7	.	.	PUNCT
dpc-5015	221	1	2010;299(4):h959	2010;299(4):h959	NUM
dpc-5015	221	2	–	–	PUNCT
dpc-5015	221	3	h974	h974	NUM
dpc-5015	221	4	.	.	PUNCT
dpc-5015	221	5	doi:10.1152	doi:10.1152	NOUN
dpc-5015	221	6	/	/	SYM
dpc-5015	221	7	ajpheart.00654.2010	ajpheart.00654.2010	PROPN
dpc-5015	221	8	.	.	PUNCT
dpc-5015	221	9	pmid:20689056	pmid:20689056	PROPN
dpc-5015	221	10	.	.	PROPN
dpc-5015	221	11	29	29	NUM
dpc-5015	221	12	.	.	PUNCT
dpc-5015	222	1	sarrazin	sarrazin	PROPN
dpc-5015	222	2	s	s	PART
dpc-5015	222	3	,	,	PUNCT
dpc-5015	222	4	adam	adam	PROPN
dpc-5015	222	5	e	e	PROPN
dpc-5015	222	6	,	,	PUNCT
dpc-5015	222	7	lyon	lyon	PROPN
dpc-5015	222	8	m	m	PROPN
dpc-5015	222	9	,	,	PUNCT
dpc-5015	222	10	et	et	PROPN
dpc-5015	222	11	al	al	PROPN
dpc-5015	222	12	.	.	PUNCT
dpc-5015	223	1	endocan	endocan	ADJ
dpc-5015	223	2	or	or	CCONJ
dpc-5015	223	3	endothelial	endothelial	ADJ
dpc-5015	223	4	cell	cell	NOUN
dpc-5015	223	5	specific	specific	ADJ
dpc-5015	223	6	molecule-1	molecule-1	PROPN
dpc-5015	223	7	(	(	PUNCT
dpc-5015	223	8	esm-1	esm-1	X
dpc-5015	223	9	):	):	PUNCT
dpc-5015	223	10	a	a	DET
dpc-5015	223	11	potential	potential	ADJ
dpc-5015	223	12	novel	novel	ADJ
dpc-5015	223	13	endothelial	endothelial	ADJ
dpc-5015	223	14	cell	cell	NOUN
dpc-5015	223	15	marker	marker	NOUN
dpc-5015	223	16	and	and	CCONJ
dpc-5015	223	17	a	a	DET
dpc-5015	223	18	new	new	ADJ
dpc-5015	223	19	target	target	NOUN
dpc-5015	223	20	for	for	ADP
dpc-5015	223	21	cancer	cancer	NOUN
dpc-5015	223	22	therapy	therapy	NOUN
dpc-5015	223	23	.	.	PUNCT
dpc-5015	224	1	biochim	biochim	PROPN
dpc-5015	224	2	biophys	biophys	PROPN
dpc-5015	224	3	acta	acta	PROPN
dpc-5015	224	4	rev	rev	PROPN
dpc-5015	224	5	cancer	cancer	NOUN
dpc-5015	224	6	.	.	PUNCT
dpc-5015	225	1	2006;1765(1):25–37	2006;1765(1):25–37	NUM
dpc-5015	225	2	.	.	PUNCT
dpc-5015	226	1	doi:10.1016	doi:10.1016	PROPN
dpc-5015	226	2	/	/	SYM
dpc-5015	226	3	j.bbcan.2005	j.bbcan.2005	PROPN
dpc-5015	226	4	.10.004	.10.004	PUNCT
dpc-5015	226	5	.	.	PUNCT
dpc-5015	227	1	pmid:16359924	pmid:16359924	NOUN
dpc-5015	227	2	.	.	PUNCT
dpc-5015	227	3	30	30	NUM
dpc-5015	227	4	.	.	PUNCT
dpc-5015	228	1	bechard	bechard	PROPN
dpc-5015	228	2	d	d	PROPN
dpc-5015	228	3	,	,	PUNCT
dpc-5015	228	4	meignin	meignin	PROPN
dpc-5015	228	5	v	v	NOUN
dpc-5015	228	6	,	,	PUNCT
dpc-5015	228	7	scherpereel	scherpereel	NOUN
dpc-5015	228	8	a	a	X
dpc-5015	228	9	,	,	PUNCT
dpc-5015	228	10	et	et	PROPN
dpc-5015	228	11	al	al	PROPN
dpc-5015	228	12	.	.	PUNCT
dpc-5015	229	1	characterization	characterization	NOUN
dpc-5015	229	2	of	of	ADP
dpc-5015	229	3	the	the	DET
dpc-5015	229	4	secreted	secrete	VERB
dpc-5015	229	5	form	form	NOUN
dpc-5015	229	6	of	of	ADP
dpc-5015	229	7	endothelial	endothelial	NOUN
dpc-5015	229	8	-	-	PUNCT
dpc-5015	229	9	cell	cell	NOUN
dpc-5015	229	10	-	-	PUNCT
dpc-5015	229	11	specific	specific	ADJ
dpc-5015	229	12	molecule	molecule	NOUN
dpc-5015	229	13	1	1	NUM
dpc-5015	229	14	by	by	ADP
dpc-5015	229	15	specific	specific	ADJ
dpc-5015	229	16	monoclonal	monoclonal	NOUN
dpc-5015	229	17	antibodies	antibodie	VERB
dpc-5015	229	18	.	.	PUNCT
dpc-5015	230	1	j	j	PROPN
dpc-5015	230	2	vasc	vasc	PROPN
dpc-5015	230	3	res	res	PROPN
dpc-5015	230	4	.	.	PUNCT
dpc-5015	231	1	2000;37(5):417–425	2000;37(5):417–425	NUM
dpc-5015	231	2	.	.	PUNCT
dpc-5015	231	3	doi:10.1159/000025788	doi:10.1159/000025788	NOUN
dpc-5015	231	4	.	.	PUNCT
dpc-5015	232	1	pmid:11053977	pmid:11053977	ADJ
dpc-5015	232	2	.	.	PUNCT
dpc-5015	233	1	31	31	NUM
dpc-5015	233	2	.	.	PUNCT
dpc-5015	234	1	bessa	bessa	PROPN
dpc-5015	234	2	j	j	PROPN
dpc-5015	234	3	,	,	PUNCT
dpc-5015	234	4	albino	albino	PROPN
dpc-5015	234	5	-	-	PUNCT
dpc-5015	234	6	teixeira	teixeira	PROPN
dpc-5015	234	7	a	a	PROPN
dpc-5015	234	8	,	,	PUNCT
dpc-5015	234	9	reina	reina	PROPN
dpc-5015	234	10	-	-	PUNCT
dpc-5015	234	11	couto	couto	PROPN
dpc-5015	234	12	m	m	PROPN
dpc-5015	234	13	,	,	PUNCT
dpc-5015	234	14	sousa	sousa	PROPN
dpc-5015	234	15	t.	t.	PROPN
dpc-5015	234	16	endocan	endocan	PROPN
dpc-5015	234	17	:	:	PUNCT
dpc-5015	234	18	a	a	DET
dpc-5015	234	19	novel	novel	NOUN
dpc-5015	234	20	biomarker	biomarker	NOUN
dpc-5015	234	21	for	for	ADP
dpc-5015	234	22	risk	risk	NOUN
dpc-5015	234	23	stratification	stratification	NOUN
dpc-5015	234	24	,	,	PUNCT
dpc-5015	234	25	prognosis	prognosis	NOUN
dpc-5015	234	26	and	and	CCONJ
dpc-5015	234	27	therapeutic	therapeutic	ADJ
dpc-5015	234	28	monitoring	monitoring	NOUN
dpc-5015	234	29	in	in	ADP
dpc-5015	234	30	human	human	ADJ
dpc-5015	234	31	cardiovascular	cardiovascular	ADJ
dpc-5015	234	32	and	and	CCONJ
dpc-5015	234	33	renal	renal	ADJ
dpc-5015	234	34	diseases	disease	NOUN
dpc-5015	234	35	.	.	PUNCT
dpc-5015	235	1	clin	clin	PROPN
dpc-5015	235	2	chim	chim	PROPN
dpc-5015	235	3	acta	acta	PROPN
dpc-5015	235	4	.	.	PUNCT
dpc-5015	236	1	2020;509:310–335	2020;509:310–335	NUM
dpc-5015	236	2	.	.	PUNCT
dpc-5015	237	1	doi:10.1016	doi:10.1016	PROPN
dpc-5015	237	2	/	/	SYM
dpc-5015	237	3	j.cca	j.cca	PROPN
dpc-5015	237	4	.2020.06.012	.2020.06.012	PUNCT
dpc-5015	237	5	.	.	PUNCT
dpc-5015	238	1	pmid:32562648	pmid:32562648	NOUN
dpc-5015	238	2	.	.	PROPN
dpc-5015	238	3	32	32	NUM
dpc-5015	238	4	.	.	PUNCT
dpc-5015	239	1	aitkenhead	aitkenhead	VERB
dpc-5015	239	2	m	m	PROPN
dpc-5015	239	3	,	,	PUNCT
dpc-5015	239	4	wang	wang	PROPN
dpc-5015	239	5	sj	sj	PROPN
dpc-5015	239	6	,	,	PUNCT
dpc-5015	239	7	nakatsu	nakatsu	PROPN
dpc-5015	239	8	mn	mn	PROPN
dpc-5015	239	9	,	,	PUNCT
dpc-5015	239	10	et	et	PROPN
dpc-5015	239	11	al	al	PROPN
dpc-5015	239	12	.	.	PUNCT
dpc-5015	240	1	identification	identification	NOUN
dpc-5015	240	2	of	of	ADP
dpc-5015	240	3	endothelial	endothelial	ADJ
dpc-5015	240	4	cell	cell	NOUN
dpc-5015	240	5	genes	gene	NOUN
dpc-5015	240	6	expressed	express	VERB
dpc-5015	240	7	in	in	ADP
dpc-5015	240	8	an	an	DET
dpc-5015	240	9	in	in	X
dpc-5015	240	10	vitro	vitro	X
dpc-5015	240	11	model	model	NOUN
dpc-5015	240	12	of	of	ADP
dpc-5015	240	13	angiogenesis	angiogenesis	NOUN
dpc-5015	240	14	:	:	PUNCT
dpc-5015	240	15	induction	induction	NOUN
dpc-5015	240	16	of	of	ADP
dpc-5015	240	17	esm-1	esm-1	X
dpc-5015	240	18	,	,	PUNCT
dpc-5015	240	19	βig	βig	NOUN
dpc-5015	240	20	-	-	PUNCT
dpc-5015	240	21	h3	h3	NOUN
dpc-5015	240	22	,	,	PUNCT
dpc-5015	240	23	and	and	CCONJ
dpc-5015	240	24	nrcam	nrcam	PROPN
dpc-5015	240	25	.	.	PUNCT
dpc-5015	241	1	microvasc	microvasc	PROPN
dpc-5015	241	2	res	res	PROPN
dpc-5015	241	3	.	.	PUNCT
dpc-5015	242	1	2002;63(2	2002;63(2	NUM
dpc-5015	242	2	):	):	PUNCT
dpc-5015	242	3	159–171	159–171	NUM
dpc-5015	242	4	.	.	PUNCT
dpc-5015	243	1	doi:10.1006	doi:10.1006	ADJ
dpc-5015	243	2	/	/	SYM
dpc-5015	243	3	mvre.2001.2392	mvre.2001.2392	NOUN
dpc-5015	243	4	.	.	PUNCT
dpc-5015	243	5	pmid:11846534	pmid:11846534	NOUN
dpc-5015	243	6	.	.	PUNCT
dpc-5015	244	1	33	33	NUM
dpc-5015	244	2	.	.	PUNCT
dpc-5015	245	1	celik	celik	PROPN
dpc-5015	245	2	t	t	PROPN
dpc-5015	245	3	,	,	PUNCT
dpc-5015	245	4	balta	balta	PROPN
dpc-5015	245	5	s	s	PROPN
dpc-5015	245	6	,	,	PUNCT
dpc-5015	245	7	karaman	karaman	PROPN
dpc-5015	245	8	m	m	PROPN
dpc-5015	245	9	,	,	PUNCT
dpc-5015	245	10	et	et	PROPN
dpc-5015	245	11	al	al	PROPN
dpc-5015	245	12	.	.	PROPN
dpc-5015	246	1	endocan	endocan	PROPN
dpc-5015	246	2	,	,	PUNCT
dpc-5015	246	3	a	a	DET
dpc-5015	246	4	novel	novel	ADJ
dpc-5015	246	5	marker	marker	NOUN
dpc-5015	246	6	of	of	ADP
dpc-5015	246	7	endothelial	endothelial	ADJ
dpc-5015	246	8	dysfunction	dysfunction	NOUN
dpc-5015	246	9	in	in	ADP
dpc-5015	246	10	patients	patient	NOUN
dpc-5015	246	11	with	with	ADP
dpc-5015	246	12	essential	essential	ADJ
dpc-5015	246	13	hypertension	hypertension	NOUN
dpc-5015	246	14	:	:	PUNCT
dpc-5015	246	15	comparative	comparative	ADJ
dpc-5015	246	16	effects	effect	NOUN
dpc-5015	246	17	of	of	ADP
dpc-5015	246	18	amlodipine	amlodipine	NOUN
dpc-5015	246	19	and	and	CCONJ
dpc-5015	246	20	valsartan	valsartan	PROPN
dpc-5015	246	21	.	.	PUNCT
dpc-5015	247	1	blood	blood	NOUN
dpc-5015	247	2	press	press	NOUN
dpc-5015	247	3	.	.	PUNCT
dpc-5015	248	1	2015;24(1):55–60	2015;24(1):55–60	X
dpc-5015	248	2	.	.	PUNCT
dpc-5015	249	1	doi:10.3109/08037051.2014.961363	doi:10.3109/08037051.2014.961363	PROPN
dpc-5015	249	2	.	.	PUNCT
dpc-5015	250	1	pmid	pmid	NOUN
dpc-5015	250	2	:	:	PUNCT
dpc-5015	250	3	25251992	25251992	NUM
dpc-5015	250	4	.	.	PUNCT
dpc-5015	251	1	34	34	NUM
dpc-5015	251	2	.	.	PUNCT
dpc-5015	251	3	gallo	gallo	PROPN
dpc-5015	251	4	rl	rl	PROPN
dpc-5015	251	5	,	,	PUNCT
dpc-5015	251	6	granstein	granstein	PROPN
dpc-5015	251	7	rd	rd	PROPN
dpc-5015	251	8	,	,	PUNCT
dpc-5015	251	9	kang	kang	PROPN
dpc-5015	251	10	s	s	PROPN
dpc-5015	251	11	,	,	PUNCT
dpc-5015	251	12	et	et	PROPN
dpc-5015	251	13	al	al	PROPN
dpc-5015	251	14	.	.	PROPN
dpc-5015	252	1	standard	standard	ADJ
dpc-5015	252	2	classification	classification	NOUN
dpc-5015	252	3	and	and	CCONJ
dpc-5015	252	4	pathophysiology	pathophysiology	NOUN
dpc-5015	252	5	of	of	ADP
dpc-5015	252	6	rosacea	rosacea	NOUN
dpc-5015	252	7	:	:	PUNCT
dpc-5015	252	8	the	the	DET
dpc-5015	252	9	2017	2017	NUM
dpc-5015	252	10	update	update	NOUN
dpc-5015	252	11	by	by	ADP
dpc-5015	252	12	the	the	DET
dpc-5015	252	13	national	national	PROPN
dpc-5015	252	14	rosacea	rosacea	PROPN
dpc-5015	252	15	society	society	PROPN
dpc-5015	252	16	expert	expert	PROPN
dpc-5015	252	17	committee	committee	PROPN
dpc-5015	252	18	.	.	PUNCT
dpc-5015	253	1	j	j	PROPN
dpc-5015	253	2	am	be	AUX
dpc-5015	253	3	acad	acad	ADJ
dpc-5015	253	4	dermatol	dermatol	NOUN
dpc-5015	253	5	.	.	PUNCT
dpc-5015	254	1	2018;78(1	2018;78(1	NOUN
dpc-5015	254	2	):	):	PUNCT
dpc-5015	255	1	148–155	148–155	NUM
dpc-5015	255	2	.	.	PUNCT
dpc-5015	255	3	doi:10.1016	doi:10.1016	PROPN
dpc-5015	255	4	/	/	SYM
dpc-5015	255	5	j.jaad.2017.08.037	j.jaad.2017.08.037	PROPN
dpc-5015	255	6	.	.	PROPN
dpc-5015	255	7	pmid:29241751	pmid:29241751	PROPN
dpc-5015	255	8	.	.	PUNCT
dpc-5015	256	1	35	35	NUM
dpc-5015	256	2	.	.	PUNCT
dpc-5015	257	1	wilkin	wilkin	PROPN
dpc-5015	257	2	j	j	PROPN
dpc-5015	257	3	,	,	PUNCT
dpc-5015	257	4	dahl	dahl	PROPN
dpc-5015	257	5	m	m	PROPN
dpc-5015	257	6	,	,	PUNCT
dpc-5015	257	7	detmar	detmar	PROPN
dpc-5015	257	8	m	m	PROPN
dpc-5015	257	9	,	,	PUNCT
dpc-5015	257	10	et	et	PROPN
dpc-5015	257	11	al	al	PROPN
dpc-5015	257	12	.	.	PROPN
dpc-5015	257	13	standard	standard	ADJ
dpc-5015	257	14	grading	grade	VERB
dpc-5015	257	15	system	system	NOUN
dpc-5015	257	16	for	for	ADP
dpc-5015	257	17	rosacea	rosacea	NOUN
dpc-5015	257	18	:	:	PUNCT
dpc-5015	257	19	report	report	NOUN
dpc-5015	257	20	of	of	ADP
dpc-5015	257	21	the	the	DET
dpc-5015	257	22	national	national	PROPN
dpc-5015	257	23	rosacea	rosacea	PROPN
dpc-5015	257	24	society	society	PROPN
dpc-5015	257	25	expert	expert	PROPN
dpc-5015	257	26	committee	committee	PROPN
dpc-5015	257	27	on	on	ADP
dpc-5015	257	28	the	the	DET
dpc-5015	257	29	classification	classification	NOUN
dpc-5015	257	30	and	and	CCONJ
dpc-5015	257	31	staging	staging	NOUN
dpc-5015	257	32	of	of	ADP
dpc-5015	257	33	rosacea	rosacea	NOUN
dpc-5015	257	34	.	.	PUNCT
dpc-5015	258	1	j	j	PROPN
dpc-5015	258	2	am	be	AUX
dpc-5015	258	3	acad	acad	PROPN
dpc-5015	258	4	der‑	der‑	NOUN
dpc-5015	258	5	matol	matol	NOUN
dpc-5015	258	6	.	.	PUNCT
dpc-5015	259	1	2004;50(6):907–912	2004;50(6):907–912	NUM
dpc-5015	259	2	.	.	PUNCT
dpc-5015	259	3	doi:10.1016	doi:10.1016	PROPN
dpc-5015	259	4	/	/	SYM
dpc-5015	259	5	j.jaad.2004.01.012	j.jaad.2004.01.012	NOUN
dpc-5015	259	6	.	.	PUNCT
dpc-5015	259	7	pmid:15153893	pmid:15153893	PROPN
dpc-5015	259	8	.	.	PUNCT
dpc-5015	260	1	36	36	NUM
dpc-5015	260	2	.	.	PUNCT
dpc-5015	261	1	forton	forton	PROPN
dpc-5015	261	2	f.	f.	PROPN
dpc-5015	261	3	standardized	standardize	VERB
dpc-5015	261	4	skin	skin	NOUN
dpc-5015	261	5	surface	surface	NOUN
dpc-5015	261	6	biopsy	biopsy	NOUN
dpc-5015	261	7	:	:	PUNCT
dpc-5015	261	8	method	method	NOUN
dpc-5015	261	9	to	to	PART
dpc-5015	261	10	estimate	estimate	VERB
dpc-5015	261	11	the	the	DET
dpc-5015	261	12	demodex	demodex	NOUN
dpc-5015	261	13	folliculorum	folliculorum	NOUN
dpc-5015	261	14	density	density	NOUN
dpc-5015	261	15	,	,	PUNCT
dpc-5015	261	16	not	not	PART
dpc-5015	261	17	to	to	PART
dpc-5015	261	18	study	study	VERB
dpc-5015	261	19	the	the	DET
dpc-5015	261	20	demodex	demodex	NOUN
dpc-5015	261	21	folliculorum	folliculorum	NOUN
dpc-5015	261	22	prevalence	prevalence	NOUN
dpc-5015	261	23	.	.	PUNCT
dpc-5015	262	1	j	j	PROPN
dpc-5015	262	2	eur	eur	PROPN
dpc-5015	262	3	acad	acad	PROPN
dpc-5015	262	4	dermatol	dermatol	NOUN
dpc-5015	262	5	venereol	venereol	NOUN
dpc-5015	262	6	.	.	PUNCT
dpc-5015	263	1	2007	2007	NUM
dpc-5015	263	2	;	;	PUNCT
dpc-5015	263	3	21(9):1301–1302	21(9):1301–1302	NUM
dpc-5015	263	4	.	.	PUNCT
dpc-5015	263	5	doi:10.1111	doi:10.1111	ADJ
dpc-5015	263	6	/	/	SYM
dpc-5015	263	7	j.1468	j.1468	NOUN
dpc-5015	263	8	-	-	PUNCT
dpc-5015	263	9	3083.2007.02455.x	3083.2007.02455.x	NUM
dpc-5015	263	10	.	.	PUNCT
dpc-5015	264	1	pmid:17894752	pmid:17894752	VERB
dpc-5015	264	2	.	.	PROPN
dpc-5015	264	3	37	37	NUM
dpc-5015	264	4	.	.	PUNCT
dpc-5015	265	1	balta	balta	PROPN
dpc-5015	265	2	s	s	PROPN
dpc-5015	265	3	,	,	PUNCT
dpc-5015	265	4	mikhailidis	mikhailidis	ADJ
dpc-5015	265	5	dp	dp	NOUN
dpc-5015	265	6	,	,	PUNCT
dpc-5015	265	7	demirkol	demirkol	PROPN
dpc-5015	265	8	s	s	PROPN
dpc-5015	265	9	,	,	PUNCT
dpc-5015	265	10	et	et	PROPN
dpc-5015	265	11	al	al	PROPN
dpc-5015	265	12	.	.	PROPN
dpc-5015	266	1	endocan	endocan	PROPN
dpc-5015	266	2	:	:	PUNCT
dpc-5015	266	3	a	a	DET
dpc-5015	266	4	novel	novel	ADJ
dpc-5015	266	5	inflammatory	inflammatory	ADJ
dpc-5015	266	6	indicator	indicator	NOUN
dpc-5015	266	7	in	in	ADP
dpc-5015	266	8	cardiovascular	cardiovascular	ADJ
dpc-5015	266	9	disease	disease	NOUN
dpc-5015	266	10	?	?	PUNCT
dpc-5015	267	1	atheroscle‑	atheroscle‑	PROPN
dpc-5015	267	2	rosis	rosis	NOUN
dpc-5015	267	3	.	.	PUNCT
dpc-5015	268	1	2015;243(1):339–343	2015;243(1):339–343	PROPN
dpc-5015	268	2	.	.	PUNCT
dpc-5015	269	1	doi:10.1016	doi:10.1016	PROPN
dpc-5015	269	2	/	/	SYM
dpc-5015	269	3	j.atherosclerosis	j.atherosclerosis	PROPN
dpc-5015	269	4	.2015.09.030	.2015.09.030	PROPN
dpc-5015	269	5	.	.	PUNCT
dpc-5015	270	1	pmid:26448266	pmid:26448266	NOUN
dpc-5015	270	2	.	.	PROPN
dpc-5015	271	1	38	38	NUM
dpc-5015	271	2	.	.	PUNCT
dpc-5015	272	1	abdou	abdou	PROPN
dpc-5015	272	2	ag	ag	PROPN
dpc-5015	272	3	,	,	PUNCT
dpc-5015	272	4	hammam	hammam	PROPN
dpc-5015	272	5	m	m	PROPN
dpc-5015	272	6	,	,	PUNCT
dpc-5015	272	7	saad	saad	PROPN
dpc-5015	272	8	e	e	PROPN
dpc-5015	272	9	,	,	PUNCT
dpc-5015	272	10	hassan	hassan	PROPN
dpc-5015	272	11	raa	raa	PROPN
dpc-5015	272	12	.	.	PUNCT
dpc-5015	273	1	the	the	DET
dpc-5015	273	2	significance	significance	NOUN
dpc-5015	273	3	of	of	ADP
dpc-5015	273	4	endocan	endocan	ADJ
dpc-5015	273	5	immunohistochemical	immunohistochemical	ADJ
dpc-5015	273	6	expression	expression	NOUN
dpc-5015	273	7	in	in	ADP
dpc-5015	273	8	chronic	chronic	ADJ
dpc-5015	273	9	plaque	plaque	NOUN
dpc-5015	273	10	psoriasis	psoriasis	NOUN
dpc-5015	273	11	.	.	PUNCT
dpc-5015	274	1	j	j	PROPN
dpc-5015	274	2	cosmet	cosmet	PROPN
dpc-5015	274	3	dermatol	dermatol	NOUN
dpc-5015	274	4	.	.	PUNCT
dpc-5015	275	1	2021;20(7):2260–2266	2021;20(7):2260–2266	NOUN
dpc-5015	275	2	.	.	PUNCT
dpc-5015	276	1	doi:10.1111	doi:10.1111	ADJ
dpc-5015	276	2	/	/	SYM
dpc-5015	276	3	jocd.14086	jocd.14086	PROPN
dpc-5015	276	4	.	.	PUNCT
dpc-5015	276	5	pmid:33742537	pmid:33742537	NOUN
dpc-5015	276	6	.	.	PROPN
dpc-5015	276	7	39	39	NUM
dpc-5015	276	8	.	.	PUNCT
dpc-5015	277	1	tian	tian	ADJ
dpc-5015	277	2	h	h	PROPN
dpc-5015	277	3	,	,	PUNCT
dpc-5015	277	4	huang	huang	PROPN
dpc-5015	277	5	jj	jj	PROPN
dpc-5015	277	6	,	,	PUNCT
dpc-5015	277	7	golzio	golzio	VERB
dpc-5015	277	8	c	c	NOUN
dpc-5015	277	9	,	,	PUNCT
dpc-5015	277	10	et	et	PROPN
dpc-5015	277	11	al	al	PROPN
dpc-5015	277	12	.	.	PUNCT
dpc-5015	278	1	endoglin	endoglin	PROPN
dpc-5015	278	2	interacts	interact	VERB
dpc-5015	278	3	with	with	ADP
dpc-5015	278	4	vegfr2	vegfr2	NOUN
dpc-5015	278	5	to	to	PART
dpc-5015	278	6	promote	promote	VERB
dpc-5015	278	7	angiogenesis	angiogenesis	NOUN
dpc-5015	278	8	.	.	PUNCT
dpc-5015	279	1	faseb	faseb	PROPN
dpc-5015	279	2	j.	j.	PROPN
dpc-5015	279	3	2018;32(6	2018;32(6	NUM
dpc-5015	279	4	):	):	PUNCT
dpc-5015	279	5	2934–2949	2934–2949	NUM
dpc-5015	279	6	.	.	PUNCT
dpc-5015	279	7	doi:10.1096	doi:10.1096	NOUN
dpc-5015	279	8	/	/	SYM
dpc-5015	279	9	fj.201700909r	fj.201700909r	PROPN
dpc-5015	279	10	.	.	PUNCT
dpc-5015	279	11	pmid:29622072	pmid:29622072	NOUN
dpc-5015	279	12	.	.	PUNCT
dpc-5015	280	1	j	j	PROPN
dpc-5015	280	2	am	be	AUX
dpc-5015	280	3	acad	acad	ADJ
dpc-5015	280	4	dermatol	dermatol	NOUN
dpc-5015	280	5	.	.	PUNCT
dpc-5015	281	1	2014;71(1):100	2014;71(1):100	NUM
dpc-5015	281	2	-	-	PUNCT
dpc-5015	281	3	107	107	NUM
dpc-5015	281	4	.	.	PUNCT
dpc-5015	282	1	doi:10.1016	doi:10.1016	PROPN
dpc-5015	282	2	/	/	SYM
dpc-5015	282	3	j.	j.	PROPN
dpc-5015	282	4	jaad.2014.01.892	jaad.2014.01.892	PROPN
dpc-5015	282	5	.	.	PUNCT
dpc-5015	283	1	pmid:24656728	pmid:24656728	NOUN
dpc-5015	283	2	11	11	NUM
dpc-5015	283	3	.	.	PUNCT
dpc-5015	284	1	buhl	buhl	PROPN
dpc-5015	284	2	t	t	PROPN
dpc-5015	284	3	,	,	PUNCT
dpc-5015	284	4	sulk	sulk	PROPN
dpc-5015	284	5	m	m	PROPN
dpc-5015	284	6	,	,	PUNCT
dpc-5015	284	7	nowak	nowak	PROPN
dpc-5015	284	8	p	p	PROPN
dpc-5015	284	9	,	,	PUNCT
dpc-5015	284	10	et	et	PROPN
dpc-5015	284	11	al	al	PROPN
dpc-5015	284	12	.	.	PROPN
dpc-5015	285	1	molecular	molecular	ADJ
dpc-5015	285	2	and	and	CCONJ
dpc-5015	285	3	morphological	morphological	ADJ
dpc-5015	285	4	characterization	characterization	NOUN
dpc-5015	285	5	of	of	ADP
dpc-5015	285	6	inflammatory	inflammatory	ADJ
dpc-5015	285	7	infiltrate	infiltrate	NOUN
dpc-5015	285	8	in	in	ADP
dpc-5015	285	9	rosacea	rosacea	NOUN
dpc-5015	285	10	reveals	reveal	VERB
dpc-5015	285	11	activation	activation	NOUN
dpc-5015	285	12	of	of	ADP
dpc-5015	285	13	th1	th1	PROPN
dpc-5015	285	14	/	/	SYM
dpc-5015	285	15	th17	th17	PROPN
dpc-5015	285	16	pathways	pathway	NOUN
dpc-5015	285	17	.	.	PUNCT
dpc-5015	286	1	j	j	PROPN
dpc-5015	286	2	invest	invest	VERB
dpc-5015	286	3	dermatol	dermatol	NOUN
dpc-5015	286	4	.	.	PUNCT
dpc-5015	287	1	2015;135(9	2015;135(9	X
dpc-5015	287	2	):	):	PUNCT
dpc-5015	287	3	2198	2198	NUM
dpc-5015	287	4	-	-	PUNCT
dpc-5015	287	5	2208	2208	NUM
dpc-5015	287	6	.	.	PUNCT
dpc-5015	288	1	doi:10.1038	doi:10.1038	NOUN
dpc-5015	288	2	/	/	SYM
dpc-5015	288	3	jid.2015.141	jid.2015.141	PROPN
dpc-5015	288	4	.	.	PUNCT
dpc-5015	289	1	pmid:25848978	pmid:25848978	PROPN
dpc-5015	289	2	12	12	NUM
dpc-5015	289	3	.	.	PUNCT
dpc-5015	290	1	gazzinelli	gazzinelli	PROPN
dpc-5015	290	2	rt	rt	PROPN
dpc-5015	290	3	,	,	PUNCT
dpc-5015	290	4	denkers	denkers	PROPN
dpc-5015	290	5	ey	ey	PROPN
dpc-5015	290	6	.	.	PROPN
dpc-5015	290	7	protozoan	protozoan	NOUN
dpc-5015	290	8	encounters	encounter	VERB
dpc-5015	290	9	with	with	ADP
dpc-5015	290	10	toll	toll	NOUN
dpc-5015	290	11	-	-	PUNCT
dpc-5015	290	12	like	like	ADJ
dpc-5015	290	13	receptor	receptor	NOUN
dpc-5015	290	14	signalling	signal	VERB
dpc-5015	290	15	pathways	pathway	NOUN
dpc-5015	290	16	:	:	PUNCT
dpc-5015	290	17	implications	implication	NOUN
dpc-5015	290	18	for	for	ADP
dpc-5015	290	19	host	host	NOUN
dpc-5015	290	20	parasitism	parasitism	NOUN
dpc-5015	290	21	.	.	PUNCT
dpc-5015	291	1	nat	nat	PROPN
dpc-5015	291	2	rev	rev	PROPN
dpc-5015	291	3	immunol	immunol	NOUN
dpc-5015	291	4	.	.	PUNCT
dpc-5015	292	1	2006;6(12):895–906	2006;6(12):895–906	NUM
dpc-5015	292	2	.	.	PUNCT
dpc-5015	292	3	doi:10.1038	doi:10.1038	NOUN
dpc-5015	292	4	/	/	SYM
dpc-5015	292	5	nri1978	nri1978	NOUN
dpc-5015	292	6	.	.	PUNCT
dpc-5015	293	1	pmid:17110955	pmid:17110955	NOUN
dpc-5015	293	2	13	13	NUM
dpc-5015	293	3	.	.	PUNCT
dpc-5015	294	1	yamasaki	yamasaki	PROPN
dpc-5015	294	2	k	k	PROPN
dpc-5015	294	3	,	,	PUNCT
dpc-5015	294	4	kanada	kanada	PROPN
dpc-5015	294	5	k	k	PROPN
dpc-5015	294	6	,	,	PUNCT
dpc-5015	294	7	macleod	macleod	PROPN
dpc-5015	294	8	dt	dt	PROPN
dpc-5015	294	9	,	,	PUNCT
dpc-5015	294	10	et	et	PROPN
dpc-5015	294	11	al	al	PROPN
dpc-5015	294	12	.	.	PROPN
dpc-5015	295	1	tlr2	tlr2	PROPN
dpc-5015	295	2	expression	expression	NOUN
dpc-5015	295	3	is	be	AUX
dpc-5015	295	4	increased	increase	VERB
dpc-5015	295	5	in	in	ADP
dpc-5015	295	6	rosacea	rosacea	NOUN
dpc-5015	295	7	and	and	CCONJ
dpc-5015	295	8	stimulates	stimulate	VERB
dpc-5015	295	9	enhanced	enhance	VERB
dpc-5015	295	10	serine	serine	NOUN
dpc-5015	295	11	protease	protease	NOUN
dpc-5015	295	12	production	production	NOUN
dpc-5015	295	13	by	by	ADP
dpc-5015	295	14	keratinocytes	keratinocyte	NOUN
dpc-5015	295	15	.	.	PUNCT
dpc-5015	296	1	j	j	PROPN
dpc-5015	296	2	invest	invest	VERB
dpc-5015	296	3	dermatol	dermatol	NOUN
dpc-5015	296	4	.	.	PUNCT
dpc-5015	297	1	2011;131(3	2011;131(3	NUM
dpc-5015	297	2	):	):	PUNCT
dpc-5015	298	1	688–697	688–697	NUM
dpc-5015	298	2	.	.	PUNCT
dpc-5015	298	3	doi:10.1038	doi:10.1038	NOUN
dpc-5015	298	4	/	/	SYM
dpc-5015	298	5	jid.2010.351	jid.2010.351	PROPN
dpc-5015	298	6	.	.	PUNCT
dpc-5015	299	1	pmid:21107351	pmid:21107351	PROPN
dpc-5015	299	2	14	14	NUM
dpc-5015	299	3	.	.	PUNCT
dpc-5015	300	1	steinhoff	steinhoff	PROPN
dpc-5015	300	2	m	m	PROPN
dpc-5015	300	3	,	,	PUNCT
dpc-5015	300	4	ständer	ständer	NOUN
dpc-5015	300	5	s	s	PART
dpc-5015	300	6	,	,	PUNCT
dpc-5015	300	7	seeliger	seeliger	NOUN
dpc-5015	300	8	s	s	NOUN
dpc-5015	300	9	,	,	PUNCT
dpc-5015	300	10	et	et	PROPN
dpc-5015	300	11	al	al	PROPN
dpc-5015	300	12	.	.	PUNCT
dpc-5015	300	13	modern	modern	ADJ
dpc-5015	300	14	aspects	aspect	NOUN
dpc-5015	300	15	of	of	ADP
dpc-5015	300	16	cutaneous	cutaneous	ADJ
dpc-5015	300	17	neurogenic	neurogenic	ADJ
dpc-5015	300	18	inflammation	inflammation	NOUN
dpc-5015	300	19	.	.	PUNCT
dpc-5015	301	1	arch	arch	ADJ
dpc-5015	301	2	dermatol	dermatol	NOUN
dpc-5015	301	3	.	.	PUNCT
dpc-5015	302	1	2003	2003	NUM
dpc-5015	302	2	;	;	PUNCT
dpc-5015	303	1	139(11):1479–1488	139(11):1479–1488	NUM
dpc-5015	303	2	.	.	PUNCT
dpc-5015	304	1	doi:10.1001	doi:10.1001	PROPN
dpc-5015	304	2	/	/	SYM
dpc-5015	304	3	archderm.139.11.1479	archderm.139.11.1479	PROPN
dpc-5015	304	4	.	.	PUNCT
dpc-5015	305	1	pmid	pmid	NOUN
dpc-5015	305	2	:	:	PUNCT
dpc-5015	305	3	14557275	14557275	NUM
dpc-5015	305	4	15	15	NUM
dpc-5015	305	5	.	.	PUNCT
dpc-5015	306	1	segovia	segovia	PROPN
dpc-5015	306	2	j	j	PROPN
dpc-5015	306	3	,	,	PUNCT
dpc-5015	306	4	sabbah	sabbah	PROPN
dpc-5015	306	5	a	a	PRON
dpc-5015	306	6	,	,	PUNCT
dpc-5015	306	7	mgbemena	mgbemena	NOUN
dpc-5015	306	8	v	v	NOUN
dpc-5015	306	9	,	,	PUNCT
dpc-5015	306	10	et	et	PROPN
dpc-5015	306	11	al	al	PROPN
dpc-5015	306	12	.	.	PUNCT
dpc-5015	306	13	tlr2	tlr2	PROPN
dpc-5015	306	14	/	/	SYM
dpc-5015	306	15	myd88	myd88	PROPN
dpc-5015	306	16	/	/	SYM
dpc-5015	306	17	nf	nf	ADJ
dpc-5015	306	18	-	-	PUNCT
dpc-5015	306	19	κb	κb	NOUN
dpc-5015	306	20	pathway	pathway	NOUN
dpc-5015	306	21	,	,	PUNCT
dpc-5015	306	22	reactive	reactive	ADJ
dpc-5015	306	23	oxygen	oxygen	NOUN
dpc-5015	306	24	species	specie	NOUN
dpc-5015	306	25	,	,	PUNCT
dpc-5015	306	26	potassium	potassium	NOUN
dpc-5015	306	27	efflux	efflux	NOUN
dpc-5015	306	28	activates	activate	VERB
dpc-5015	306	29	nlrp3	nlrp3	PROPN
dpc-5015	306	30	/	/	SYM
dpc-5015	306	31	asc	asc	PROPN
dpc-5015	306	32	inflammasome	inflammasome	VERB
dpc-5015	306	33	during	during	ADP
dpc-5015	306	34	respiratory	respiratory	ADJ
dpc-5015	306	35	syncytial	syncytial	ADJ
dpc-5015	306	36	virus	virus	NOUN
dpc-5015	306	37	infection	infection	NOUN
dpc-5015	306	38	.	.	PUNCT
dpc-5015	307	1	plos	plos	PROPN
dpc-5015	307	2	one	one	NUM
dpc-5015	307	3	.	.	PUNCT
dpc-5015	308	1	2012;7(1):e29695	2012;7(1):e29695	NUM
dpc-5015	308	2	.	.	PUNCT
dpc-5015	308	3	doi:10.1371	doi:10.1371	ADJ
dpc-5015	308	4	/	/	SYM
dpc-5015	308	5	journal	journal	PROPN
dpc-5015	308	6	.pone.0029695	.pone.0029695	PROPN
dpc-5015	308	7	.	.	PUNCT
dpc-5015	309	1	pmid:22295065	pmid:22295065	VERB
dpc-5015	309	2	16	16	NUM
dpc-5015	309	3	.	.	PUNCT
dpc-5015	310	1	meyer	meyer	PROPN
dpc-5015	310	2	-	-	PUNCT
dpc-5015	310	3	hoffert	hoffert	PROPN
dpc-5015	310	4	u	u	PROPN
dpc-5015	310	5	,	,	PUNCT
dpc-5015	310	6	schröder	schröder	PROPN
dpc-5015	310	7	jm	jm	PROPN
dpc-5015	310	8	.	.	PROPN
dpc-5015	310	9	epidermal	epidermal	ADJ
dpc-5015	310	10	proteases	protease	NOUN
dpc-5015	310	11	in	in	ADP
dpc-5015	310	12	the	the	DET
dpc-5015	310	13	pathogenesis	pathogenesis	NOUN
dpc-5015	310	14	of	of	ADP
dpc-5015	310	15	rosacea	rosacea	NOUN
dpc-5015	310	16	.	.	PUNCT
dpc-5015	311	1	j	j	PROPN
dpc-5015	311	2	invest	invest	VERB
dpc-5015	311	3	dermatol	dermatol	NOUN
dpc-5015	311	4	symp	symp	NOUN
dpc-5015	311	5	proc	proc	NOUN
dpc-5015	311	6	.	.	PUNCT
dpc-5015	312	1	2011;15(1	2011;15(1	NUM
dpc-5015	312	2	):	):	PUNCT
dpc-5015	312	3	16–23	16–23	NUM
dpc-5015	312	4	.	.	PUNCT
dpc-5015	312	5	doi:10.1038	doi:10.1038	NOUN
dpc-5015	312	6	/	/	SYM
dpc-5015	313	1	jidsymp.2011.2	jidsymp.2011.2	PROPN
dpc-5015	313	2	.	.	PROPN
dpc-5015	313	3	pmid:22076323	pmid:22076323	ADJ
dpc-5015	313	4	17	17	NUM
dpc-5015	313	5	.	.	PUNCT
dpc-5015	313	6	steinstraesser	steinstraess	ADJ
dpc-5015	313	7	l	l	NOUN
dpc-5015	313	8	,	,	PUNCT
dpc-5015	313	9	kraneburg	kraneburg	PROPN
dpc-5015	313	10	u	u	PROPN
dpc-5015	313	11	,	,	PUNCT
dpc-5015	313	12	jacobsen	jacobsen	PROPN
dpc-5015	313	13	f	f	PROPN
dpc-5015	313	14	,	,	PUNCT
dpc-5015	313	15	et	et	PROPN
dpc-5015	313	16	al	al	PROPN
dpc-5015	313	17	.	.	PROPN
dpc-5015	313	18	host	host	NOUN
dpc-5015	313	19	defense	defense	NOUN
dpc-5015	313	20	peptides	peptide	NOUN
dpc-5015	313	21	and	and	CCONJ
dpc-5015	313	22	their	their	PRON
dpc-5015	313	23	antimicrobial	antimicrobial	ADJ
dpc-5015	313	24	-	-	PUNCT
dpc-5015	313	25	immunomodulatory	immunomodulatory	ADJ
dpc-5015	313	26	duality	duality	NOUN
dpc-5015	313	27	.	.	PUNCT
dpc-5015	314	1	immunobiology	immunobiology	NOUN
dpc-5015	314	2	.	.	PUNCT
dpc-5015	315	1	2011;216(3):322–333	2011;216(3):322–333	X
dpc-5015	315	2	.	.	PUNCT
dpc-5015	315	3	doi:10.1016	doi:10.1016	PROPN
dpc-5015	315	4	/	/	SYM
dpc-5015	315	5	j.imbio	j.imbio	NOUN
dpc-5015	315	6	.2010.07.003	.2010.07.003	PROPN
dpc-5015	315	7	.	.	PUNCT
dpc-5015	316	1	pmid:20828865	pmid:20828865	ADJ
dpc-5015	316	2	18	18	NUM
dpc-5015	316	3	.	.	PUNCT
dpc-5015	317	1	liu	liu	PROPN
dpc-5015	317	2	pt	pt	PROPN
dpc-5015	317	3	,	,	PUNCT
dpc-5015	317	4	stenger	stenger	PROPN
dpc-5015	317	5	s	s	PROPN
dpc-5015	317	6	,	,	PUNCT
dpc-5015	317	7	li	li	PROPN
dpc-5015	317	8	h	h	PROPN
dpc-5015	317	9	,	,	PUNCT
dpc-5015	317	10	et	et	PROPN
dpc-5015	317	11	al	al	PROPN
dpc-5015	317	12	.	.	PUNCT
dpc-5015	317	13	toll	toll	NOUN
dpc-5015	317	14	-	-	PUNCT
dpc-5015	317	15	like	like	ADJ
dpc-5015	317	16	receptor	receptor	NOUN
dpc-5015	317	17	triggering	trigger	VERB
dpc-5015	317	18	of	of	ADP
dpc-5015	317	19	a	a	DET
dpc-5015	317	20	vitamin	vitamin	NOUN
dpc-5015	317	21	d	d	NOUN
dpc-5015	317	22	-	-	PUNCT
dpc-5015	317	23	mediated	mediate	VERB
dpc-5015	317	24	human	human	ADJ
dpc-5015	317	25	antimicrobial	antimicrobial	ADJ
dpc-5015	317	26	response	response	NOUN
dpc-5015	317	27	.	.	PUNCT
dpc-5015	318	1	science	science	NOUN
dpc-5015	318	2	.	.	PUNCT
dpc-5015	319	1	2006;311(5768):1770–1773	2006;311(5768):1770–1773	NUM
dpc-5015	319	2	.	.	PUNCT
dpc-5015	319	3	doi:10.1126	doi:10.1126	PROPN
dpc-5015	319	4	/	/	SYM
dpc-5015	320	1	science.1123933	science.1123933	PROPN
dpc-5015	320	2	.	.	PROPN
dpc-5015	320	3	pmid:16497887	pmid:16497887	PROPN
dpc-5015	320	4	.	.	PROPN
dpc-5015	320	5	19	19	NUM
dpc-5015	320	6	.	.	PUNCT
dpc-5015	320	7	yamasaki	yamasaki	PROPN
dpc-5015	320	8	k	k	PROPN
dpc-5015	320	9	,	,	PUNCT
dpc-5015	320	10	di	di	PROPN
dpc-5015	320	11	nardo	nardo	PROPN
dpc-5015	320	12	a	a	PROPN
dpc-5015	320	13	,	,	PUNCT
dpc-5015	320	14	bardan	bardan	PROPN
dpc-5015	320	15	a	a	X
dpc-5015	320	16	,	,	PUNCT
dpc-5015	320	17	et	et	PROPN
dpc-5015	320	18	al	al	PROPN
dpc-5015	320	19	.	.	PROPN
dpc-5015	320	20	increased	increase	VERB
dpc-5015	320	21	serine	serine	NOUN
dpc-5015	320	22	protease	protease	NOUN
dpc-5015	320	23	activity	activity	NOUN
dpc-5015	320	24	and	and	CCONJ
dpc-5015	320	25	cathelicidin	cathelicidin	NOUN
dpc-5015	320	26	promotes	promote	VERB
dpc-5015	320	27	skin	skin	NOUN
dpc-5015	320	28	inflammation	inflammation	NOUN
dpc-5015	320	29	in	in	ADP
dpc-5015	320	30	rosacea	rosacea	NOUN
dpc-5015	320	31	.	.	PUNCT
dpc-5015	321	1	nat	nat	PROPN
dpc-5015	321	2	med	med	PROPN
dpc-5015	321	3	.	.	PUNCT
dpc-5015	322	1	2007;13(8):975–980	2007;13(8):975–980	X
dpc-5015	322	2	.	.	PROPN
dpc-5015	322	3	doi:10.1038	doi:10.1038	PROPN
dpc-5015	322	4	/	/	SYM
dpc-5015	322	5	nm1616	nm1616	PROPN
dpc-5015	322	6	.	.	PUNCT
dpc-5015	323	1	pmid:17676051	pmid:17676051	PROPN
dpc-5015	323	2	20	20	NUM
dpc-5015	323	3	.	.	PUNCT
dpc-5015	324	1	jang	jang	PROPN
dpc-5015	324	2	y	y	PROPN
dpc-5015	324	3	,	,	PUNCT
dpc-5015	324	4	sim	sim	PROPN
dpc-5015	324	5	j	j	PROPN
dpc-5015	324	6	,	,	PUNCT
dpc-5015	324	7	kang	kang	PROPN
dpc-5015	324	8	h	h	PROPN
dpc-5015	324	9	,	,	PUNCT
dpc-5015	324	10	kim	kim	PROPN
dpc-5015	324	11	y	y	PROPN
dpc-5015	324	12	,	,	PUNCT
dpc-5015	324	13	lee	lee	PROPN
dpc-5015	324	14	es	es	PROPN
dpc-5015	324	15	.	.	PUNCT
dpc-5015	324	16	immunohistochemical	immunohistochemical	ADJ
dpc-5015	324	17	expression	expression	NOUN
dpc-5015	324	18	of	of	ADP
dpc-5015	324	19	matrix	matrix	NOUN
dpc-5015	324	20	metalloproteinases	metalloproteinase	NOUN
dpc-5015	324	21	in	in	ADP
dpc-5015	324	22	the	the	DET
dpc-5015	324	23	granulomatous	granulomatous	ADJ
dpc-5015	324	24	rosacea	rosacea	NOUN
dpc-5015	324	25	compared	compare	VERB
dpc-5015	324	26	with	with	ADP
dpc-5015	324	27	the	the	DET
dpc-5015	324	28	non	non	ADJ
dpc-5015	324	29	-	-	ADJ
dpc-5015	324	30	granulomatous	granulomatous	ADJ
dpc-5015	324	31	rosacea	rosacea	NOUN
dpc-5015	324	32	.	.	PUNCT
dpc-5015	325	1	j	j	PROPN
dpc-5015	325	2	eur	eur	PROPN
dpc-5015	325	3	acad	acad	PROPN
dpc-5015	325	4	dermatol	dermatol	NOUN
dpc-5015	325	5	venereol	venereol	NOUN
dpc-5015	325	6	.	.	PUNCT
dpc-5015	326	1	2011;25(5):544–548	2011;25(5):544–548	X
dpc-5015	326	2	.	.	PUNCT
dpc-5015	327	1	doi:10.1111	doi:10.1111	PROPN
dpc-5015	327	2	/j.1468	/j.1468	PROPN
dpc-5015	327	3	-	-	PUNCT
dpc-5015	327	4	3083.2010.03824.x	3083.2010.03824.x	NUM
dpc-5015	327	5	.	.	PUNCT
dpc-5015	328	1	pmid:20840577	pmid:20840577	ADJ
dpc-5015	328	2	.	.	PUNCT
dpc-5015	329	1	21	21	NUM
dpc-5015	329	2	.	.	X
dpc-5015	329	3	schwab	schwab	NOUN
dpc-5015	329	4	vd	vd	PROPN
dpc-5015	329	5	,	,	PUNCT
dpc-5015	329	6	sulk	sulk	PROPN
dpc-5015	329	7	m	m	PROPN
dpc-5015	329	8	,	,	PUNCT
dpc-5015	329	9	seeliger	seeliger	NOUN
dpc-5015	329	10	s	s	NOUN
dpc-5015	329	11	,	,	PUNCT
dpc-5015	329	12	et	et	PROPN
dpc-5015	329	13	al	al	PROPN
dpc-5015	329	14	.	.	PROPN
dpc-5015	329	15	neurovascular	neurovascular	PROPN
dpc-5015	329	16	and	and	CCONJ
dpc-5015	329	17	neuroimmune	neuroimmune	NOUN
dpc-5015	329	18	aspects	aspect	NOUN
dpc-5015	329	19	in	in	ADP
dpc-5015	329	20	the	the	DET
dpc-5015	329	21	pathophysiology	pathophysiology	NOUN
dpc-5015	329	22	of	of	ADP
dpc-5015	329	23	rosacea	rosacea	NOUN
dpc-5015	329	24	.	.	PUNCT
dpc-5015	330	1	j	j	PROPN
dpc-5015	330	2	in‑	in‑	PROPN
dpc-5015	330	3	vest	vest	ADJ
dpc-5015	330	4	dermatol	dermatol	NOUN
dpc-5015	330	5	symp	symp	NOUN
dpc-5015	330	6	proc	proc	NOUN
dpc-5015	330	7	.	.	PUNCT
dpc-5015	331	1	2011;15(1):53–62	2011;15(1):53–62	NUM
dpc-5015	331	2	.	.	NOUN
dpc-5015	331	3	doi:10.1038	doi:10.1038	NOUN
dpc-5015	331	4	/jidsymp.2011.9	/jidsymp.2011.9	X
dpc-5015	331	5	.	.	PUNCT
dpc-5015	332	1	pmid:22076329	pmid:22076329	VERB
dpc-5015	332	2	.	.	PUNCT
dpc-5015	333	1	22	22	NUM
dpc-5015	333	2	.	.	PUNCT
dpc-5015	334	1	casas	casas	PROPN
dpc-5015	334	2	c	c	PROPN
dpc-5015	334	3	,	,	PUNCT
dpc-5015	334	4	paul	paul	PROPN
dpc-5015	334	5	c	c	PROPN
dpc-5015	334	6	,	,	PUNCT
dpc-5015	334	7	lahfa	lahfa	PROPN
dpc-5015	334	8	m	m	PROPN
dpc-5015	334	9	,	,	PUNCT
dpc-5015	334	10	et	et	PROPN
dpc-5015	334	11	al	al	PROPN
dpc-5015	334	12	.	.	PUNCT
dpc-5015	335	1	quantification	quantification	NOUN
dpc-5015	335	2	of	of	ADP
dpc-5015	335	3	demodex	demodex	NOUN
dpc-5015	335	4	folliculorum	folliculorum	NOUN
dpc-5015	335	5	by	by	ADP
dpc-5015	335	6	pcr	pcr	PROPN
dpc-5015	335	7	in	in	ADP
dpc-5015	335	8	rosacea	rosacea	NOUN
dpc-5015	335	9	and	and	CCONJ
dpc-5015	335	10	its	its	PRON
dpc-5015	335	11	relationship	relationship	NOUN
dpc-5015	335	12	to	to	ADP
dpc-5015	335	13	skin	skin	NOUN
dpc-5015	335	14	innate	innate	ADJ
dpc-5015	335	15	immune	immune	ADJ
dpc-5015	335	16	activation	activation	NOUN
dpc-5015	335	17	.	.	PUNCT
dpc-5015	336	1	exp	exp	NOUN
dpc-5015	336	2	dermatol	dermatol	NOUN
dpc-5015	336	3	.	.	PUNCT
dpc-5015	337	1	2012;21(12):906–910	2012;21(12):906–910	NUM
dpc-5015	337	2	.	.	PUNCT
dpc-5015	338	1	doi:10.1111	doi:10.1111	NOUN
dpc-5015	338	2	/	/	SYM
dpc-5015	338	3	exd.12017	exd.12017	PROPN
dpc-5015	338	4	.	.	PUNCT
dpc-5015	338	5	pmid:23157908	pmid:23157908	NOUN
dpc-5015	338	6	.	.	PUNCT
dpc-5015	339	1	23	23	NUM
dpc-5015	339	2	.	.	PUNCT
dpc-5015	339	3	schoonderwoerd	schoonderwoerd	PROPN
dpc-5015	339	4	mj	mj	PROPN
dpc-5015	339	5	,	,	PUNCT
dpc-5015	339	6	goumans	goumans	PROPN
dpc-5015	339	7	m	m	PROPN
dpc-5015	339	8	-	-	PROPN
dpc-5015	339	9	jt	jt	PROPN
dpc-5015	339	10	,	,	PUNCT
dpc-5015	339	11	hawinkels	hawinkel	VERB
dpc-5015	339	12	lj	lj	PROPN
dpc-5015	339	13	.	.	PUNCT
dpc-5015	340	1	endoglin	endoglin	PROPN
dpc-5015	340	2	:	:	PUNCT
dpc-5015	340	3	beyond	beyond	ADP
dpc-5015	340	4	the	the	DET
dpc-5015	340	5	endothelium	endothelium	NOUN
dpc-5015	340	6	.	.	PUNCT
dpc-5015	341	1	biomolecules	biomolecule	NOUN
dpc-5015	341	2	.	.	PUNCT
dpc-5015	342	1	2020;10(2):289	2020;10(2):289	NUM
dpc-5015	342	2	.	.	PUNCT
dpc-5015	343	1	doi:10.3390	doi:10.3390	PROPN
dpc-5015	343	2	/	/	SYM
dpc-5015	343	3	biom10020289	biom10020289	PROPN
dpc-5015	343	4	.	.	PUNCT
dpc-5015	344	1	pmid:32010848	pmid:32010848	NOUN
dpc-5015	344	2	.	.	PROPN
dpc-5015	345	1	24	24	NUM
dpc-5015	345	2	.	.	PUNCT
dpc-5015	346	1	gougos	gougo	NOUN
dpc-5015	346	2	a	a	DET
dpc-5015	346	3	,	,	PUNCT
dpc-5015	346	4	letarte	letarte	PROPN
dpc-5015	346	5	m.	m.	NOUN
dpc-5015	346	6	identification	identification	NOUN
dpc-5015	346	7	of	of	ADP
dpc-5015	346	8	a	a	DET
dpc-5015	346	9	human	human	ADJ
dpc-5015	346	10	endothelial	endothelial	NOUN
dpc-5015	346	11	cell	cell	NOUN
dpc-5015	346	12	antigen	antigen	ADJ
dpc-5015	346	13	with	with	ADP
dpc-5015	346	14	monoclonal	monoclonal	NOUN
dpc-5015	346	15	antibody	antibody	NOUN
dpc-5015	346	16	44g4	44g4	NUM
dpc-5015	346	17	produced	produce	VERB
dpc-5015	346	18	against	against	ADP
dpc-5015	346	19	a	a	DET
dpc-5015	346	20	pre	pre	ADJ
dpc-5015	346	21	-	-	ADJ
dpc-5015	346	22	b	b	ADJ
dpc-5015	346	23	leukemic	leukemic	ADJ
dpc-5015	346	24	cell	cell	NOUN
dpc-5015	346	25	line	line	NOUN
dpc-5015	346	26	.	.	PUNCT
dpc-5015	347	1	j	j	PROPN
dpc-5015	347	2	immunol	immunol	NOUN
dpc-5015	347	3	.	.	PUNCT
dpc-5015	348	1	1988;141(6):1925–1933	1988;141(6):1925–1933	NUM
dpc-5015	348	2	.	.	PUNCT
dpc-5015	348	3	doi:10.4049	doi:10.4049	PROPN
dpc-5015	348	4	/	/	SYM
dpc-5015	348	5	jimmunol.141.6.1925	jimmunol.141.6.1925	PROPN
dpc-5015	348	6	.	.	PROPN
dpc-5015	348	7	pmid:2450347	pmid:2450347	NOUN
dpc-5015	348	8	.	.	PUNCT
dpc-5015	349	1	25	25	NUM
dpc-5015	349	2	.	.	PUNCT
dpc-5015	349	3	gougos	gougo	NOUN
dpc-5015	349	4	a	a	DET
dpc-5015	349	5	,	,	PUNCT
dpc-5015	349	6	letarte	letarte	PROPN
dpc-5015	349	7	m.	m.	PROPN
dpc-5015	349	8	primary	primary	ADJ
dpc-5015	349	9	structure	structure	NOUN
dpc-5015	349	10	of	of	ADP
dpc-5015	349	11	endoglin	endoglin	NOUN
dpc-5015	349	12	,	,	PUNCT
dpc-5015	349	13	an	an	DET
dpc-5015	349	14	rgd	rgd	NOUN
dpc-5015	349	15	-	-	PUNCT
dpc-5015	349	16	containing	contain	VERB
dpc-5015	349	17	glycoprotein	glycoprotein	NOUN
dpc-5015	349	18	of	of	ADP
dpc-5015	349	19	human	human	ADJ
dpc-5015	349	20	endothelial	endothelial	ADJ
dpc-5015	349	21	cells	cell	NOUN
dpc-5015	349	22	.	.	PUNCT
dpc-5015	350	1	j	j	PROPN
dpc-5015	350	2	biol	biol	PROPN
dpc-5015	350	3	chem	chem	NOUN
dpc-5015	350	4	.	.	PUNCT
dpc-5015	351	1	1990;265(15):8361–8364	1990;265(15):8361–8364	NUM
dpc-5015	351	2	.	.	PUNCT
dpc-5015	352	1	pmid:2346718	pmid:2346718	NOUN
dpc-5015	352	2	.	.	NOUN
dpc-5015	352	3	8	8	NUM
dpc-5015	352	4	original	original	ADJ
dpc-5015	352	5	article	article	NOUN
dpc-5015	352	6	|	|	ADV
dpc-5015	352	7	dermatol	dermatol	ADJ
dpc-5015	352	8	pract	pract	NOUN
dpc-5015	352	9	concept	concept	NOUN
dpc-5015	352	10	.	.	PUNCT
dpc-5015	353	1	2025;15(3):5015	2025;15(3):5015	NUM
dpc-5015	353	2	2005;1(4):277–290	2005;1(4):277–290	NUM
dpc-5015	353	3	.	.	PUNCT
dpc-5015	353	4	doi:10.2147	doi:10.2147	NOUN
dpc-5015	353	5	/	/	SYM
dpc-5015	353	6	vhrm.2005.1.4.277	vhrm.2005.1.4.277	PROPN
dpc-5015	353	7	.	.	PUNCT
dpc-5015	354	1	pmid	pmid	NOUN
dpc-5015	354	2	:	:	PUNCT
dpc-5015	354	3	17315600	17315600	NUM
dpc-5015	354	4	.	.	PUNCT
dpc-5015	355	1	43	43	NUM
dpc-5015	355	2	.	.	PUNCT
dpc-5015	356	1	wladis	wladis	PROPN
dpc-5015	356	2	ej	ej	PROPN
dpc-5015	356	3	,	,	PUNCT
dpc-5015	356	4	carlson	carlson	PROPN
dpc-5015	356	5	ja	ja	PROPN
dpc-5015	356	6	,	,	PUNCT
dpc-5015	356	7	wang	wang	PROPN
dpc-5015	356	8	ms	ms	PROPN
dpc-5015	356	9	,	,	PUNCT
dpc-5015	356	10	et	et	PROPN
dpc-5015	356	11	al	al	PROPN
dpc-5015	356	12	.	.	PUNCT
dpc-5015	356	13	toll	toll	NOUN
dpc-5015	356	14	-	-	PUNCT
dpc-5015	356	15	like	like	ADJ
dpc-5015	356	16	receptors	receptor	NOUN
dpc-5015	356	17	and	and	CCONJ
dpc-5015	356	18	vascular	vascular	ADJ
dpc-5015	356	19	markers	marker	NOUN
dpc-5015	356	20	in	in	ADP
dpc-5015	356	21	ocular	ocular	ADJ
dpc-5015	356	22	rosacea	rosacea	NOUN
dpc-5015	356	23	.	.	PUNCT
dpc-5015	357	1	ophthalmic	ophthalmic	ADJ
dpc-5015	357	2	plast	plast	PROPN
dpc-5015	357	3	reconstr	reconstr	NOUN
dpc-5015	357	4	surg	surg	NOUN
dpc-5015	357	5	.	.	PUNCT
dpc-5015	358	1	2013;29(4):290–293	2013;29(4):290–293	X
dpc-5015	358	2	.	.	PUNCT
dpc-5015	358	3	doi:10.1097	doi:10.1097	NOUN
dpc-5015	358	4	/	/	SYM
dpc-5015	358	5	iop.0b013e3182947a14	iop.0b013e3182947a14	PROPN
dpc-5015	358	6	.	.	PUNCT
dpc-5015	359	1	pmid:23839635	pmid:23839635	PROPN
dpc-5015	359	2	44	44	NUM
dpc-5015	359	3	.	.	PUNCT
dpc-5015	360	1	li	li	PROPN
dpc-5015	360	2	q	q	PROPN
dpc-5015	360	3	,	,	PUNCT
dpc-5015	360	4	lin	lin	PROPN
dpc-5015	360	5	f	f	PROPN
dpc-5015	360	6	,	,	PUNCT
dpc-5015	360	7	ke	ke	PROPN
dpc-5015	360	8	d	d	PROPN
dpc-5015	360	9	,	,	PUNCT
dpc-5015	360	10	et	et	PROPN
dpc-5015	360	11	al	al	PROPN
dpc-5015	360	12	.	.	PROPN
dpc-5015	360	13	combination	combination	NOUN
dpc-5015	360	14	of	of	ADP
dpc-5015	360	15	endoglin	endoglin	NOUN
dpc-5015	360	16	and	and	CCONJ
dpc-5015	360	17	ascvd	ascvd	NOUN
dpc-5015	360	18	risk	risk	NOUN
dpc-5015	360	19	assessment	assessment	NOUN
dpc-5015	360	20	improves	improve	VERB
dpc-5015	360	21	carotid	carotid	ADJ
dpc-5015	360	22	subclinical	subclinical	ADJ
dpc-5015	360	23	atherosclerosis	atherosclerosis	NOUN
dpc-5015	360	24	recognition	recognition	NOUN
dpc-5015	360	25	.	.	PUNCT
dpc-5015	361	1	j	j	PROPN
dpc-5015	361	2	atheroscler	atheroscler	PROPN
dpc-5015	361	3	thromb	thromb	PROPN
dpc-5015	361	4	.	.	PUNCT
dpc-5015	362	1	2019;26(5):50898	2019;26(5):50898	NUM
dpc-5015	362	2	.	.	PUNCT
dpc-5015	363	1	doi:10.5551	doi:10.5551	PROPN
dpc-5015	363	2	/jat.50898	/jat.50898	PROPN
dpc-5015	363	3	.	.	PUNCT
dpc-5015	364	1	pmid:31406054	pmid:31406054	NOUN
dpc-5015	364	2	40	40	NUM
dpc-5015	364	3	.	.	PUNCT
dpc-5015	365	1	kılıc	kılıc	PROPN
dpc-5015	365	2	s	s	PROPN
dpc-5015	365	3	,	,	PUNCT
dpc-5015	365	4	mermutlu	mermutlu	PROPN
dpc-5015	365	5	si	si	X
dpc-5015	365	6	,	,	PUNCT
dpc-5015	365	7	şehitoğlu	şehitoğlu	ADJ
dpc-5015	365	8	h	h	NOUN
dpc-5015	365	9	,	,	PUNCT
dpc-5015	365	10	et	et	PROPN
dpc-5015	365	11	al	al	PROPN
dpc-5015	365	12	.	.	PROPN
dpc-5015	365	13	elevated	elevated	PROPN
dpc-5015	365	14	serum	serum	NOUN
dpc-5015	365	15	endocan	endocan	ADJ
dpc-5015	365	16	levels	level	NOUN
dpc-5015	365	17	in	in	ADP
dpc-5015	365	18	patients	patient	NOUN
dpc-5015	365	19	with	with	ADP
dpc-5015	365	20	rosacea	rosacea	NOUN
dpc-5015	365	21	:	:	PUNCT
dpc-5015	365	22	a	a	DET
dpc-5015	365	23	new	new	ADJ
dpc-5015	365	24	therapeutic	therapeutic	ADJ
dpc-5015	365	25	target	target	NOUN
dpc-5015	365	26	?	?	PUNCT
dpc-5015	366	1	indian	indian	PROPN
dpc-5015	366	2	j	j	PROPN
dpc-5015	366	3	dermatol	dermatol	NOUN
dpc-5015	366	4	.	.	PUNCT
dpc-5015	367	1	2021;66(5):520	2021;66(5):520	PROPN
dpc-5015	367	2	.	.	PUNCT
dpc-5015	368	1	doi:10.4103	doi:10.4103	PROPN
dpc-5015	368	2	/	/	SYM
dpc-5015	368	3	ijd.ijd_401_21	ijd.ijd_401_21	PROPN
dpc-5015	368	4	.	.	PUNCT
dpc-5015	369	1	pmid:35068507	pmid:35068507	NOUN
dpc-5015	369	2	.	.	PUNCT
dpc-5015	370	1	41	41	NUM
dpc-5015	370	2	.	.	PUNCT
dpc-5015	371	1	sánchez	sánchez	NOUN
dpc-5015	371	2	-	-	PUNCT
dpc-5015	371	3	elsner	elsner	PROPN
dpc-5015	371	4	t	t	PROPN
dpc-5015	371	5	,	,	PUNCT
dpc-5015	371	6	botella	botella	PROPN
dpc-5015	371	7	lm	lm	PROPN
dpc-5015	371	8	,	,	PUNCT
dpc-5015	371	9	velasco	velasco	PROPN
dpc-5015	371	10	b	b	PROPN
dpc-5015	371	11	,	,	PUNCT
dpc-5015	371	12	et	et	PROPN
dpc-5015	371	13	al	al	PROPN
dpc-5015	371	14	.	.	PUNCT
dpc-5015	372	1	endoglin	endoglin	PROPN
dpc-5015	372	2	expression	expression	NOUN
dpc-5015	372	3	is	be	AUX
dpc-5015	372	4	regulated	regulate	VERB
dpc-5015	372	5	by	by	ADP
dpc-5015	372	6	transcriptional	transcriptional	ADJ
dpc-5015	372	7	cooperation	cooperation	NOUN
dpc-5015	372	8	between	between	ADP
dpc-5015	372	9	the	the	DET
dpc-5015	372	10	hypoxia	hypoxia	NOUN
dpc-5015	372	11	and	and	CCONJ
dpc-5015	372	12	transforming	transform	VERB
dpc-5015	372	13	growth	growth	NOUN
dpc-5015	372	14	factor	factor	NOUN
dpc-5015	372	15	-	-	PUNCT
dpc-5015	372	16	β	β	NOUN
dpc-5015	372	17	pathways	pathway	NOUN
dpc-5015	372	18	.	.	PUNCT
dpc-5015	373	1	j	j	PROPN
dpc-5015	373	2	biol	biol	PROPN
dpc-5015	373	3	chem	chem	NOUN
dpc-5015	373	4	.	.	PUNCT
dpc-5015	374	1	2002;277(46):43799–43808	2002;277(46):43799–43808	NUM
dpc-5015	374	2	.	.	PUNCT
dpc-5015	374	3	doi:10.1074	doi:10.1074	PROPN
dpc-5015	374	4	/	/	PUNCT
dpc-5015	375	1	jbc.m207160200	jbc.m207160200	PROPN
dpc-5015	375	2	.	.	PUNCT
dpc-5015	376	1	pmid:12228247	pmid:12228247	ADP
dpc-5015	376	2	42	42	NUM
dpc-5015	376	3	.	.	PUNCT
dpc-5015	377	1	furuya	furuya	PROPN
dpc-5015	377	2	m	m	PROPN
dpc-5015	377	3	,	,	PUNCT
dpc-5015	377	4	nishiyama	nishiyama	NOUN
dpc-5015	377	5	m	m	PROPN
dpc-5015	377	6	,	,	PUNCT
dpc-5015	377	7	kasuya	kasuya	VERB
dpc-5015	377	8	y	y	PROPN
dpc-5015	377	9	,	,	PUNCT
dpc-5015	377	10	et	et	PROPN
dpc-5015	377	11	al	al	PROPN
dpc-5015	377	12	.	.	PROPN
dpc-5015	377	13	pathophysiology	pathophysiology	PROPN
dpc-5015	377	14	of	of	ADP
dpc-5015	377	15	tumor	tumor	NOUN
dpc-5015	377	16	neovascularization	neovascularization	NOUN
dpc-5015	377	17	.	.	PUNCT
dpc-5015	378	1	vasc	vasc	PROPN
dpc-5015	378	2	health	health	NOUN
dpc-5015	378	3	risk	risk	NOUN
dpc-5015	378	4	manag	manag	NOUN
dpc-5015	378	5	.	.	PUNCT